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Improving chronic illness care: new models for care delivery 
The burden of chronic conditions, including rheumatic diseases, increases [1] and in order 
to ensure access to appropriate and comprehensive care, a redesign of the health care 
system is necessary [2]. Care for the chronically ill differs from acute care in many ways. 
Acute care is characterised by incidental, short-term and reactive interventions. In 
contrast, chronic care challenges the health care system to pursue a planned, long-term, 
and proactive approach, focussing on keeping an individual as healthy as possible [3]. Key 
issues for chronic care are i) adherence to practice guidelines, ii) a high level of 
coordination, iii) an active follow-up, and iv) patients trained to manage their illness 
themselves. Being an active participator in the care process requires self-management 
skills from patients. Strategies and effective interventions that support patients’ self-
management should therefore be available [4].  
New models for care delivery comprise new roles for allied health professionals, the use of 
new technology (or the use of existing technology in a new and novel way), and a redesign 
of support systems [5]. These new models for quality improvement in chronic illness care 
indicate that strategies for improvement should be multidimensional, i.e. they should take 
the whole system into account [3]. It is clear that care for chronically ill as described 
above, requires fine tuning with regard to resources that are available in the community 
and in the health care system, e.g. sports and activities for healthy movement and 
physiotherapy. It also requires the development of appropriate, effective interventions 
that support patients’ self-management, and the provision of decision support for health 
care professionals. Finally, it is mandatory to define clear roles, even beyond traditional 
tasks, for all members of the multidisciplinary team, and to provide appropriate training 
and education to fulfil these roles. The connection between all activities for care 
improvement enhances results of the single elements [6].  
 
Care for patients with rheumatic diseases  
Numerous rheumatic diseases have been recognised and defined and jointly they form the 
most prevalent chronic conditions in the world: 10%-20% of the adult population suffers 
from any kind of rheumatism [7]. In general, care delivery for patients with rheumatic 
diseases includes diagnosis, treatment and management, but also prevention of co-
morbidities. Care aims to reduce disability, to restore function and autonomy, and to 
support patients in dealing with the consequences of having a chronic disease.  
The content and the context of care delivery for patients with rheumatic diseases depend 
on the nature of the disease and on international, national and regional agreements about 
treatment, follow-up and collaboration between professionals [8-18]. A growing insight in 
advantages of a multidisciplinary and comprehensive approach has resulted in a more 
holistic oriented care [19-23].  
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Traditionally, the general practitioner and the rheumatologist are responsible for the 
management, but often other professionals, such as the physiotherapist, occupational 
therapist, social worker, psychologist, podotherapist or dietician, address specific 
problems that occur in the course of the disease.  
Rheumatology nurses are increasingly recognised as valued members of the 
multidisciplinary teams. They support patients in a broad spectrum of disease-related 
problems. Rheumatology nursing care focuses on health promotion and aims to ensure 
patients’ capability to participating in treatment decisions, managing their own symptoms 
and risks of treatment [24-26], and to support patients’ coping with the disease [27]. In 
order to achieve these goals, nursing care comprises monitoring of disease consequences 
at the level of daily activities, participation and psychosocial consequences, patient 
education, support and education for relatives, and counselling [19, 28]. Nursing care 
further provides an assessment of problems and a coordination of services, all of which 
have been valued by patients [29, 30].  
The rheumatology nursing specialty has developed alongside rheumatology as a separate 
medical specialism [31, 32]. Increasingly, nurses are involved in monitoring disease 
activity, drug treatment, and drug side effects, and in managing exacerbations [33, 34]. In 
addition, they play an increasing role in the diagnostic process [35, 36]. This role 
development of rheumatology nurses reflects a tendency towards evidence-based and 
proactive care for patients with chronic diseases in which nurses combine nursing care 
with medical tasks [37, 38]. 
For certain rheumatic diseases, current literature suggests that rheumatology patients are 
dissatisfied with the quality of health care. More than 30% of the patients with 
fibromyalgia, which is a non-inflammatory chronic pain disorder without satisfactory 
medical treatment options, consider that the current care should be improved. They 
report a delay in diagnosis and feel that their symptoms are not managed well [39]. In 
addition, the care for patients with rheumatoid arthritis, a well-defined disease 
characterised by chronic inflammatory arthritis and with multiple medical treatments 
available, has been found to be suboptimal too. Care is not consistent with guidelines for 
early, aggressive treatment and access to care is not optimal [40]. This thesis is therefore 
focussed on activities aiming to improve the holistic care for patients with fibromyalgia 
and for patients with chronic inflammatory diseases.  
 
Issues for care improvement in rheumatology 
Fibromyalgia 
Fibromyalgia (FM) is a disorder characterised by generalised musculoskeletal pain, fatigue, 
the perception of muscle weakness, sleep and concentration disturbances. In addition, 
other vaguely defined symptoms may be present. The severity of symptoms varies among 
patients [41]. Comorbid disorders, such as depression and anxiety, occur frequently and 
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contribute to a poor quality of life [42]. The prevalence of FM is estimated between 0.5%-
5% and the large majority of the patients (90%) is female in the working age [43]. Unlike 
chronic inflammatory diseases, FM does not result in structural deformities, but many 
patients perceive functional limitations in daily activities at home and at work. The impact 
on the patient’s life and the societal burden of the disorder (high health care resource 
expenditures and an inability to work) is substantial and justifies an ongoing search for 
appropriate care [44, 45].  
Research on underlying pathophysiological mechanisms, such as central sensitization, has 
resulted in a better understanding of the disorder, but the precise cause is still unknown. 
Cure is an unrealistic treatment goal and the evidence about effective interventions is 
limited, making the management of FM a challenging issue [46, 47]. In the literature, a 
preference for multimodal and/or multidisciplinary approaches is advocated [11, 12, 22, 
48-50]. This approach may comprise physiotherapy, cognitive-behavioral therapy 
completed with patient education and social support, as well as pharmacological 
interventions [51-54]. Increasingly, a timely intervention is considered pivotal in order to 
prevent further function loss and pain behaviour [55] and obviously, the availability of and 
access to such an intervention is essential.  
The heterogeneity in study populations of FM patients is compelling and shows that the 
complexity of problems varies widely, but it also hampers appropriate care and treatment. 
The variety of phenotypes suggests that a tailored approach may be better than a generic 
approach and that a broad pallet of potential interventions, which are provided according 
to the individual’s needs, may be required. Research in this field suggests satisfactory 
results [56] and attempts have been made to provide more practical tools for a rapid 
evaluation of complexity [57]. Over 80% of the patients with FM are managed in primary 
care by general practitioners and physiotherapists, and a large diversity of interventions is 
applied [58]. This diversity shows that existing guidelines are not sufficient to support the 
professionals in taking decisions about appropriate management [12, 59].  
 
Chronic inflammatory arthritis 
Diseases such as rheumatoid arthritis (RA), axial spondyloarthritis (SpA) or ankylosing 
spondylitis (AS) and peripheral spondyloarthritis are systemic in nature and are 
characterised by chronic inflammation. In RA, inflammation is predominantly present in 
the peripheral joints whereas in AS, the axial skeleton (spine, sacroiliac joints) is mainly 
affected. Abnormal reactions of the immune system are at the basis of these diseases. 
Inflammation may result in pain, fatigue, stiffness, and limitations in daily functioning. 
Deformities of the joints or spine may occur and contribute to functional limitations. 
Symptoms usually occur in a circular pattern of flares and periods with low disease 
activity, which are rather unpredictable. The worldwide prevalences are estimated 0.5%-
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1% for RA, and 1%-1.5% for SpA  [7]. Gender differences occur: RA is 2 to 4 times more 
common in women than in men and develops in the working age, whilst SpA has an  
approximately equal gender distribution and usually develops in the teens or twenties [7].  
The treatment of chronic inflammatory arthritis focuses first and above all on interfering 
with the immune system. Early treatment regimens including conventional Disease 
Modifying Anti-Rheumatic Drugs (DMARDs) have shown their effectiveness [60, 61]. 
Moreover, an increased insight in immunologic processes has resulted in the development 
of biologic drugs which improved the possibilities to suppress disease activity in the last 
decennia [62]. Increasingly, the treatment target is clinical remission or, if that is not 
possible, low disease activity [15]. In many patients, the new treatment regimens and the 
use of biologic drugs have resulted in a revolutionary decrease of disease activity and in 
improved functional capacity and work participation. Even if low disease activity is 
achieved, the impact of the disease on the patient’s daily life remains present [63, 64]. The 
impact of inflammatory arthritis may be increased by the presence of an underlying 
depression disorder, a well-known comorbidity [65].  
A multidisciplinary approach aims to ensure appropriate care for each patient with chronic 
inflammatory arthritis. In its management, the role of rheumatology nurses has changed, 
incorporating technical and patient-management skills that were previously belonging to 
the physician’s domain [66]. Patients are involved in treatment decisions (shared decision 
making) as a full understanding and a full agreement may enhance compliance [67]. The 
immunosuppressant nature of the medications that are used in the therapy may 
contribute to a higher risk of infection. Treatment therefore requires vigilant monitoring 
by professionals as well as an attentive attitude of patients in order to recognise the 
appropriate symptoms so that they can ask for timely help [24, 68, 69]. Also, patient-
centredness is considered an important quality dimension [70, 71]. The patient’s 
perspective is considered pivotal in determining the required content and organisation of 
care, and also in making decisions about the quality of care [72, 73].  
Nurse-centred interventions are considered essential to effectively tackle the challenges 
of chronic illness in an economic and integrated fashion [33, 34, 74-76]. Evaluation among 
patients has shown acceptability and satisfaction with the care provided [77]. However, 
there is a lack of clear definitions about the content of care and the role and competences 
of nurses. Also, the precise tasks and responsibilities of the team members depend on 
national and local regulations and contexts [78]. Furthermore, rheumatology as a nursing 
specialty does not exist in all countries. Consequently, care given by rheumatology nurses 
is not equally available for all patients with rheumatic diseases.  
The demands on knowledge and skills of nurses have increased accordingly. Knowledge 
about disease state, clinical expertise in administration, and monitoring of adverse events 
is required [24], as well as skills with regard to patient-centred support, patient education, 
information sharing, and coordination of care [25]. The content of nursing education 
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differs across countries, since curricula are not homogeneous and often not clearly 
described.  
 
Main research questions 
The main research questions in this thesis reflect the opportunities for care improvement 
that were outlined before. For fibromyalgia the focus is on the availability of resources, 
e.g. effective interventions, and on decision support, and the following research questions 
were formulated: 
1. Is an intensive multidisciplinary intervention with aftercare for newly diagnosed 
patients with fibromyalgia effective in reducing the use of health care resources 
and in improving participation and quality of life?  
2. How do costs develop in newly diagnosed patients with fibromyalgia that receive 
different types of interventions? 
3. What are the potential predictors of health improvement in newly diagnosed 
patients with fibromyalgia? 
4. How can we support health care professionals in primary care in order to 
improve the management of fibromyalgia?  
 
With respect to inflammatory arthritis, care improvement focuses on emphasising the role 
of the rheumatology nurse and the following research questions were formulated: 
1. What is the best standard for rheumatology nursing care?  
2. What is the level of agreement with this standard among different countries, and 
what are barriers for implementation? 
3. What are patients’ priorities for rheumatology nursing care? 
 
Outline of the thesis 
This thesis describes our research with regard to care improvement for patients with 
fibromyalgia and chronic inflammatory arthritis. The background is introduced in  
Chapter 1. 
 
Part I of the thesis focuses on patients with fibromyalgia.  
Chapter 2 describes the evaluation of a multidisciplinary intervention with aftercare for 
recently diagnosed patients. The effectiveness of the intervention was assessed in a 
randomised controlled trial comparing the results of the intervention with aerobic 
exercise and with usual care.  
Economic consequences are increasingly important and have been taken into account.  
Chapter 3 reports on the 2-year cost-of-illness in patients of the above mentioned cohort 
receiving three different types of interventions.  
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An analysis of predictors for improved health in the cohort recently diagnosed patients 
after two years is presented in Chapter 4.  
The final chapter of Part I focuses on care improvement in primary care. Results of a  
project in which an educational program, a multidisciplinary guideline and a checklist for 
referral for general practitioners and physiotherapists were developed, are described in 
Chapter 5.  
 
Part II of this thesis focuses on the role of the nurse in the care for patients with 
inflammatory arthritis. In order to standardise care, European League Against Rheumatism 
(EULAR) recommendations for the role of the nurse in the management of inflammatory 
arthritis have been developed by an international and multidisciplinary task force and are 
presented in Chapter 6.  
In Chapter 7 the dissemination and the external evaluation of the recommendations 
among nurses, rheumatologists and patients in 22 European countries and in the United 
States of America are described. This chapter also provides recommendations for further 
implementation.  
More research is needed about the effects of nursing interventions. Patients’ priorities 
should direct the research agenda and therefore patients’ opinions and expectations were 
explored. The results of the latter study are described in Chapter 8.  
 
Finally, the research presented in this thesis is summarised and discussed in Chapter 9.  
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Part I 
Improving care for patients with fibromyalgia 
 
            Frida Kahlo (1907–1954), Mexican painter 
 
‘To explain Frida’s chronic illness, we offer an alternative diagnosis. Our opinion is that she 
suffered posttraumatic fibromyalgia. This prevalent syndrome is characterized by  
persistent widespread pain, chronic fatigue, sleep disorders, and vegetative symptoms, 
and by the presence of tender points in well-defined anatomic areas.’ 
 
 
Martinez-Lavin M, Amigo M-C, Coindreau J, Canoso J. Fibromyalgia in Frida Kahlo’s life and 
art. Arthritis & Rheumatism. 2000; 43(3):708–709. 
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Chapter 2 
Challenges in demonstrating the effectiveness of 
multidisciplinary treatment on quality of life, 
participation and health care utilisation  
in patients with fibromyalgia:  
a randomised controlled trial 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Van Eijk-Hustings Y, Kroese M, Tan F, Boonen A, Bessems-Beks M, Landewé R. 
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Abstract 
Objective. The aim of this study was to examine the effectiveness of a multidisciplinary 
intervention with aftercare, compared to aerobic exercise and usual care in recently 
diagnosed patients with fibromyalgia. 
Methods. In a Zelen-like design, eligible patients from the outpatient rheumatology clinics 
of three medical centres in the South of the Netherlands were consecutively recruited and 
pre-randomised to the multidisciplinary intervention (n=108), aerobic exercise (n=47) or 
usual care (n=48). The multidisciplinary intervention consisted of a 12-week course of 
socio-therapy, physiotherapy, psychotherapy and creative arts therapy (three half days 
per week), followed by five aftercare meetings in nine months. Aerobic exercise was given 
twice a week in a 12-week course. Usual care varied but incorporated at least education 
and life style advice. Primary outcomes were health-related quality of life, participation 
and health care utilisation. Secondary outcome was the Fibromyalgia Impact 
Questionnaire. Total follow-up in the study was 21-24 months.  
Results. As willingness to participate in the aerobic exercise intervention was limited, this 
group has been analysed but interpretation of the data is considered arguable. Within the 
multidisciplinary intervention group, a statistically significantly improved health-related 
quality of life, and a statistically significant reduction in number of hours sick leave, 
number of contacts with General Practitioners, and number of contacts with medical 
specialists was found. Moreover, statistically significant improvements were found on the 
Fibromyalgia Impact Questionnaire, which increased after the intervention. However, no 
statistically significantly between-group differences were found at the endpoint of the 
study.  
Conclusion. The multidisciplinary intervention seemed to yield positive effects, but firm 
conclusions with regard to effectiveness cannot be formulated due to small between 
group differences and limitations of the study. 
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Introduction 
Fibromyalgia (FM) is a chronic pain disorder with a worldwide prevalence of 0.5%-5%, 
preferentially affecting women in the working age [1]. The most prominent manifestation 
of FM is widespread, persistent musculoskeletal pain. In addition, a variety of other 
manifestations such as fatigue, concentration problems, depression, anxiety and 
symptoms of irritable bowel syndrome may occur [2], resulting in a loss of well-being, 
participation and functioning [3, 4]. The economic burden of FM is considerable as it is 
associated with high utilisation of health care resources and loss of working days [5-7]. 
Because of its multifaceted nature, FM is assumed to be managed best by multimodal 
and/or multidisciplinary approaches [8, 9]. A meta-analysis of non-pharmacological, 
multimodal interventions showed limited effects [10], contributing to the ongoing 
discussion on the content, duration, intensity, adherence and long term effects of these 
programs [10, 11]. Increasingly, experts consider that early intervention can enhance 
treatment efficacy, as they expect this to prevent pain behaviour and adaptation to 
dysfunctioning [12]. Health care utilisation and participation in major life areas are 
increasingly valued as important outcomes, in addition to classic outcome measures that 
concentrate on key domains of FM like pain, fatigue and physical functioning [13]. 
An intensive, multidisciplinary intervention with aftercare for patients with recently 
diagnosed FM was developed and tested in a pilot study among 100 patients with nine 
months follow-up. The approach was found feasible and the pilot study suggested a 
sustained improvement in quality of life and functioning during the treatment and 
aftercare period [14]. A larger, randomised controlled study with a follow-up time 
extending the duration of the intervention was considered pivotal in order to examine the 
sustainability of effects and to understand non-specific effects opposed to specific effects 
which are attributable to the multidisciplinary intervention. In the present study, the 
intensive multidisciplinary program with aftercare is tested in a randomised controlled 
trial (RCT) with health-related quality of life (HR-Qol), participation and health care 
utilisation as primary outcomes. 
 
Patients and methods 
Study participants and design 
The study was designed as a pragmatic RCT [15], comparing the effectiveness of the 
multidisciplinary intervention (MD) with aerobic exercise (AE) and usual care (UC). In the 
period from January 2004 until August 2006, recently (< three months) diagnosed FM 
patients according to the American College of Rheumatology criteria [2], literate and 
between 18 and 65 years old, were consecutively recruited from the outpatient 
rheumatology clinics of three medical centres in the South of the Netherlands (Maastricht 
University Medical Centre (MUMC), Atrium Medical Centre, Heerlen and Orbis Medical 
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Centre, Sittard). To avoid biased results by patients’ expectations, a pre-randomised 
Zelen-like study-design [16] was chosen.  
Eligible patients were asked to participate in, as they were told, ‘an observational study on 
the natural course of FM’, and at the same time they were asked whether they were 
willing to participate in future studies. After informed consent, they were randomly 
assigned to the treatment arms. Randomisation was performed using computer generated 
random numbers in opaque, sealed envelopes, following the order of consent to 
participate in the observational study. Only those who were randomised to MD or AE 
were invited to participate in the intervention without being informed about the 
alternative treatment conditions. Patients in the UC group were not informed about any 
intervention.  
Because of the intensity of the MD program, patients randomised to the MD group were 
interviewed by the research assistant and excluded from participation in the intervention 
in case of 1) pregnancy, 2) involvement in litigation concerning work disability procedures, 
3) use of other non-pharmacological treatments such as psychological or physical 
treatment, interfering with the intervention, 4) alcohol or drugs abuse and 5) use of 
walking devices.  
The study was approved by the Medical Ethical Committees of the three medical centres 
and is registered under number ISRCTN32542621.  
 
Interventions 
The MD intervention was designed as a 2-phased group program, aiming to optimise daily 
functioning through coping with pain and disability. The total program took one year and 
was offered in an outpatient convalescence setting, affiliated to MUMC.  
Phase l consisted of a 12-week course, three half days per week, with two therapy 
sessions of 1,5 hours duration per day. A trained and experienced multidisciplinary team 
offered a program of socio-therapy, physiotherapy, psychotherapy and creative arts 
therapy, using group interaction as an additional tool but also paying attention to the 
patient’s specific needs. Socio-therapy was given twice a week at the start and at the end 
of the week. It included education and connected the parts of the program. It was based 
on transactional analysis [17, 18] and aimed to increase social behaviour strategies and 
social support.  
Physiotherapy was given twice a week. The program was focused on graded activity, 
based on time-contingent instead of pain-contingent training and aimed to improve 
physical fitness and functioning, and at learning to enjoy exercise. It comprised aerobic 
exercises, strength training of arms and legs, different forms of relaxation, and exercises 
focusing on alternative patterns of movement in order to improve awareness and reduce 
muscle tone during daily activities. The program was scheduled based on the individual  
patient’s results on the 6-minute walk test, the 3-minute step test and on three minutes  
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of working with the shoulder press measured by the physiotherapist at the start of the 
program. If necessary, instruction and support by an occupational therapist could take 
part of the physiotherapy. Psychotherapy was given once a week and consisted of general 
information about fibromyalgia and pain mechanisms. Methods of core qualities [19], 
rational emotive therapy [20-22] and transactional analysis [17, 18] were used in the 
sessions. Creative arts therapy was given once a week and focussed on the opportunity to 
express feelings by visual arts instead of verbal expressions. The first phase was built up 
around four themes, used in all therapies:  
Theme 1. Communication: discover suppressed feelings and emotions; 
Theme 2. Take care of yourself: discover limitations and learn to draw the line; 
Theme 3. Stress, strength, anger and conflict: discover qualities; 
Theme 4. Balance: a new start. 
Phase ll was an aftercare program and consisted of five meetings, scheduled over a period 
of nine months. The purpose of these meetings was to repeat the key messages about 
coping in order to preserve the behavioral change achieved in phase l. In addition to these 
meetings, a maximum of seven individual therapy sessions with one of the therapists 
could be scheduled if considered necessary by therapist and patient. An MD group with 9 
to 10 patients started every six weeks. If too small number of patients wanted to 
participate in the intervention, additional patients from the outpatient clinic who did not 
participate in the study were added to fill the groups. 
The AE intervention consisted of a 12-week group course which was given twice a week by 
a trained physiotherapist in a community gym, on the floor. Every session started with a 
10-minute warming-up, comprising aerobic exercise and stretching, followed by an 
aerobic part during 30 minutes. The low-intensity aerobic part aimed to reach 55%-64% of 
the predicted maximum heart rate. Patients were instructed to check heart rate by self-
control after the warming-up and after the aerobic part a few times during the course. 
They were asked to communicate this with the trainer to check if the intensity of their 
aerobic training was sufficient. Then, resistance training was applied during 15 minutes to 
strengthen major muscle groups. During the course, the intensity of the resistance training 
increased in weights, frequency and tempo. Finally, every session was finished with a 5-
minute cool-down [23]. Participants received a Digital Video Disc presenting exercises to 
do at home, and they were advised to perform these once a week. These home exercises 
were not monitored. The AE group should also consist of 9 to 10 persons and started 
when enough participants for the intervention were available.  
The UC arm received care as usual that comprised at least individualised education about 
FM and lifestyle advice by a rheumatologist or a specialised rheumatology nurse within 
one or two consultations, but could also include a diversity of other treatments such as 
physiotherapy, or social support from the rheumatology nurse. 
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Outcome measures  
Primary outcomes were HR-Qol, participation and health care utilisation. The secondary 
outcome was the impact of FM on daily functioning. All outcome measures were self-
reported. At inflow in the study, all patients provided data on demographic and disease 
characteristics. Total follow-up of the study was 21 to 24 months for the three groups. 
Follow-up duration varied since patients started the intervention at different time points. 
Follow-up questionnaires were sent to all patients immediately following the 12-week 
program and 18 months afterwards, the endpoint of the study. Because the UC group did 
not receive a planned intervention, the measurements of each respondent were randomly 
linked to respondents in either the MD group or the AE group to achieve similar time 
points. 
HR-Qol was measured by the 5-dimensional EuroQol (EQ-5D) [24, 25]. The EQ-5D is a 
validated instrument to assess general health-related quality of life. This instrument 
consists of two components: a descriptive system that expresses a societal value for 
health (range from -0.59 to 1.00, worst possible to best possible health) and an overall 
impression of health, measured by a Visual Analogue Scale (VAS, range from 0 to 100, 
worst possible to best possible health).  
Participation comprised work productivity, unpaid tasks and chores (e.g. household), 
leisure (e.g. sports, hobbies) and social activities. A self-developed questionnaire 
measured contractual hours paid work and hours sick leave retrospectively. Time spent on 
unpaid tasks, chores, leisure and social activities in the past two months was measured by 
an adapted activity questionnaire [26].  
The use of FM-related health care resources was measured retrospectively by a 2-monthly 
cost questionnaire [27]. Questions considered number of contacts with general 
practitioners (GPs), medical specialists (e.g. rheumatologists, orthopaedists), 
physiotherapists and other paramedical therapists (e.g. psychotherapists). 
The impact of FM on daily functioning was assessed by the Fibromyalgia Impact 
Questionnaire (FIQ) [28, 29], a 10-item multidimensional instrument on function in the 
past week. The 10 items are physical functioning, numbers of days feel good, number of 
days missed work, interference of symptoms with ability to activities, pain, fatigue, 
unrefreshed sleep, stiffness, anxiety and depression. Each item-score was standardised on 
a 0-10 scale and a FIQ-total score (0-100) was calculated [28].  
 
Sample size calculation 
Sample size calculation was based on results of the pilot study on HR-Qol [14], because no 
robust data on expected change in the other primary outcomes were available in the 
literature. With a 0.15 units difference on the EQ-5D, standard deviation = 0.32, β = 0.20 
and α = 0.05, and allowing for a drop-out of 30%, a total of 204 patients was needed. In 
this 3-arm pragmatic clinical trial with MD expected to show most (durable) effect, an 
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unbalanced design was chosen in the following ratio: MD vs AE vs UC = 2 vs 1 vs 1, so that 
the majority of patients would get MD as their treatment. 
 
Statistical analyses 
Data were analysed using the intention-to-treat principle. Due to the limited willingness to 
participate in the interventions after randomisation, per-protocol analyses were also 
performed. Patients dropping out from the intervention continued their participation in 
the observational study, so follow-up data were obtained. Missing questionnaires that 
appeared not only in the group of patients who participated in the interventions but also 
in the group of non-participants varied per measurement. Missing data were carefully 
investigated and found to be random. A multilevel analysis (mixed effects model) was 
used to assess longitudinal effectiveness [30]. In this analysis, all available data are used 
and therefore, also patients with incomplete data could be included [31]. As differences in 
the outcome variables occurred at inflow of the study, these values were added in the 
final models. 
Effect sizes (ESs) (Cohen’s d) and their confidence intervals (CIs) were calculated for 
between-group differences at the endpoint of the study [32, 33]. Cohen defined an ES of ≥ 
0.2 as small, ≥ 0.5 as moderate and ≥ 0.8 as large [32]. ES calculations were based on the 
results of the mixed model analyses and were considered as statistically significant if zero 
was not included in the CI [33]. Data were analysed using SPSS, version 18.0 (SPSS Inc., 
Chicago, IL). 
 
Results 
A study flowchart is presented in Figure 2.1. From 242 eligible patients, 203 consented to 
participate in the observational study. They were randomised and allocated to the MD 
group (n=108), the AE group (n=47), and the UC group (n=48). After randomisation, the 
actual willingness to participate in the interventions was limited. In the MD group, seven 
patients did not attend > 70% of the scheduled sessions, as the intensity was difficult to 
combine with the care for their children, or interfered with other problems. Other reasons 
for attrition were difficulties with transportation and a lack of motivation. In the AE group, 
less than half of the randomised patients consented to start the intervention. Reasons 
mentioned were a lack of interest and difficulties with transportation. With regard to 12 
patients, we do not know the reason. Of those who started the intervention, only eight 
patients attended > 70% of the scheduled sessions. Reasons mentioned were physical 
problems and difficulties in combining the program with the care for their children. With 
regard to seven patients, we do not know the reason.  
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Figure 2.1 Study flowchart  
MD multidisciplinary intervention, AE aerobic exercise, UC usual care 
ITT intention-to-treat, PP per-protocol 
 
Table 2.1 Characteristics study population at inflow in the study 
MD multidisciplinary intervention, AE aerobic exercise. UC usual care 
 MD n=108 AE n=47 UC n=48 
 Started 
n=67 
Not 
started 
n=41 
Started 
n=19 
Not 
started 
n=28 
 
Age, mean (SD), years  41.6 (8.8) 41.3 (11.0) 43.9 (7.6) 39.1 (9.6) 42.9 (11.0) 
Female, % 94.0 92.7 100 100 97.9 
Duration of FM-related symptoms 
before diagnosis, mean (SD), years  
7.1 (6.8) 6.1 (5.4) 6.2 (7.0) 7.3 (6.1) 7.1 (6.4) 
Married/cohabiting, %  80.6 90.2 84.2 85.7 83.4 
Educational level, %  
        Low 
        Medium 
        High 
 
56.7 
29.9 
13.4 
 
58.5 
31.7 
9.8 
 
68.4 
26.3 
5.2 
 
53.6 
35.7 
10.7 
 
38.7 
40.9 
20.4 
Employed, %   52.5 48.8 57.9 57.1 50.0 
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Table 2.1 shows the characteristics of the study population at inflow in the study. Most 
participants were women and average FM-related symptom duration was seven years. 
Characteristics did not differ statistically significantly between patients who started the  
interventions and patients who did not start. As willingness to participate in the AE group 
was limited, this group has been analysed but interpretation of the data is considered 
arguable.  
 
Overall, intention-to-treat analyses showed improvements within the MD group and small 
differences between the groups at the endpoint of the study. Per protocol-analyses 
differed to some extent, but showed similar trends, as is shown in the tables. 
Within the MD group, statistically significant improvements were found in HR-Qol and 
improvements increased after finishing the 12-week program. Between the MD group and 
the UC group, a small, not statistically significant, difference at the endpoint of the study 
(ES 0.22, CI -0.12 to 0.56) was found on the EQ-VAS in favour of the MD group (Table 2.2).  
Table 2.2 Within-group and between-group results with regard to HR-Qol 
MD multidisciplinary intervention, AE aerobic exercise, UC usual care. 
ITT intention-to-treat, PP per-protocol 
* p < 0.05, difference within group; ** p < 0.001, difference within group
  
a
 Estimated marginal means (standard error) based on mixed model analysis with random intercept/random 
slope 
Results for participation are presented in Table 2.3. Within the MD group, a statistically 
significant reduction of hours sick leave was found and this decrease continued in the 
course of the study. Between the MD group and the UC group, a small, not statistically 
significant, difference at the endpoint of the study (ES -0.23, CI -0.57 to 0.11) was found in 
hours unpaid tasks and chores. 
 Intervention 
MD  ITT (n=108) 
           PP (n=67) 
AE      ITT (n=47) 
           PP (n=19) 
UC           (n=48) 
Inflow After the 
12-week 
program 
Endpoint 
 
Effect size 
between 
intervention 
group and UC at 
endpoint (CI 95%) 
EQ-5D 
a 
(-0.59-1) 
(higher is better) 
MD                 ITT 
                        PP 
0.36 (0.03) 0.49 (0.03) 0.55 (0.03)* 0.12 (-0.22, 0.46) 
0.34 (0.04) 0.48 (0.04) 0.54 (0.04)* 0.09 (-0.28, 0.46) 
AE                  ITT  0.41 (0.05) 0.47 (0.05) 0.54 (0.05) 0.10 (-0.31, 0.50) 
                        PP 0.40 (0.05) 0.54 (0.07) 0.62 (0.08) 0.33 (-0.21, 0.86) 
UC  0.51 (0.04) 0.50 (0.04) 0.51 (0.05)  
EQ-VAS
 a 
(0-100) 
 (higher is better) 
MD                 ITT 
                        PP 
48.1 (1.7) 54.0 (1.9) 57.3 (2.3)* 0.22 (-0.12, 0.56) 
45.7 (2.1) 55.1 (2.4) 57.6 (2.8)* 0.24 (-0.13, 0.61) 
AE                  ITT  53.2 (2.5) 53.9 (3.2) 53.3 (3.6) 0.05 (-0.35, 0.45) 
                        PP 57.1 (3.1) 56.4 (4.3) 59.6 (5.6) 0.32 (-0.22, 0.85) 
UC         54.0 (2.6) 48.3 (2.9) 51.9 (3.3)  
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Table 2.3 Within-group and between-group results with regard to participation 
 Intervention 
MD ITT  (n=108) 
         PP  (n=67) 
AE    ITT  (n=47) 
         PP   (n=19) 
UC           (n=48) 
Inflow After the 
12-week 
program 
Endpoint 
 
Effect size 
between 
intervention 
group and UC at 
endpoint (CI 95%) 
Contractual hours paid work 
per week 
b
 
MD                ITT 
                        PP 
13.1 (1.3) 11.3 (0.8) 11.0 (0.8) 0.00 (-0.34, 0.34) 
13.4 (1.7) 10.2 (1.0) 10.1 (1.0) -0.10 (-0.47, 0.27) 
AE                  ITT 13.4 (2.0) 10.7 (1.3) 11.4 (1.3) -0.01 (-0.41, 0.39) 
                        PP 13.5 (1.2) 10.6 (1.7) 11.4 (1.9) 0.04 (-0.49, 0.57) 
UC 11.6 (2.0) 12.3 (1.2) 11.0 (1.1)  
Hours sick leave per week 
b
 MD                 ITT 
                        PP 
9.2 (1.0) 4.8 (0.8) 1.2 (0.8)** 0.13 (-0.21, 0.47) 
10.4 (1.2) 5.5 (1.0) 0.8 (1.0)** 0.18 (-0.19, 0.55) 
AE                  ITT 5.8 (1.2) 3.4 (1.2) 2.5 (1.2) 0.04 (-0.37, 0.44) 
                        PP 7.6 (1.5) 3.7 (1.7) 1.2 (1.9) 0.13 (-0.40, 0.66) 
UC 3.3 (1.2) 3.7 (1.2) 2.3 (1.0)  
Hours unpaid tasks and 
chores per week 
b
 
MD                 ITT 
                        PP 
33.6 (2.2) 28.4 (1.8) 27.6 (1.8) -0.23 (-0.57, 0.11) 
29.2 (2.7) 26.1 (2.2) 27.4 (2.2) -0.25 (-0.62, 0.12) 
AE                  ITT 35.3 (3.5) 27.6 (2.9) 22.2 (2.9)* -0.56 (-0.93, -0.11) 
                        PP 35.0 (3.6) 23.1 (4.1) 16.5 (4.4)* -0.82 (-1.37, -0.27) 
UC 28.5 (2.9) 28.6 (2.7) 32.0 (2.6)  
Hours leisure and social  
activities per week 
b
 
MD                 ITT 
                        PP 
12.0 (0.9) 12.0 (0.9) 12.7 (0.9) 0.03 (-0.31, 0.37) 
12.4 (1.2) 13.0 (1.1) 12.7 (1.1) 0.03 (-0.34, 0.40) 
AE                  ITT 10.7 (1.2) 11.3 (1.4) 10.3 (1.4) -0.23 (-0.61, 0.20) 
                        PP 10.2 (1.4) 11.7 (1.9) 9.9 (2.1) -0.26 (-0.80, 0.27) 
UC 12.4 (1.4) 12.5 (1.4) 12.4 (1.3)  
MD multidisciplinary intervention, AE aerobic exercise, UC usual care. 
ITT intention-to-treat, PP per-protocol 
* p < 0.05, difference within group; ** p < 0.001, difference within group 
b
  Estimated marginal means (standard error) based on mixed model analysis with random intercept 
Table 2.4 shows the results with regard to health care utilisation. Within the MD group, a 
statistically significant reduction in number of contacts with GPs was found. Between the 
MD group and the UC group a small, not statistically significant, difference at the endpoint 
of the study (ES -0.28, CI -0.66 to 0.09) was found in favour of the UC group. Within both 
the MD and the UC group, a statistically significant reduction in number of contacts with 
medical specialists was found during the course of the study. Between the MD group and 
the UC group, a small, not statistically significant, difference at the endpoint of the study 
(ES -0.28, CI -0.62 to 0.06) was found with regard to number of contacts with other 
paramedical professionals, in favour of the UC group.  
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Table 2.4 Within-group and between-group results with regard to health care utilisation 
 Intervention 
MD ITT   (n=108) 
         PP    (n=67) 
AE    ITT    (n=47) 
         PP     (n=19) 
UC             (n=48) 
Inflow After the  
12- 
week 
program 
Endpoint 
 
Effect size 
between 
intervention  
group and UC at 
endpoint (CI 95%) 
Nr of contacts GPs 
b
 
c
 MD                     ITT 
                            PP 
2.3 (0.3) 1.0 (0.2) 0.9 (0.2)** -0.11 (-0.45, 0.23) 
2.6 (0.4) 0.7 (0.3) 1.3 (0.3)* -0.28 (-0.66, 0.09) 
AE                       ITT 3.3 (0.8) 1.5 (0.4) 1.0 (0.4)* -0.10 (-0.48, 0.32) 
                            PP 4.0 (0.9) 1.7 (0.5) 1.0 (0.6) -0.15 (-0.68, 0.39) 
UC  1.4 (0.3) 0.5 (0.3) 0.7 (0.3)  
Nr of contacts  
medical specialists 
b
 
c
  
MD                     ITT 
                            PP 
1.9 (0.1) 0.1 (0.1) 0.3 (0.1)** -0.14 (-0.48, 0.20) 
2.1 (0.1) 0.2 (0.1) 0.3 (0.1)** -0.17 (-0.54, 0.20) 
AE                       ITT 1.9 (0.2) 0.3 (0.1) 0.4 (0.1)** -0.29 (-0.58, 0.22) 
                            PP 1.9 (0.1) 0.3 (0.2) 0.2 (0.2)** -0.03 (-0.56, 0.50) 
UC  1.6 (0.1) 0.2 (0.1) 0.2 (0.1)**  
Nr of contacts  
physiotherapists 
b
 
c
  
MD                     ITT 
                            PP 
2.7 (0.5) 2.2 (0.5) 2.6 (0.5) 0.04 (-0.30, 0.38) 
2.6 (0.6) 2.1 (0.7) 3.1 (0.7) -0.06 (-0.43, 0.31) 
AE                       ITT 1.9 (0.2) 0.3 (0.1) 0.4 (0.1)** -0.29 (-0.58, 0.22) 
                            PP 4.0 (1.1) 2.3 (1.2) 2.2 (1.3) 0.11 (-0.42, 0.64) 
UC  1.0 (0.5) 3.4 (0.7) 2.8 (0.7)  
Nr of contacts  
other paramedical  
professionals 
b
 
c
  
MD                     ITT 
                            PP 
1.1 (0.3) 0.8 (0.3) 1.0 (0.3) -0.28 (-0.62, 0.06) 
1.3 (0.4) 0.7 (0.4) 1.3 (0.4) -0.36 (-0.73, 0.02) 
AE                       ITT  1.1 (0.4) 0.6 (0.5) 2.1 (0.5) -0.68 (-1.00, -018) 
                            PP      0.7 (0.6) 0.7 (0.6)  0.4 (0.7) -0.74 (-1.28, -0.19) 
UC       0.6 (0.2) 0.8 (0.4)  0.2 (0.4)  
MD multidisciplinary intervention, AE aerobic exercise, UC usual care. 
ITT intention-to-treat, PP per-protocol 
* p < 0.05, difference within group; ** p < 0.001, difference within group 
b
  Estimated marginal means (standard error) based on mixed model analysis with random intercept  
c
  Total number consultations over a period of 2 months prior to measurement 
Differences in impact of FM on daily functioning are presented in Table 2.5. Within the MD 
group, statistically significant improvements were found on almost all FIQ-subscales and 
on the FIQ-total score and improvements increased in the course of the study. Between 
the MD and the UC group a small, not statistically significant, difference at the endpoint of 
the study (ES 0.25, CI -0.09 to 0.59) was found with regard to the FIQ-total score in favour 
of the MD group.  
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Table 2.5 Within-group and between-group results with regard to impact of FM on daily functioning 
Fibromyalgia Impact  
Questionnaire  
Intervention 
MD ITT    (n=108) 
        PP     (n=67) 
AE   ITT     (n=47) 
       PP       (n=19) 
UC             (n=48) 
Inflow After the 
12-week 
program 
Endpoint Effect size 
between 
intervention group 
and UC at 
endpoint(CI 95%) 
Physical function
  a
  
(0-10, lower is better) 
MD                       ITT 
                               PP 
4.2 (0.2) 3.9 (0.2) 3.6 (0.2) 0.12 (-0.22, 0.46) 
4.5 (0.2) 4.1 (0.2) 3.7 (0.3) 0.08 (-0.29, 0.45) 
AE                         ITT 3.6 (0.2) 3.7 (0.3) 3.6 (0.4) 0.11 (-0.29, 0.52) 
                               PP 3.7 (0.2) 3.6 (0.4) 3.6 (0.6) 0.12 (-0.41, 0.65) 
UC  3.4 (0.3) 4.0 (0.3) 3.9 (0.3)  
Days feel good
  a
  
 (0-10, lower is better) 
 
MD                       ITT 
                               PP 
7.3 (0.2) 5.6 (0.3) 5.2 (0.3)** 0.24 (-0.10, 0.58) 
7.8 (0.3) 5.7 (0.3) 5.5 (0.4)** 0.15 (-0.22, 0.52) 
AE                         ITT 6.9 (0.3) 5.5 (0.4) 4.6 (0.5) 0.41 (0.00, 0.81) 
                               PP 6.9 (0.5) 5.0 (0.6) 4.5 (0.8)* 0.44 (-0.09, 0.98) 
UC  6.0 (0.4) 6.5 (0.4) 5.9 (0.5)  
Days not missed work 
a
 
(0-10, lower is better) 
MD                       ITT 
                               PP 
2.8 (0.5) 2.1 (0.5) 1.0 (0.4)* -0.06 (-0.40, 0.28) 
3.6 (0.7) 2.4 (0.6) 0.5 (0.6)* 0.04 (-0.33, 0.41) 
AE                         ITT 2.0 (0.5) 0.4 (0.5) 1.6 (0.7) -0.18 (-0.59, 0.22) 
                               PP 2.8 (0.9) 0.5 (0.8) 1.7 (1.0) -0.21 (-0.74, 0.32) 
UC  0.7 (0.4) 1.1 (0.7) 0.7 (0.7)  
Job ability 
a
 
(0-10, lower is better) 
MD                       ITT 
                               PP 
7.4 (0.3) 6.0 (0.3) 5.6 (0.3)** 0.06 (-0.28, 0.40) 
8.0 (0.3) 6.4 (0.4) 5.6 (0.4)** 0.06 (-0.31, 0.43) 
AE                         ITT 6.3 (0.3) 5.6 (0.4) 5.1 (0.5) 0.20 (-0.20, 0.60 
                               PP 5.9 (0.4) 6.0 (0.6) 4.3 (0.8) 0.43 (-0.10, 0.97) 
UC  5.8 (0.4) 6.1 (0.4) 5.8 (0.5)  
Pain
 a
  
(0-10, lower is better) 
MD                       ITT 
                               PP 
6.3 (0.2) 5.5 (0.2) 5.3 (0.2)** -0.01 (-0.35, 0.33) 
6.3 (0.2) 5.4 (0.2) 5.4 (0.3)* -0.06 (-0.43, 0.31) 
AE                         ITT 6.2 (0.3) 5.3 (0.3) 5.2 (0.4) 0.05 (-0.36, 0.44) 
                               PP 6.1 (0.3) 5.3 (0.4) 4.2 (0.5) 0.46 (-0.08, 0.99) 
UC  5.5 (0.3) 5.7 (0.3) 5.3 (0.3)  
Fatigue 
a
 
(0-10, lower is better) 
MD                       ITT 
                              PP 
8.3 (0.2) 7.5 (0.2) 7.0 (0.3)** 0.18 (-0.16, 0.52) 
8.3 (0.2) 7.4 (0.3) 7.2 (0.3)* 0.12 (-0.25, 0.49) 
AE                         ITT 8.0 (0.2) 7.4 (0.2) 7.0 (0.4) 0.18 (-0.22, 0.59) 
                               PP 7.7 (0.3) 7.2 (0.5) 6.0 (0.6) 0.57 (0.03, 1.11) 
UC  7.4 (0.3) 7.2 (0.3) 7.5 (0.4)  
Unrefreshed sleep 
a
 
 (0-10, lower is better) 
 
MD                       ITT 
                               PP 
8.2 (0.2)        7.5 (0.2)    7.1 (0.3)** 0.19 (-0.15, 0.53) 
8.5 (0.2)        7.3 (0.3)    7.2 (0.3)** 0.16 (-0.21, 0.53) 
AE                         ITT 8.1 (0.26)        7.0 (0.33)    7.2 (0.40)* 0.16 (-0.60, 0.90) 
                               PP 7.7 (0.3)        6.8 (0.5)    6.3 (0.6) 0.50 (-0.04, 1.03) 
UC  7.6 (0.3)        7.2 (0.3)    7.6 (0.4)  
Stiffness 
a
 
(0-10, lower is better) 
MD                       ITT 
                               PP 
7.1 (0.2)        6.7 (0.2)    6.1 (0.3)* 0.07 (-0.27, 0.41) 
7.1 (0.2)        6.6 (0.3)    6.1 (0.3) 0.07 (-0.30, 0.44) 
AE                         ITT 7.3 (0.2)        6.2 (0.3)    5.9 (0.4)* 0.14 (-0.26, 0.54) 
                               PP 7.2 (0.4)        5.5 (0.5)    4.9 (0.7) 0.49 (-0.05, 1.03) 
UC  6.8 (0.4)        6.3 (0.3)    6.3 (0.4)  
Anxiety 
a 
(0-10, lower is better) 
MD                       ITT 
                               PP 
5.9 (0.3)        5.0 (0.2)    4.7 (0.3)* 0.03 (-0.31, 0.37) 
6.0 (0.3)        4.9 (0.3)    4.4 (0.4)* 0.14 (-0.24, 0.51) 
AE                         ITT 4.9 (0.3)        4.6 (0.4)    5.0 (0.5) -0.06 (-0.46, 0.34) 
                               PP 5.2 (0.4)        4.9 (0.6)    4.9 (0.7) -0.03 (-0.56, 0.50) 
UC  4.8 (0.4)        5.2 (0.4)    4.8 (0.4)  
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Table 2.5 continued 
Depression 
 a 
(0-10, lower is better) 
MD                       ITT 
                               PP 
5.2 (0.3) 4.1 (0.3) 3.9 (0.3)* 0.10 (-0.24, 0.44) 
5.2 (0.3) 4.0 (0.3) 3.9 (0.3)* 0.10 (-0.27, 0.47) 
AE                         ITT 4.8 (0.3) 4.6 (0.4) 5.0 (0.5) 0.09 (-0.31, 0.49) 
                               PP 4.9 (0.4) 4.1 (0.6) 3.6 (0.7) 0.20 (-0.33, 0.73) 
UC  4.2 (0.4) 4.5 (0.4) 4.2 (0.4)  
FIQ-total 
a
 
(0-100, lower is better) 
MD                       ITT 
                               PP 
64.5 (1.4) 55.1 (1.5) 50.9 (2.0)** 0.25 (-0.09, 0.59) 
66.3 (1.8) 54.6 (1.9) 51.2 (2.3)** 0.25 (-0.12, 0.62) 
AE                         ITT 60.0 (2.1) 53.2 (2.4) 52.0 (3.2)* 0.22 (-0.20, 0.61) 
                               PP 59.2 (2.5) 52.3 (3.6) 47.4 (4.7) 0.42 (-0.12, 0.95) 
UC  55.4 (2.3) 58.1 (2.3) 56.2 (2.9)  
MD multidisciplinary intervention, AE aerobic exercise, UC usual care. 
ITT intention-to-treat, PP per-protocol 
* p < 0.05, difference within group; ** p < 0.001, difference within group 
a 
Estimated marginal means (standard error) based on mixed model analysis with random intercept/random 
slope  
 
Discussion 
To our knowledge, this is the first trial in recently diagnosed FM patients examining the 
effect of a multidisciplinary intervention on HR-Qol, participation, and health care 
utilisation. Patients in the MD group experienced statistically significant improvements in 
HR-Qol and reduced their absence from paid work, visits to GPs and visits to medical 
specialists. Improvements were found immediately after completion of the intervention, 
largely sustained and even increased, also during the follow-up period which was one year 
after completion of the 2-phased program. Patients in the UC group experienced no 
changes in HR-Qol and only a statistically significantly reduction in the number of contacts 
with medical specialists was found. However, at the end of the study, the differences 
between the MD group and the UC group were small and not statistically significant for 
any of the outcomes studied. 
Despite relevant improvements, HR-Qol was still low at the end of the trial confirming the 
large impact of FM on quality of life [34]. While overall health care utilisation tended to 
decrease, the high number of visits to physiotherapists during the study may be explained 
by the advice to perform physical activity and muscle training which was given in all 
groups as usual. In the Dutch health care system, patients may prefer reimbursed 
opportunities, like physiotherapy, above community programs. Results from interventions 
in FM patients with regard to health care utilisation are limited [35, 36]. It is arguable if 
diagnosing the disorder may have some treatment effect in itself [37]. However, 
improvements in the UC group suggest that it influenced our results with regard to the 
reduction in health care utilisation. Results on the FIQ are largely comparable with results 
from other studies but in contrast to other studies the found results sustained and even 
increased in the MD group, also during the follow-up period, which was one year  after  
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finishing the 2-phased program [11]. 
The MD intervention was characterised by a low attrition, resembling the situation in the 
pilot-study, which suggests that the treatment indeed has met the needs and expectations 
of the patients that consented to participate [14]. The limited consent to participate in the 
AE group is similar to what was seen in other studies and suggests that AE meets the 
needs of only a select group of FM patients [38]. We mainly aimed to study the impact of 
the intervention in patients in the early stages of the disease. Surprisingly, the mean 
symptom duration in the study population turned out to be seven years. Apparently, 
patients retrospectively recognised earlier symptoms as FM symptoms.  
Some methodological challenges appeared in the study. First, in view of known difficulties 
to perform blinded or placebo-control group studies in multidisciplinary interventions, a 
Zelen-design was chosen in order to avoid bias by expectation. Following this design, 
patients were invited to participate in the interventions only after randomisation, 
immediately after they were diagnosed by the rheumatologist. Some patients asked for a 
time period to learn more about FM and to get more insight in their needs before starting 
the intervention. Consequently, they sometimes decided not to start after all. Although 
this likely reflects what happens in clinical practice it also affected the power of the study. 
More insight in the variation of expectations and attitudes from patients towards non-
pharmacological interventions is needed, preferably in the light of available evidence 
about such interventions. An in-depth exploration of the patient’s expectations and 
attitude may be an alternative for the Zelen-design to address the issue of expectation-
bias in future research on effective interventions for FM [39]. Expectation bias in RCTs is 
usually ignored since patients can refuse to participate when they are invited. Second, 
invariably the largest changes were found in the MD group. Despite randomisation, the 
MD group turned out to be group with the worst condition at inflow and thus had the 
largest potential for improvement. Although these data are suggestive for regression to 
the mean, the choice for mixed model analysis results in an accurate representation of the 
improvements over time. However, the baseline differences affect the interpretation of 
the study results as it cannot be excluded that improvements would have been similar if 
the groups were comparable at inflow in the study. Third, as in many studies, 
heterogeneity of the study population appeared. Some literature showed more 
homogeneity and promising results, due to selection of patients [40] or to intangible 
effects [41, 42]. However, given the large number of studies, discussion about the tools to 
classify FM patients into different phenotypic subgroups is still going on. Finally, when 
interpreting results it should be taken into account that these results apply to patients 
referred to rheumatology outpatient clinics and cannot be generalised to patients in other 
settings such as patients in a GP setting. 
In summary, this pragmatic trial in recently diagnosed patients with FM, which comprised 
several outcomes of societal relevance, was not able to show statistically significantly 
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between-group differences at the end of the study. The absence of between-group 
differences can be partially explained by both (a) a lack of statistical power of our study, 
attributable to a limited willingness for participation in the interventions, and (b) baselines 
between-group differences despite randomisation. Notwithstanding, the study findings do 
give insight in changes that occur in longitudinal outcomes, independent from 
interventions. They furthermore contribute to insight in barriers for the implementation of 
care programs for patients with FM. Methodological limitations of the study prevent to 
draw a firm conclusion about specific effects attributable to the multidisciplinary 
intervention.  
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Abstract  
Objective. The aim of this study was to understand the course of costs over a 2-year 
period in a cohort of recently diagnosed fibromyalgia patients who are offered one of 
three possible interventions.  
Methods. Following the diagnosis, patients were assigned to a multidisciplinary program 
(MD), aerobic exercise (AE) or usual care (UC). Health care costs and costs for patients and 
families were collected by means of 2-monthly questionnaires. Mixed linear model 
analyses (MLM) were used to examine the course of costs over time. Linear regression 
was used to explore predictors of health care costs in the post treatment period.  
Results. 203 participants, 90% women, mean (SD) age 41.7 (9.8) years, were included in 
the cohort. Intervention costs per patient varied from € 864 to € 1,392 for MD, and were  
€ 121 for AE. Health care costs in each group decreased after diagnosis. MLM indicated 
that further health care costs, excluding the program costs of MD and AE, increased again 
over time, but in the UC group this increase already started pre-treatment. In contrast, 
patient & family costs increased over time in all groups without initial decrease after 
diagnosis. Annualised health care costs at post treatment varied between € 1,872 and       
€ 2,310 per patient and were associated with worse functioning and high health care costs 
at diagnosis. 
Conclusion. In patients with FM, health care costs decrease after diagnosis. Offering 
patients a specific treatment program after the diagnostic phase incurs substantial costs, 
and only marginally reduces the increase in costs that is seen in patients receiving UC. 
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Introduction 
Fibromyalgia (FM) is characterised by chronic widespread musculoskeletal pain, often 
accompanied by other clinical manifestations such as fatigue and stiffness, but also 
cognitive dysfunction or mood disorders [1, 2]. FM typically affects women in the working 
age. The prevalence of FM as reported among adults in Europe and in the US varies 
between 2% and 4% [3, 4]. While the aetiology of FM is unknown, the impact for the 
patient is high in terms of physical and mental suffering [5]. Moreover, FM is associated 
with substantial health care resource utilisation and productivity loss, resulting in 
considerable societal cost-of-illness [3, 6-8]. The average societal cost per patient of FM is 
comparable or even higher than of rheumatoid arthritis (RA) or ankylosing spondylitis (AS). 
When accounting for the prevalence, however, the societal burden of FM is higher than 
that of RA or AS [9, 10].  
A variety of interventions have been studied, among which multi-modal non-
pharmacological programs as well as pharmacological therapies [11, 12]. However, the 
effectiveness of these interventions showed conflicting results [13-17]. In the absence of 
substantial clinical effects, the cost-effectiveness of treatments in FM is disappointing. The 
importance of a prompt diagnosis and the start of an early intervention are increasingly 
recognised [18, 19], but results about effects of early interventions are limited to one 
randomised controlled trial on integrated group therapy that showed sustained 
improvement in patients with shorter disease duration [20]. Research based on claims 
databases suggested an influence of the diagnosis of FM itself on health care costs, but 
results are conflicting; two studies showed that a diagnosis of FM increases costs, 
primarily attributable to an increased use of medication in the course of the disease in 
usual care [21, 22], while two others suggested a reduction in costs attributable to a 
decrease in the number of visits to health care providers [23, 24]. The clinical burden of 
FM and the gaps of available evidence based treatment recommendations justify a 
continuous quest for innovations aimed at improving the outcomes [11, 12]. Such 
innovations should show effectiveness but also cost-effectiveness. 
The present research aims to provide insight in costs over a 2-year period in a cohort of 
FM patients that were recently diagnosed by a rheumatologist and were assigned in a 
pragmatic trial to one of three different interventions: a partially individualised 
multidisciplinary intervention with aftercare (MD), aerobic exercise (AE) and usual care 
(UC).  
 
Methods  
A 2-year analysis of costs in a pragmatic trial embedded in an observational study.  
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Participants 
A cohort of 203 recently diagnosed FM patients (according to the American College of 
Rheumatology criteria) [1] from the Rheumatology Department were asked to participate 
in an observational study. Patients that consented were randomised to MD (n=108), AE 
(n=47), or UC (n=48). Patients assigned to MD or AE were again asked to consent to 
participate in the programs. The study was approved by the Medical Ethical Committees 
of the participating medical centres. The precise procedures in this pragmatic trial, 
registration number ISRCTN32542621, have been published elsewhere [25]. 
 
Interventions 
The MD intervention program was a 2-phased group program of one year. Phase l 
consisted of a 12-week course (three half days per week) with two therapy sessions of 1,5 
hours per day of socio-therapy, physiotherapy, psychotherapy or creative arts therapy. 
Phase ll was an aftercare program that was provided over the course of the remaining 
year and consisted of five group meetings, scheduled over a period of nine months. In 
addition to these meetings, a maximum of seven individual therapy sessions with one of 
the therapists could be scheduled if considered necessary by the therapist and/or the 
patient. The AE intervention program was a 12-week group course which was given twice 
a week by a trained physiotherapist in a community gym, based on recommendations for 
exercise [26]. The UC arm received only ‘care as usual’ that comprised at least 
individualised education about FM and lifestyle advice by a rheumatologist or a specialised 
rheumatology nurse within one or two consultations, but could also include referral to 
other treatments, such as physiotherapy, or social support from the rheumatology nurse.  
 
Baseline variables 
Demographic characteristics (age, gender, education) and health status were assessed by 
means of patient-reported questionnaires at entry in the observational study. Health 
status comprised symptom duration and Fibromyalgia Impact Questionnaire (FIQ) that 
consists of 10 items on health in the past week: physical functioning, numbers of days feel 
good, number of days missed work, interference of symptoms with ability to activities, 
pain, fatigue, unrefreshed sleep, stiffness, anxiety, and depression [27]. Each item-score 
was standardised on a 0-10 scale after which a FIQ-total score (0-100) was calculated [27].  
 
Cost questionnaires and cost valuation 
Self-reported health care resource use and costs for patients and their families served as a 
basis for the cost analysis and were collected by means of a 2-monthly questionnaire over 
a total study period of two years. In each questionnaire patients had to indicate the 
number of visits to general practitioners (GPs), medical specialists, physiotherapists, and 
other paramedical therapists such as psychologists, the prescribed medication taken, the 
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kind of assistive devices purchased, and the number of hours professional home help 
received during the two months prior to measurement [28]. Next, patients had to indicate 
the frequency with which they had participated in different types of health activities, the 
number and type of over the counter drugs that were purchased, the number of hours 
help from spouses, other relatives, or paid household help received, and the number of 
prepared meals used, during the two months prior to measurement [28].  
From these items, costs were calculated. Health care costs were calculated by multiplying 
the number of each resource used with its unit cost, derived from the Dutch Cost Manual 
or the Pharmacoeconomic Compass. If prices were not available, market prices or tariffs 
were used [29-31]. With regard to ‘patient & family costs’, the number of resources used 
were multiplied by patient reported price or unit costs, or, in the case of informal home 
care, by shadow prices [31]. Finally, total health care costs or patient & family costs were 
calculated by summing the costs from each resource category. Costs for travel expenses 
per patient were included in the total costs for visits. Total direct costs were the sum of 
health care costs and patient & family costs. All cost items and price values are presented 
in Table 3.1. 
 
Intervention costs 
The time input from all health care providers in the MD or AE group sessions were the 
basis of the calculation of all direct costs of the interventions. Total costs were calculated 
by summing the product of each hour of work by the salary per hour, including 39% 
charges for social security. For the total intervention period, 45% charges for overhead, 
such as for use of accommodation, were added [31]. Then, the total calculated costs for 
MD or AE were divided by the mean number of participants per group, resulting in a price 
per person per program. Intervention costs were included for every person that started 
the interventions, even if patients did not complete the programs. Again, costs for travel 
expenses were included in all visits. If the sources for costs provided a unit cost for a year 
before 2010, costs were indexed using the Dutch consumer price index rate (Centraal 
Bureau voor de Statistiek, Den Haag, Netherlands, www.cbs.nl) [31] (see Table 3.1). 
 
Periods of interest 
To understand the course of resource utilisation and average costs over different clinical 
meaningful episodes, we distinguished four periods: the diagnostic phase, representing 
the two months before referral to the rheumatologists and the rheumatologist’s diagnosis 
of FM (diagnosis), the average 2-monthly costs in the period after the diagnosis, but 
before the intervention (pre-treatment), the costs during the intervention (during 
treatment) and the average 2-monthly costs in the period after the intervention (post 
treatment). The start of the MD and AE program varied in time among individual patients. 
As a consequence, the average number of questionnaires available for the period between 
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diagnosis, but before the start of the MD or AE programs varied between 2 and 6, and 
after the programs between 5 and 9, while the main intervention period itself was always 
represented by one questionnaire. Since the UC group did not receive a planned 
intervention, the number of questionnaires for each period of interest were randomly 
linked to respondents in either the MD group or the AE group to achieve similar time 
periods.  
Table 3.1 Cost categories, units and sources of estimate, costs in Euro (€) per unit (including travelling expenses) 
Cost category Source of estimate Cost per unit, €  
Interventions   
Multidisciplinary program    
     Phase I: program Hakkaart-van Roijen, calculated [31]  863.94/program 
     Phase II: aftercare Hakkaart van Roijen, calculated [31] 85.79/program  
     Individual socio therapy Hakkaart-van Roijen, calculated [31] 50.23/contact 
     Individual creative therapy Hakkaart van Roijen, calculated [31] 50.23/contact 
     Individual psychotherapy Hakkaart-van Roijen, calculated [31] 63.17/contact 
          Aerobic exercise Hakkaart van Roijen, calculated [31] 120.47/program 
Health care costs   
    General practitioner   
          Practice Hakkaart-van Roijen [31] 31.58/contact 
          Home visits Hakkaart-van Roijen [31]  43.56/contact 
          Telephone Hakkaart-van Roijen [31] 14.18/contact 
          Out of hours services, practice Hakkaart-van Roijen [31] 67.42/contact 
          Out of hours services, telephone   Hakkaart-van Roijen [31] 26.26/contact 
    Medical specialist outpatient service        
          Academic Hakkaart-van Roijen [31] 135.08/contact 
          Not academic Hakkaart-van Roijen [31] 69.23/contact 
    Paramedical professionals   
          Physiotherapy Hakkaart-van Roijen [31] 39.91/contact 
          Cesar or Mensendieck therapy Hakkaart-van Roijen [31] 38.90/contact 
          Occupational therapy Hakkaart-van Roijen [31] 38.90/contact 
          Social work Hakkaart-van Roijen [31] 69.29/contact 
          Activity therapy Hakkaart-van Roijen, calculated [31] 
(a)
 19.90/contact 
          Psychotherapy Hakkaart-van Roijen [31] 82.96/contact 
          Other  Patient reported costs Various/contact 
    Prescribed medications Pharmaco therapeutic compass 2007 [29] Various/DDD
(b)
 
    Assistive devices Estimated market price 
(c)
 Various 
    Professional home help Hours [31] 24.31/hour 
 Patient and family costs   
    Health activities Patient reported costs Various 
    Over the counter medications Patient reported costs Various  
    Prepared meals Estimated market price  7.26/meal 
    Paid home help Patient reported costs Various/hour 
    Informal care Hakkaart-van Roijen [31] 12.66/hour 
a. Group session, based on costs for social work: costs individual session/4,  b. DDD: daily defined dosage  
c.     Various websites: www.thuiszorgwinkel.nl, www.groenekruisdomicurazorg.nl, www.medireva.nl  
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Statistical analysis 
Patients were analysed in the groups to which they were assigned. Missing data occurred 
during the course of the study (12%-30%), and in order to achieve complete data, missing 
data were imputed using a non-parametric regression forest method [32].  
Health resource use and costs across treatment groups and time points are presented as 
means (SDs) or medians with interquartile ranges (IQR), or as percentages if appropriate. 
Mixed linear model analyses (MLM) were used to assess differences between the 
intervention groups in the longitudinal course of health care costs and patient & family 
costs, with the baseline values of the dependent variables as covariates in the models. 
Mean between-group differences of the direct costs in and excluding intervention costs 
over the 2-year period were tested using a non-parametric bootstrap method to obtain 
95% confidence intervals.  
To explore predictors of the health care costs after the treatment program, a linear 
regression analysis on the square roots transformed costs was performed, entering as 
predictors age, symptom duration, educational level, FIQ-total score, and health care costs 
in the diagnostic phase. Data imputation was performed using R2.10.1 and all other 
analyses were performed using IBM SPSS Statistics 20.0. 
 
Results 
Baseline characteristics of the patients are presented in Table 3.2. The mean age was 41 
years, and the majority of patients were female. Between 13% and 20%, had a high 
educational level and about half of the patients were employed. Results on the 
effectiveness of the three interventions within this cohort have been published recently 
[25]. 
Table 3.2 Characteristics of the patients at entry into the observational cohort 
MD multidisciplinary intervention, AE aerobic exercise, UC usual care 
FIQ Fibromyalgia Impact Questionnaire 
 MD  
(n=108) 
AE  
(n=47) 
UC  
(n=48) 
Age, mean (SD), years  41.5 (9.6) 41.0 (9.0) 42.9 (11.0) 
Female, %  93.5 100 97.9 
Duration FM-related symptoms, mean (SD), years  6.9 (6.2) 6.9 (6.1) 7.1 (6.4) 
FIQ-total score (0-100), mean (SD)  64.5 (13.7) 60.0 (12.3) 55.4 (15.1) 
Married or cohabiting, % 84.2 85.1 83.4 
Educational level, %  
        Low 
        Medium 
        High 
 
56.9 
30.8 
12.3 
 
57.8 
33.3 
8.9 
 
38.7 
40.9 
20.4 
Work status, % employed  49.5 57.6 50.0 
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The course of health care as well as patient & family resource utilisation in the three 
groups is presented in Table 3.3.  
Table 3.3 Health care and patient & family resource use per patient  
MD n=108 
AE n=47 
UC n=48 
 Diagnosis Pre-treatment
A
 During 
treatment 
Post treatment
B
 
 Health care 
 GP 
 
 
 Medical 
specialists 
 
Physiotherapist 
 
 
Other 
paramedical 
professionals 
Formal home help 
 
 
Use prescribed 
drugs (% yes) 
 
Use assistive 
devices (% yes) 
 
MD 
AE 
UC 
MD 
AE 
UC 
MD 
AE 
UC 
MD 
AE 
UC 
MD 
AE 
UC 
MD 
AE 
UC 
MD 
AE 
UC 
 
2.3, 1.0 (0.0,3.0) 
3.3, 1.0 (0.0,2.0) 
1.4, 1.0 (0.0,2.0) 
2.0, 2.0 (1.0,2.0) 
1.9, 2.0 (1.0,2.0) 
1.6, 1.5 (1.0,2.0) 
2.7, 0.0 (0.0,4.0) 
2.9, 0.0 (0.0,4.0) 
1.0, 0.0 (0.0,3.0) 
1.1, 0.0 (0.0,0.0) 
1.1, 0.0 (0.0,1.0) 
0.6, 0.0 (0.0,0.0) 
0.1, 0.0 (0.0,0.0) 
0.0, 0.0 (0.0,0.0) 
0.1, 0.0 (0.0,0.0) 
73.1 
59.6 
66.7 
5.6 
2.1 
6.3 
 
1.0, 0.5 (0.0,1.3) 
1.0, 0.5 (0.0,1.5) 
0.4, 0.0 (0.0,0.5) 
0.3, 0.0 (0.0,0.4) 
0.4, 0.0 (0.0,0.5) 
0.4, 0.0 (0.0,0.5) 
1.8, 0.0 (0.0,2.0) 
2.2, 0.0 (0.0,4.0) 
1.3, 0.0 (0.0,0.9) 
0.6, 0.0 (0.0,0.6) 
1.2, 0.5 (0.0,1.8) 
1.2, 0.0 (0.0,1.0) 
0.2, 0.0 (0.0,0.0) 
0.0, 0.0 (0.0,0.0) 
0.1, 0.0 (0.0,0.0) 
58.6 
60.5 
41.3 
7.2 
5.8 
3.2 
 
1.2, 1.0 (0.0,1.8) 
2.1, 1.0 (0.0,2.5) 
0.5, 0.0 (0.0,0.5) 
0.2, 0.0 (0.0,0.2) 
0.2, 0.0 (0.0,0.2) 
0.4, 0.0 (0.0,0.6) 
2.3, 0.0 (0.0,2.3) 
2.2, 1.0 (0.0,1.3) 
2.6, 0.0 (0.0,2.6) 
0.8, 0.0 (0.0,0.9) 
1.0, 0.0 (0.0,1.7) 
1.2, 0.0 (0.0,2.6) 
0.4, 0.0 (0.0,0.0) 
1.0, 0.0 (0.0,0.0) 
0.6, 0.0 (0.0,0.0) 
60.0 
56.3 
39.5 
3.5 
6.3 
5.3 
 
1.1, 0.8 (0.3,1.6) 
1.2, 0.8 (0.4,1.7) 
0.8, 0.9 (0.3,1.1) 
0.5, 0.2 (0.0,1.0) 
0.8, 0.7 (0.1,1.6) 
0.5, 0.4 (0.0,0.9) 
3.2, 2.1 (0.3,5.3) 
2.3, 1.7 (1.1,2.1) 
2.7, 1.6 (0.2,2.9) 
1.9, 0.9 (0.0,4.1) 
2.0, 1.9 (0.2,3.5) 
1.6, 1.3 (0.0,3.1) 
0.4, 0.0 (0.0,0.0) 
1.1, 0.0 (0.0,0.0) 
0.5, 0.0 (0.0,0.0) 
52.3 
53.0 
48.5 
3.4 
5.5 
8.8 
 Patient & family  
Paid home help 
 
MD 
 
0.1, 0.0 (0.0,0.0) 
 
0.1, 0.0 (0.0,0.0) 
 
0.0, 0.0 (0.0,0.0) 
 
0.3, 0.0 (0.0,0.5) 
  AE 0.2, 0.0 (0.0,0.0) 0.2, 0.0 (0.0,0.0) 0.4, 0.0 (0.0,0.8) 0.8, 0.0 (0.0,1.7) 
  UC 0.0, 0.0 (0.0,0.0) 0.2, 0.0 (0.0,0.0) 0.1, 0.0 (0.0,0.0) 0.1, 0.0 (0.0,0.2) 
Informal care MD 0.4, 0.0 (0.0,0.0) 0.6, 0.0 (0.0,0.0) 1.6, 0.0 (0.0,1.5) 0.9, 0.0 (0.0,1.1) 
  AE 0.1, 0.0 (0.0,0.0) 0.7, 0.0 (0.0,0.5) 1.2, 0.0 (0.0,1.3) 1.1, 0.4 (0.0,1.6) 
  UC 0.3, 0.0 (0.0,0.0) 0.3, 0.0 (0.0,0.0) 0.6, 0.0 (0.0,0.4) 0.6, 0.0 (0.0,0.8) 
Prepared meals MD 0.0, 0.0 (0.0,0.0) 0.0, 0.0 (0.0,0.0) 0.1, 0.0 (0.0,0.0) 0.0, 0.0 (0.0,0.0) 
  AE 0.0, 0.0 (0.0,0.0) 0.0, 0.0 (0.0,0.0) 0.0, 0.0 (0.0,0.1) 0.0, 0.0 (0.0,0.0) 
  UC 0.0, 0.0 (0.0,0.0) 0.0, 0.0 (0.0,0.0) 0.0, 0.0 (0.0,0.0) 0.0, 0.0 (0.0,0.0) 
Perform health 
activities (% yes) 
MD 24.1 21.7 29.4 33.1 
AE 27.7 36.0 34.4 35.0 
UC 16.7 28.6 39.5 18.8 
Use over the 
counter 
medication (%yes) 
MD 53.7 47.4 42.4 45.0 
AE 40.4 37.2 31.3 31.3 
UC 56.3 57.1 68.4 58.8 
MD multidisciplinary intervention, AE aerobic exercise, UC usual care 
A, B
 Average 2-monthly mean, median (IQR) or percentages of resource use over the period 
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Visits to GPs, medical specialists, physiotherapists and other paramedical professionals all 
decreased in each group after the diagnostic phase. In the AE group, visits to medical 
specialists and other paramedical professionals further decreased during the intervention 
program, whereas visits to the physiotherapist increased in the MD and UC group, and the 
use of formal home help increased in the three groups. After the intervention (post 
treatment), visits to medical specialists, physiotherapists and other paramedical 
professionals increased again in each group, but remained lower than in the diagnostic 
phase for visits to GPs, medical specialist, and medication utilisation, while becoming 
higher compared to pre-treatment for visits to physiotherapists, paramedical 
professionals and formal home care. With regard to patient & family costs, the largest 
increase in costs was seen in attending health activities, and in need for help, e.g. paid 
home help or informal care.  
Figure 3.1 The course of health care costs and patient & family costs  
The figure presents median, IQR, range and outliers. Costs per 2 month, averaged over the period  
MD multidisciplinary intervention, AE aerobic exercise, UC usual care 
Figure 3.1 shows that the average health care costs, excluding intervention costs, 
decreased statistically significantly after diagnosis, but before the intervention program in 
all groups. During the intervention program, costs in the AE group tended to decrease 
further and remained unchanged in the MD group, but showed a statistically significant 
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increase in the UC group. Post treatment, health care costs increased in all groups, 
although not statistically significant in the AE group. MLM confirmed that time had a 
different influence on the course of costs in the three groups with statistically significant 
differences between the MD and UC group (F = 2.6, p = 0.07) and between the AE and UC 
group (F = 5.3, p = 0.01) (not presented). Patient & family costs increased in the three 
groups. MLM indicated no statistically significant between-group differences.  
 
While the changes during and after the intervention program were marginal, the 
intervention costs for MD were € 864 per person in phase I; for phase II the price 
depended on the number of individual contacts but varied between € 86 and € 528 per 
person; for AE the price was € 121 per person. The resulting total direct costs per person 
(with and without program costs) over the total observation periods after the diagnostic 
phase are presented in Table 3.4. Total direct costs including the intervention costs were 
highest in MD. However, between-group differences were not statistically significant.  
Table 3.4 Costs in € per patient over the total 2 years after the diagnostic phase 
  Costs    
UC MD Mean 
difference  
(CI) ‡ 
AE Mean 
difference  
(CI) ‡ 
Health care costs 
 
3800,3625  
(1681,5788) 
3510,3151 
(1204,5294) 
-290 
(-1134,605) 
3594,3337  
(1990,5103) 
-207 
(-1207,806) 
Patient & family costs 452,453 
 (100,710) 
565,426  
(147,937) 
113 
(-14,250) 
678,711  
(258,1030) 
227  
(60,388) 
Total costs 
Excluding intervention 
costs 
 
Including intervention 
costs 
 
4252,3973 
 (2054,6488) 
 
4252,3973  
(2054,6488) 
 
4075,3766 
(1872,6167) 
 
4740,4510 
(2248,6651) 
 
-177 
(-1095,767) 
 
488 
(-418,1458) 
 
4272,3725  
(2127,5788) 
 
4321,3725  
(2127,5788) 
 
20  
(-1067,1158) 
 
69 
(-1025,1202) 
Costs are presented in mean, median (interquartile range) 
MD multidisciplinary intervention, AE aerobic exercise, UC usual care 
‡ Mean diﬀerence: bootstrapped mean diﬀerence (95% conﬁdence interval) from UC 
When exploring factors that contributed to the level of health care costs incurred by 
patients once the treatment programs were finished, it showed that high health care costs 
during the diagnostic phase and a high impact of FM (FIQ) already at entry in the cohort 
independently predicted post-program costs (see Table 3.5). 
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Table 3.5 Prediction of cost in the post treatment period 
Predictors assessed at 
diagnosis 
(n=203) 
Unstandardised 
Coefficients 
 Standardised 
Coefficients 
 t p-value 95.0% Confidence 
Interval (CI) for B 
B Std. 
Error 
Beta Lower  
Bound 
Upper 
 Bound 
(Constant) 6.7 3.7  1.8 0.07 -0.595 14.065 
FIQ-total score 0.093 0.038 0.173 2.5 0.01 0.019 0.167 
Health care costs 0.004 0.001 0.187 2.7 0.01 0.001 0.007 
Age 0.080 0.054 0.104 1.5 0.14 -0.025 0.186 
Duration symptoms 0.117 0.083 0.096 1.4 0.16 -0.046 0.281 
Education -0.861 0.760 -0.080 -1.1 0.26 -2.361 0.638 
R
2 
11.9% 
Dependent Variable: square root transformed health care costs post treatment 
FIQ Fibromyalgia Impact Questionnaire 
 
Discussion 
This article describes the course of costs in a cohort of patients that were referred to a 
rheumatologist who diagnosed them with FM, and offered patients, soon after the 
diagnosis, one of three interventions along a randomised pragmatic trial. It was found that 
health care costs decreased immediately following the diagnosis by the rheumatologists in 
each group, even before the start of specific treatment programs. However, during and 
after the treatment period the health care costs increased in all three groups, although 
not statistically significant in the AE group. Trends over time were different for the patient 
& family costs, where the initial decrease after diagnosis was not seen and where all 
groups showed a (non-significant) trend towards increase in costs in the further follow-up 
and completely independent of the treatment offered. The costs of the MD and AE 
intervention program contributed substantially to the total costs in these groups. 
Since we failed to show any effects of the interventions on different aspects of quality of 
life, including the 5-dimensional EuroQol (EQ-5D) [33] and FIQ in in our previously 
published study [25], a classical cost-minimisation study of the pragmatic trial could have 
been considered. However, such approach would have ignored the course of the costs 
incurred during diagnosis and the large decrease in costs after the diagnostic phase and 
before the start of a specific intervention program. Notwithstanding it is clear that the 
total direct costs including intervention costs tended to be higher (although not 
statistically significant) in the MD and AE group compared to the UC group, suggesting 
higher costs for similar effects.  
The higher costs around the period of diagnosis likely reflect the unmet needs of patients 
for confirmation of the diagnosis and for a better treatment plan in a period that 
complaints are high; the decrease in costs (and improvement in health) could partially be 
attributed to regression to the mean. However, it cannot be excluded that the diagnosis 
itself contributes to (temporary) reassurance of patients and partly explains the reduction 
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in consultations and costs following the diagnosis and even before the start of the 
treatment programs [23, 34]. Our findings confirm results of studies that showed reduced 
costs due to a decreased number of visits to health care providers after diagnosis [23, 24]. 
Our study comprised a cohort of recently diagnosed patients, but in the cohort there was 
not necessarily a recent onset of FM. Likely, patients had been managed by their GPs 
during a longer period. Well trained GPs in the Netherlands can diagnose and manage FM 
appropriately [35], but it is recognised that some GPs avoid mentioning the diagnosis FM 
for several reasons. Apparently, a number of patients raise concerns about the exact 
diagnosis and about the treatment options and these patients can be referred to a 
rheumatologist. 
Overall our study suggests that, also from a cost perspective, usual care is appropriate for 
many patients. In the usual care setting they receive information and education about 
healthy behaviour and coping strategies as well as some advice for physiotherapy in order 
to support healthy movement. Patients are encouraged to implement sports and pacing 
[36, 379]. This seems to be confirmed by the increase in patient & family costs: we found 
increased costs for participating in health activities, and for increased use of paid help and 
informal care in all three groups. Occasionally, patients are supported by the 
rheumatology nurse specialist and by health care professionals in primary care, or can be 
referred to multidisciplinary group programs, but our previously published study already 
showed that effects of additional interventions are negligible. Notwithstanding, we cannot 
exclude that within a group of recently diagnosed FM patients, a subgroup of patients 
might benefit from MD or AE; an appropriate selection of patients for interventions may 
result in larger effects and may contribute to cost-effectiveness [38].  
At the end of the observational study, the average 2-monthly health care costs per patient 
were between € 312 and € 385 per two months, which would be between € 1,872 and      
€ 2,310 per year if we would annualise these costs. This is lower than reported in reviews 
on health care costs of patients with rheumatoid arthritis and ankylosing spondylitis that 
are under care of rheumatologists and were € 3,445 and € 1,992 per patient per year 
respectively [39], but in our study, costs for diagnostic procedures and inpatient costs 
were not included. Further analyses showed that a high impact of FM and high health care 
utilisation at study entry independently predicted high health care costs at the end of the 
observational study. While it is not surprising that higher experienced impact of disease 
results in more costs, it is also interesting to realise that those that were high utilisers of 
health care resources continued to be high utilisers. Resource utilisation and costs remain 
important and it remains challenging to gain further insight into the different FM 
phenotypes that would have a high chance to benefit from the different available 
interventions in order to reduce impact of disease and its costs. 
Some limitations need to be addressed. We have used data from a cohort of patients 
participating in a trial and missing data occurred within the cohort. Missing data were 
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carefully explored and were imputed. Of course, some level of uncertainty cannot be 
excluded. However, the advanced method that was used for the data imputation limits 
errors and contributes to valid data. Furthermore, we have analysed associations of 
baseline variables with high cost-of-illness after two years of follow-up, but the analysis 
explained only 12% of the variance, leaving a large proportion unexplained. Finally, we did 
not include indirect costs in our study. Only 50% of the patients were employed and this 
small sample would limit the possibility for a reliable assessment of the course of costs 
due to productivity loss.  
In summary, our results show that after diagnosing FM, the use of health care resources 
decreases, and the slight increase afterwards is largely independent of the treatments 
offered. Given the absence of beneficial health effects but additional high intervention 
costs of MD and AE, such treatments cannot be recommended for all patients with FM. 
Future research should focus on improved selection of patients that will benefit from 
specific health care innovations.  
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Abstract  
Objective. Fibromyalgia (FM) has a high impact on all aspects of health. The effect from 
interventions is usually small and characterised by uncertainty. Better insight in predictors 
for improved health is essential. The present study aimed to understand predictors for 
patient global impression of change and changes in overall health.  
Methods. Data from a longitudinal cohort of recently diagnosed FM patients (n=203) were 
used. Within this cohort, patients were pre-randomised to either a multidisciplinary 
(n=108), or an aerobic exercise (n=47) program, or usual care (n=48). Only a limited 
number of patients started with the programs (n=86) or participated fully, i.e. attended > 
70% of the scheduled sessions (n=68). Patients completed questionnaires covering all 
components of the International Classification of Functioning, Disability and Health (ICF) 
biopsychosocial model of health, which was used as a framework to structure potential 
predictors. Principal component analysis was used to reduce the number of potential 
predictors. Regression analyses were used to explore associations with the outcome 
variables.  
Results. Principal component analysis yielded five factors representing areas that covered 
different ICF components and chapters. ‘Being employed’ and ‘full participation in a 
program’ were independently associated with a better global impression of change. A 
longer duration of FM-related symptoms and more limitations in physical areas of body 
functions were independently associated with a worse impression of overall health. 
Higher levels of perceived limitations in physical and mental activities were associated 
with ‘starting to participate in a program’ and with ‘full participation in a program’. 
Conclusion. Recently diagnosed FM patients that report fewer physical limitations may 
experience more improvement in health if they are at work and have a positive attitude 
towards participating in an offered health care intervention. These findings give support to 
an active rather than to a care-avoiding attitude of health care workers in their contacts to 
these patients.  
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Introduction  
Chronic disorders are often complex in nature and may have an impact on all aspects of 
life of an individual. Optimal management strategies of these disorders aim to maximise 
physical function and to minimise limitations [1]. Fibromyalgia (FM) is a disorder, 
characterised by chronic widespread musculoskeletal pain and associated symptoms such 
as fatigue, sleep disturbance, mood disorders, and cognitive dysfunction [2]. Guidelines 
for optimal management of FM emphasise a multimodal approach in which attention is 
given to physical and psychological distress [3, 4]. Evidence on the long-term efficacy of 
multicomponent therapies is limited [5]. Treatment effects are usually quite small, and 
heterogeneity in treatment response is a well-known complication in clinical trials of 
patients with FM [6]. In order to support appropriate treatment strategies, a better insight 
into factors that are associated with improvement or deterioration in health, as perceived 
by the patients, is required. 
Apart from specific treatment, outcome in chronic illness is associated with many 
treatment-unrelated variables [7, 8]. In FM, socioeconomic status, pain, and fatigue are 
recognised risk factors for limitations in participation and sickness absence [9, 10]. Being 
employed, and the ability to control one’s own life, have been found to contribute to a 
better health state in patients [9], whereas psychological distress has been found to 
contribute to a poorer health state [11]. Self-efficacy and perceived control have been 
described as predictors of behavioral adaptations, symptom presentation and functioning 
and have been found of importance in self-management [12-14]. Catastrophising and 
pain-related anxiety have been found to promote fear-avoidant behaviour [15, 16], which 
in turn is associated with dysfunction [17].  
One of the challenges in FM research is to define the most relevant outcome to assess the 
efficacy of interventions. Both the patient’s global impression of change (PCI-C) as well as 
overall health were considered appropriate measures for perceived health in this study. 
The Outcome Measures in Rheumatology (OMERACT) initiative has identified pain, 
fatigue, multidimensional functioning, and ‘patient global’ as relevant outcomes for 
clinical trials [18-20]. PGI-C has shown to discriminate between treatments in FM trials 
[20] and is correlated with instruments that measure the domains pain, fatigue, and 
multidimensional functioning [18]. Also, patients with FM have been found to feel 
seriously disabled, and the impact of their disorder on health-related quality of life (HR-
Qol) is high [21, 22].  
Another challenge in FM research is the number of highly interrelated outcome variables. 
A useful framework to study and structure these variables is the International 
Classification of Functioning, Disability and Health (ICF). This framework confirms that the 
impact of a disease on health is a result of complex interactions between the different 
components, including body functions and body structures, activities and participation on 
the one hand, as well as contextual factors on the other hand, represented by the 
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environmental factors as well as personal factors [23, 24]. Body functions not only include 
physical functions such as muscle power functions and sensation of pain, but also mental 
functions such as emotional functions and content of thought. Activities and participation 
refer to carrying out daily routine such as work and employment, and doing housework. 
Environmental factors include interventions and the support of direct family members.  
Personal factors refer to specific elements of the individual’s background such as age and 
gender.  
The present study aims to identify factors that may predict changes in perceived health, 
using the ICF framework as a format to structure these associations.  
 
Patients and methods  
Study participants and design 
Data from a longitudinal cohort of recently diagnosed FM patients (n=203), participating in 
a clinical trial that compared the effectiveness of multidisciplinary treatment to aerobic 
exercise or usual care, were used for this study. In the trial, patients between 18 and 65 
years of age were asked to participate in an observational study after a diagnosis at the 
Rheumatology Departments of three medical centres in the South of the Netherlands 
(Maastricht University Medical Centre, Atrium Medical Centre, Heerlen, and Orbis Medical 
Centre, Sittard). Only after informed consent, patients were randomised to 
multidisciplinary treatment (n=108), aerobic exercise (n=47), or usual care (n=48).  
The multidisciplinary intervention was a 2-phase group program of one year in total. 
Phase l consisted of a 12-week course, three half days per week, with two therapy 
sessions of 1,5-hours duration per day of socio-therapy, physiotherapy, psychotherapy, 
and creative arts therapy. Phase ll was an aftercare program and consisted of five group-
meetings, scheduled over a period of nine months. In addition to these meetings, a 
maximum of seven individual therapy sessions with one of the therapists could be 
scheduled if considered necessary by therapist and/or the patient. The aerobic exercise 
intervention consisted of a 12-week group program which was given twice a week by a 
trained physiotherapist in a community gym, based on recommendations for exercise [25]. 
The usual care arm received care that comprised at least individualised education about 
FM and lifestyle advice by a rheumatologist or a specialised rheumatology nurse in one or 
two consultations, but could, if considered necessary, also include a diversity of other 
treatments such as physiotherapy, or social support from the rheumatology nurse. 
Patients were not aware of the other treatment arms and were only informed about the 
observational study. In the trial, only a limited number of patients (n=86) started with the 
allocated program and 68 patients participated fully in the programs, i.e. attended >70% 
of the scheduled sessions (see Figure 4.1). Data from all patients that participated in the 
observational study were used for the present analyses. The precise procedures in the trial 
as well as the results regarding effectiveness are described elsewhere [26].  
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Data collection 
After giving informed consent for participation in the observational study, all 203 patients 
received questionnaires at baseline and at the endpoint, at two years of follow-up. The 
questionnaires comprised all self-reported outcome measures. Demographic 
characteristics were included in the questionnaires at baseline. 
 
 
Figure 4.1 Study flowchart  
MD multidisciplinary program, AE aerobic exercise, UC usual care 
Fully participated: attended > 70% of the scheduled sessions in an intervention. Non-participants: did not start 
intervention, or attended < 70% of the scheduled sessions, or were assigned to usual care 
 
Outcome variables  
PGI-C was assessed by asking ‘How are you, compared to the moment you were told to 
have FM ?’. The patient’s rating of change was given on a categorical scale: 1 (completely 
cured), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 
(much worse), and 7 (worst ever). Subsequently, rates 1, 2, and 3 were categorised as 1 
(improved), and rates 4 to 7 were categorised as 0 (not improved).  
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Change in overall health was measured by the Visual Analogue Scale of the EuroQol (EQ-
VAS) [27, 28]. The EQ-VAS is an instrument for self-rating current health and ranges from 0 
(worst possible health) to 100 (best possible health). The score at baseline was compared 
to the score at the endpoint of the study. 
 
Potential predictors  
A large number of potential predictors were included, and their position in the ICF 
framework shows the broadness in the construct of health, related to FM that was 
covered (see Figure 4.2) [24].  
                                                        Health  
      duration symptoms 
 
      
    
                            
      
      
       
      
              
     
 
                                               
 
Figure 4.2 The ICF framework with variables used in the analyses 
Duration of FM-related symptoms in years and personal demographic factors at baseline 
that comprised age, gender, employment status, and educational level, were included. 
In addition, physical and mental functioning was measured by the Fibromyalgia Impact 
Questionnaire (FIQ) [29]. The FIQ is a multidimensional instrument and consists of 10 
subscales, measuring self-reported function. The 10 subscales concern physical function, 
days feel good, days missed work, job ability, pain, fatigue, unrefreshed sleep, stiffness, 
anxiety, and depression in the past week. Each subscale was standardised on a 0-10 scale 
with higher scores indicating greater impairment [29]. Self-efficacy was measured by the 
General Self-Efficacy scale [30], higher scores indicate better self-efficacy. Fatigue was 
measured by the Checklist Individual Strength (CIS-20) [31], which covers four dimensions 
of fatigue: fatigue severity, motivation, concentration, and physical activity level. Higher 
scores indicate more fatigue, reduced motivation, more concentration problems, and less  
activity. Catastrophising was measured by the Pain Catastrophising Scale (PCS) [32], which 
comprises three components: rumination, magnification, and helplessness. Higher scores 
Environmental factors  
program, full participation 
in program, social support 
 
   Part 1. Functioning &  
                 disability 
      
Participation 
employment status  
 
Body functions & structures  
   FIQ, CIS-fatigue severity,  
   PANAS negative affect  
        Activities 
CIS, FIQ-physical 
function 
 
 
 Part 2. Contextual 
               factors      
Personal factors  
educational level, age, 
gender, PCS, PASS, 
PANAS-postitive affect, 
GSE 
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indicate higher levels of catastrophising. Personality trait was measured by the Positive 
and Negative Affect Schedule (PANAS) [33]. Higher scores indicate higher positive or 
negative affect. Fear of pain and anxiety responses to pain were measured by the Pain 
Anxiety Symptoms Scale (PASS-20) [34]. The PASS-20 is a 4-dimensional questionnaire 
regarding anxiety responses to pain: cognitive anxiety responses, escape and avoidance 
behaviour, fear, and physical reactions. Higher scores indicate higher levels of pain-related 
anxiety responses. Finally, we asked if patients experienced social support by the question 
‘Does your partner give support in household or care tasks?’ In addition, participation in 
the MD and in the AE program was registered. Patients that stopped with the intervention 
and those attending less than 70% of the scheduled sessions were considered as ‘non-
participants’. Some patients declined the invitation to participate in an intervention and 
were also considered ‘non-participants’.  
 
Statistical analyses 
First, principal component analysis (PCA) was used to group the large number of 
potentially associated variables into a limited number of meaningful factors. The obtained 
factor loadings represent the relative importance of each variable for that factor, and 
were used in the further statistical analyses. Internal consistency of the resulting factors 
was assessed by Crohnbach’s alpha (α). When assigning names to the PCA factors, strict 
ICF terminology could not be easily applied since one factor included (domains of) 
questionnaires that covered more ICF chapters, and some subscales could cover actually 
more ICF components. Notwithstanding, the names chosen for the PCA factors remained 
faithful to the ICF concept and terminology. Then, simple associations of disease duration, 
the personal demographic variables, interventions (type to which randomised and 
participation in the assigned program), and the baseline values of the obtained factor 
scores with PGI-C and with changes in overall health after two years were explored. The 
variables that showed statistically significant associations in the simple analyses were used 
in multivariate logistic and linear regression models.  
To obtain more insight in patients’ willingness to participate in a program, logistic 
regression analyses were performed with ‘starting participation’ and ‘full participation’ as 
dependent variables, and the baseline values of the obtained factor scores as independent 
variables. Missing data (21.7%) were imputed using a linear trend-to-point procedure. 
Data were analysed using SPSS version 18.0 (SPSS Inc., Chicago, IL). 
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Results 
Table 4.1 presents baseline characteristics of the study population. Demographic 
characteristics showed a ‘usual’ FM population of predominantly female patients. Mean 
age was 42 years and more than 50% of the patients were at work. In general, the impact 
of FM on daily life was reported to be substantial. Patients showed on average a high level 
of fatigue and a poor current health state. Patients that participated fully in the MD 
program showed a statistically significantly lower level of self-efficacy (-2.3 (95% 
confidence interval (CI) 0.6 to 4.1)) and a statistically significantly higher level of fatigue 
(7.2 (-14.3 to -0.3)), compared to those that did not participate. Other differences were 
not statistically significant. 
Table 4.1 Baseline characteristics and potentially associated variables  
Values are mean (SD) unless indicated otherwise 
MD multidisciplinary program, AE aerobic exercise, UC usual care 
*   p = 0.01 statistically significant lower level of self-efficacy in participants in MD  
** p = 0.04 statistically significant higher level of fatigue in participants in MD 
 MD n=108 AE n=47 UC n=48 
 Participant 
 
n=60 
Non- 
participant 
n=48 
Participant 
 
n=8 
Non- 
participant 
n=39 
Non- 
participant 
Age 42.0 (8.8) 40.8 (10.7) 43.6 (8.7) 40.5 (9.1) 42.9 (11.0) 
Female, %  93.3 93.8 100 100 97.9 
Duration of FM-related symptoms 
before diagnosis  
7.0 (6.6) 6.3 (5.9) 8.5 (8.6) 6.5 (5.9) 7.1 (6.4) 
Educational level, %  
          Low 
          Medium 
          High 
 
51.7 
33.3 
15.0 
 
64.6 
27.1 
8.3 
 
50.0 
37.5 
12.5 
 
61.5 
30.8 
7.7 
 
38.7 
40.9 
20.4 
Employed, %   53.3 47.9 62.5 56.4 50.0 
Social support at home, %  66.7 77.1 62.5 61.5 64.6 
Fibromyalgia Impact Questionnaire 
(FIQ) total score (0-100, higher is 
worse) 
65.9 (13.5) 62.7 (13.9) 56.9 (14.2) 60.7 (11.9) 55.4 (15.1) 
General Self-Efficacy scale (10-40, 
higher is better)* 
23.5 (4.8) 25.8 (4.3) 25.1 (7.0) 25.1 (4.7) 26.6 (3.6) 
Checklist Individual Strength (CIS-20) 
(20-140, higher is worse)** 
101.2 (16.7) 93.9 (20.1) 93.6 (17.9) 97.2 (18.5) 93.6 (18.6) 
Pain Catastrophising Scale (PCS) (0-52, 
higher is worse) 
23.3 (11.6) 21.9 (11.4) 22.5 (13.3) 21.7 (12.5) 19.8 (10.2) 
Positive and negative affect schedule 
(PANAS) 
PANAS positive affect (10-50,  
higher is better)        
PANAS negative affect (10-50, 
higher is worse) 
 
 
22.8 (6.9) 
 
28.9 (9.4) 
 
 
23.8 (6.7) 
 
27.3 (10.3) 
 
 
24.6 (10.4) 
 
23.3 (8.7) 
 
 
23.2 (8.2) 
 
25.9 (8.2) 
 
 
24.8 (6.7) 
 
25.4 (9.5) 
Pain Anxiety Symptoms Scale (PASS-
20) (0-100, higher is worse) 
42.5 (19.1) 38.7 (19.6) 42.6 (25.9) 39.6 (20.0) 36.4 (15.1) 
Overall health (EQ-Vas) (0-100, higher 
is better) 
44.9 (15.0) 52.4 (20.1) 58.8 (16.6) 52.1 (16.8) 54.0 (17.0) 
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PCA yielded five distinguishable factors that are presented in Table 4.2. The internal 
consistency was moderate to good (Crohnbach’s α ranging from 0.51 to 0.91).  
Table 4.2 Factors, internal consistency (Crohnbach’s α) and factor loadings of the predictor variables  
 
The subscales ‘unrefreshed sleep’, ‘stiffness’, ‘fatigue’, ‘job ability’, ‘pain’, and ‘days feel 
good’ of the FIQ and the subscale ‘fatigue severity’ of the CIS-20 all loaded on one factor 
that covered physical aspects within the ICF component ‘body functions and structures’. 
The subscales ‘anxiety’ and ‘depression’ of the FIQ and the ‘PANAS negative affect’ loaded 
on a factor that covered the mental aspects within the ICF component ‘body functions and 
structures’. The subscales ‘physical activity level’ and ‘concentration’ of the CIS-20 and the 
subscale ‘physical function’ of the FIQ loaded on a factor covering physical and mental 
aspects within the ICF component ‘activities and participation’. All subscales of the PCS 
and the PASS-20 loaded on the factor ‘believes about pain’, which, although not yet 
formally classified in the ICF, are accepted to represent a personal factor [35] and in the 
literature are considered to be barriers for functioning. On the same line, the ‘PANAS 
positive affect’, the subscale ‘motivation’ of the CIS-20 and the ‘General Self-Efficacy scale’ 
loaded on a factor ‘positive attitude’, also accepted to be a personal factor in the ICF [35], 
Questionnaire/subscale Factor 
  Body 
functions; 
physical 
Body 
functions; 
mental 
Activities; 
physical or 
mental 
Personal 
factor; 
(barrier) 
Believes 
about pain 
Personal 
factor; 
(facilitator) 
Positive 
attitude 
Crohnbach’s α 0.67 0.62 0.51 0.91 0.69 
FIQ unrefreshed sleep 
FIQ stiffness 
FIQ fatigue 
FIQ job ability 
FIQ pain 
FIQ days feel good  
CIS fatigue severity 
0.80 
0.76 
0.74 
0.58 
0.58 
0.57 
0.58 
    
FIQ anxiety 
FIQ depression 
PANAS negative affect 
 
 
 
0.76 
0.63 
0.56 
   
CIS physical activity level 
CIS concentration 
FIQ physical function  
  0.82 
0.63 
0.47 
  
PCS magnification 
PCS helplessness 
PCS rumination 
PASS fear 
PASS cognitive reactions 
PASS escape 
PASS physical reactions 
 
 
 
  0.87 
0.85 
0.83 
0.80 
0.75 
0.72 
0.68 
 
PANAS positive affect 
CIS motivation 
General Self-Efficacy 
    0.88 
0.76 
0.41 
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but considered a facilitator for functioning. Overall, simple associations with PGI-C and 
changes in overall health were only weak or moderate. ‘Being employed’ (r. 0.18) and 
‘being assigned to the multidisciplinary program’ (r. 0.21) were weakly associated with a 
higher global impression of change, and ‘full participation in a program’ (r. 0.40) was 
moderately associated with a higher global impression of change. A longer duration of 
symptoms (r. -0.24), and limitations in ‘activities, physical or mental’ (r. -0.14), were 
weakly associated with a worse impression of overall health. Limitations in ‘body 
functions, physical’ (r. -0.33) were also moderately associated with a worse impression of 
overall health, whereas being employed (r 0.17), and a high educational level (r 0.14) were 
weakly associated with an improved impression of overall health. An overview of all 
associations with PGI-C and changes in overall health is available in Table 4.3. 
Table 4.3 Overview of all simple correlation coefficients with the outcomes 
 Improved patient global impression 
of change 
(Spearman’s rho) 
Overall 
health after 2 years  
(Pearson’s rho) 
Age  -0.07 -0.04 
Duration symptoms  -0.12 -0.24
b
 
Gender (female) 0.02 0.09 
Employed 0.18
a
 0.17
a
 
Educational level 
Low 
Medium 
High  
 
-0.12 
0.05 
0.10 
 
-0.10 
0.01 
0.14
a
 
Social support 0.07 -0.07 
Allocated itervention 
Multidisciplinary 
Aerobic exercise 
 
0.21
b
 
-0.11 
 
0.05 
-0.01 
Full participation in an intervention 0.40
b
 0.11 
Body functions, physical -0.10 -0.33
b
 
Body functions, mental 0.02 -0.07 
Activities, physical and mental 0.01 -0.14
a
 
Believes about pain 0.01 -0.11 
Positive attitude -0.09 -0.04 
Baseline value overall health 0.001 0.38
b
 
a 
p < 0.05, 
b 
p < 0.01 
With regard to PGI-C, 30.0% of the patients reported improvement but 70.0% of the 
patients did not improve. In the latter group of patients, 29.6% reported no changes and 
40.4% reported worsening compared to the moment they received a diagnosis of FM. 
Multivariate analyses showed that the odds of patients to improve on global impression of 
change was 2.4 times higher (odds ratio (OR), 2.4 (1.2 to 4.8)), for those being employed in 
comparison to those being unemployed, and the odds of patients to improve on global 
impression of change was 6.4 times higher (OR, 6.4 (2.9 to 14.5)) for patients fully 
participating in a program than for non-participants (see Table 4.4).  
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Table 4.4 Multivariate analyses of associations with improved patient global impression of change 
 OR CI p-value 
Employed (1=yes, 0=no) 2.4 1.2, 4.8 0.01 
Allocated intervention     
Usual care   0.80 
Multidisciplinary program 0.9 0.3, 2.5 0.85 
Aerobic exercise program 0.7 0.2, 2.1 0.54 
Full participation program (1=yes, 0=no) 6.4 2.9, 14.5 0.00 
Constant 0.1  0.00 
Model R
2 
(Nagelkerke) 0.25 
With regard to overall health, 52% of the patients reported improvement and 48% 
reported no improvement. In the latter group 9.9% of the patients remained unchanged 
and 38% worsened compared to baseline. As is shown in the multivariate analyses 
presented in Table 4.5, a longer duration of symptoms (regression coefficient (B), -0.5 (-
0.9 to -0.1)) and a higher level of limitations in ‘body functions, physical’ (B, -3.3 (-6.2 to -
0.5)) were independently associated with a worsening in overall health. 
Table 4.5 Multivariate analyses of associations with changes in overall health after two years 
 B CI p-value 
Duration symptoms -0.5 -0.9, -0.1 0.01 
Employed 4.1 -0.8, 9.0 0.10 
High educational level 6.7 -0.5, 14.0 0.07 
Body functions, physical -3.3 -6.2, -0.5 0.02 
Activities, physical and mental -0.6 -3.1, 2.0 0.70 
Baseline value overall health 0.3 0.1, 0.4 0.00 
Constant 38.5 27.6, 49.4 0.00 
Model R
2 
(adjusted)
 
0.20 
‘Full participation in a program’ showed a high correlation with an improved global 
impression of change. Perceived limitations in ‘activities, physical or mental’ were 
statistically significantly associated with ‘starting to participate in a program’ (OR, 1.8 (1.2 
to 2.6)) and with ‘full participation in a program’ (OR, 1.5 (1.1 to 2.2)). Perceived 
limitations in ‘body functions, physical’, in ‘body functions, mental’, ‘believes about pain’ 
and a ‘positive attitude’ were not associated with either starting to participate in a 
program or full participation in a program. Results from the exploration of associations 
with starting to participate in a program full participation in a program are available in 
Table 4.6.  
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Table 4.6 Multivariate analyses of associations between factors and start or full participation in a program 
     Starters vs non-starters    
n=86 vs n=69 
      Participants vs non-participants 
             n=68 vs n=87 
 OR CI p-value OR CI p-value 
Body functions, physical 1.0 0.7, 1.5 0.97 0.9 0.7, 1.4 0.95 
Body functions, mental 1.1 0.8, 1.1 0.79 1.1 0.8, 1.6 0.63 
Activities, physical or mental 1.8 1.2, 2.6 0.00 1.5 1.1, 2.2 0.03 
Believes about pain 1.0 0.7, 1.4 0.98 1.0 0.9, 1.0 0.86 
Positive attitude 1.1 0.7, 1.1 0.74 1.0 0.7, 1.4 0.88 
Constant  1.2  0.3 0.7  0.08 
         Model R
2 
(Nagelkerke) 0.10        Model R
2 
(Nagelkerke) 0.06 
 
Discussion  
In patients recently diagnosed with FM, ‘being employed’ and ‘full participation in a 
program’ are independently associated with improved patient global after two years, 
while less physical limitations at baseline were independently associated with improved 
overall health after two years.  
Our study aimed at applying the ICF framework to FM outcome in order to understand 
potential predictors of improved health over time. Many potentially associated variables 
were incorporated in the study to reflect the major components of the ICF, which 
supports a holistic approach of health and adheres to the biopsychosocial model of 
disease. The use of the ICF was insightful to understand the broadness of the predictors 
that were considered and to see how separate items from the different questionnaires 
group into factors related to specific ICF chapters. PCA reduced the number of potentially 
associated and highly correlated variables appropriately and yielded factors that fit the 
different components of the ICF framework. Because the items of one factor related to 
more than one chapters, strict use of ICF terminology in the naming of the factors 
resulting from the PCA was not possible, but the new names that were provided to the 
factors nicely reflected the broad ICF concepts covered. These findings reflect that the ICF 
is a useful framework to cover the impact of FM and to structure the associations of 
variables with outcomes. In addition to other measures for HR-Qol, the ICF framework 
also covers environmental factors which may contribute to a more comprehensive 
approach of disease and health [36]. 
The definition of improved health in FM has been a challenge in this study. When 
reflecting on an appropriate definition for ‘health’, a connection with the OMERACT core 
domain for outcome assessment in clinical trials has been made [18]. PGI-C and changes in 
overall health were chosen. Interestingly, somewhat different variables were associated 
with the outcomes. ‘Being employed’ has been found to be important to patients with FM, 
both on a personal level and on a societal level [37] which may explain our findings. 
Although we did not find important differences between patients at work and patients not 
at work regarding several variables, we cannot exclude that the patients at work were 
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‘healthier’ patients. The association of employment was confirmed with improved patient 
global impression of change, but not with improved overall health. Furthermore, physical 
symptoms appeared to be associated with changes in overall health, but not with global 
impression of change. The association of other personal factors such as coping styles and 
beliefs was not confirmed with any of the outcomes [13, 14, 38]. Our findings suggest that 
the chosen outcomes PGI-C and changes in overall health cover different domains of 
‘health’.  
Remarkably, ‘full participation in a program’ was associated with improved patient global 
after two years. When interpreting the results, we suggested that ‘full participation’ may 
reflect the patient’s intrinsic motivation as patients were asked if they were willing to 
participate in the programs only after randomisation. Although motivation as such was 
not measured in the study, some potential surrogates such as ‘believes about pain’ and 
‘positive attitude’ were measured. Several psychological models, used in studies with 
regard to motivation, share constructs of patients’ expectations about the consequences 
of behaviour, and the influence of patients’ perceptions of, or beliefs about, personal 
control over the behaviour [39]. Therefore, we assumed the variables in the factors 
‘beliefs about pain’ and ‘positive attitude’ to reflect motivation. However, associations 
with these personal factors were not found. Either our assumption was not correct or ‘full 
participation’ represents a different construct, which we were not able to capture.  
Whatever ‘full participation’ represents, it is a major limitation in many studies with 
regard to FM and high drop-out rates characterise the trials with regard to single and 
multicomponent interventions [5, 6, 40]. Our results suggest better outcomes for patients 
that participated fully in a program. When further exploring this in detail, we found an 
association between full participation and higher levels of limitations in physical and 
mental activities. In clinical practice, these findings may indicate that the level of 
perceived limitations in activities and a motivation to participate in a program should be 
incorporated in defining criteria for correct referral to interventions.  
Although we have found a number of significantly contributory factors to explaining 
variation in health, the explained variance remained low overall, suggesting that many 
other and still unknown factors contribute to changes in perceived health. Our findings are 
based on data from a cohort of FM patients, participating in a trial comparing the effects 
of an intensive multidisciplinary intervention with aerobic exercise and with usual care. As 
most patients attended the multidisciplinary intervention, the generalisability of our 
findings is probably limited to this intervention.  
In summary, this study that explored predictors of changes in perceived health in the 
context of the ICF framework of functioning and health, suggests that recently diagnosed 
patients with FM may experience a better global impression of health change if they are at 
work and have a positive attitude towards participating in an offered health care 
intervention. A longer duration of symptoms and more reported physical limitations 
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negatively contribute to overall health. These findings give support to promoting an active 
-rather than a care-avoiding- attitude of health care workers in their contacts to recently 
diagnosed patients with FM, but it also shows that the level of perceived limitations 
should be taken into account when referring patients to appropriate interventions.  
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Abstract 
Objective. To improve the quality and person-centredness of primary health care for 
fibromyalgia patients by supporting health care professionals.  
Methods. The Chronic Care Model was used as a framework to develop combined 
interventions: an educational program, a multidisciplinary guideline, and a checklist for 
referral, for general practitioners and physiotherapists in two regions in the South of the 
Netherlands. After the educational program, the guideline and the checklist for referral 
were tested in daily practice during six months. A pre-post design was used to measure 
changes in fibromyalgia care as perceived by the health care professionals. Changes were 
measured by the ‘Assessment Chronic Illness Care’ (ACIC) questionnaire. The 
questionnaire evaluates team opinions about the level and nature of improvements in 
response to interventions. Feasibility of the guideline and the checklist for referral were 
asked for in interviews.  
Results. Guideline and checklist for referral were tested by 12 general practitioners and 23 
physiotherapists, forming 12 ‘practice teams’. After the 6-month test period, the ACIC 
showed statistically significant improvements in all elements of care. 
The guideline and the checklist for referral were found feasible. 
Conclusion. Health care professionals in primary care reported improvements in 
fibromyalgia care, but also faced difficulties in changing daily practice. Additional activities 
are needed for further care improvement. Future research should examine the 
generalisibility of findings and whether and how an improved quality of care is perceived 
by fibromyalgia patients. 
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Introduction  
The burden of fibromyalgia (FM) for patients and for society is considerable. Patients 
suffer from chronic widespread musculoskeletal pain and fatigue, frequently accompanied 
by other symptoms such as concentration problems, sleep disturbance, irritable bowel 
syndrome and mood disorders [1, 2]. FM results in a poor quality of life, a high utilisation 
of health care resources and a substantial loss of work days [3, 4].  
Research has shown a large diversity in interventions and a large number of referrals from 
primary to secondary or tertiary care and vice versa as professionals are uncertain about 
appropriate interventions [5]. Furthermore, FM is a controversial disorder. Research has 
shown conflicting evidence with regard to making the diagnosis. It may contribute to 
somatisation and to an increased use of health care resources [6], but a reduction of 
uncertainty in patients may improve coping with the disorder, resulting in lower utilisation 
of health care resources [7-9].  
The patient’s suffering as well as the societal consequences of the disorder justify well 
organised care for people with FM. The Chronic Care Model provides a framework for 
improvement of chronic illness care (see Figure 5.1) [10]. The framework shows that 
outcomes of care are a result of combined and effective interventions, simultaneously 
focused on the level of community services, health care services, health care 
professionals, and patients. A productive interaction between a well-trained and proactive 
team of health care professionals and patients is considered pivotal to quality 
improvement. Self-management support empowers the patient. An active patient in the 
decision-making process improves agreement between management strategies and 
patients’ values and choices [11].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 The Chronic Care Model 
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In the late 1990s, shortcomings in health care services with regard to FM care were 
observed in the region of Maastricht, the Netherlands. In order to address these 
shortcomings, a stepwise approach has been chosen to develop a care program for 
patients with FM, focused on early diagnosis and early intervention. To reduce waiting 
lists and to improve accessibility to the program, an outpatient nurse-led diagnostic 
process has been implemented [12, 13]. In addition to the diagnostic procedure, the 
rheumatology nurse specialist gives information, education and support to patients, 
aiming at the enhancement of self-management [12]. If necessary, patients are referred 
for appropriate interventions. To meet the need for early intervention, a multidisciplinary 
program with aftercare meetings has been developed. The program aims to optimise self-
management and daily functioning through coping with the disorder. It was tested in 
terms of feasibility [14] and it is currently being evaluated with regard to its effectiveness 
[15].  
It was decided to focus on primary care, as 80% to 90% of FM patients are managed in this 
setting [5]. In-depth exploration of the nature of ongoing problems highlighted three 
topics for further quality improvement. First, the knowledge of general practitioners (GPs) 
and physiotherapists about FM, its underlying mechanisms and treatment should be 
improved. Second, agreement between professionals about treatment strategies for FM 
should be improved and third, referral for appropriate treatment options should be 
facilitated and encouraged.  
The project described in this article aimed to address these issues and assessed if quality 
improvement was achieved with reference to the perspectives of the professionals 
themselves. 
 
Methods 
Participants 
The project commenced in the East- and West-South of Limburg, the Netherlands, in July 
2009 and was of 18 months duration. A steering group, comprising representatives of GPs, 
physiotherapists, rheumatologists, rehabilitation specialists, and a representative of the 
patients association for FM (F.E.S.), supported the process. In a regional newsletter a 
convenience sample of 10 GPs and 10 physiotherapists in the region was invited to 
participate in the project. Response from GPs was limited and therefore the 
physiotherapists from both regions, who already consented to participate, were asked to 
advance the names of GPs with whom they had some nature of existing collaboration. 
Subsequently, these 63 GPs were sent formal invitations by the project-team. The GPs 
that finally decided to participate in the project and the matching physiotherapists were 
labelled as ‘practice teams’.  
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Interventions 
To improve knowledge of the practice teams, a multidisciplinary educational program was 
developed, consisting of three interactive sessions of four hours each, over a 3-month 
period. The first session comprised ‘information about FM’, ‘a biopsychosocial approach 
for exploration of symptoms’, and ‘the concept of somatisation’. The second session 
comprised ‘behavioral approach’, ‘education of patients’, ‘motivation of patients’ and 
‘graded activity’. The third session comprised ‘communication between professionals’ and 
‘communication with patients’. A fourth session, six months later, presented the 
additional topic ‘Motivational Interviewing’. In the third session the practice teams also 
formulated criteria for information and feedback. The program was accredited by the 
professional organisations of GPs and physiotherapists. 
To improve agreement about diagnosis and treatment strategies, a 4-chapter 
multidisciplinary guideline has been described (see Box 5.1). The guideline presents 
evidence, content and organisation of care and every chapter ends with a set of 
recommendations for good care. Existing international guidelines were used as a basis for 
the evidence [8, 16, 17]. In addition, 14 interviews with health care professionals and with 
a patient were performed to collect opinions about the content and organisation of care. 
A short report of every interview was made and was sent to the interviewee for 
verification.  
Box 5.1 Content multidisciplinary guideline 
 
Chapter 1. Multidimensional problem exploration and diagnosis of FM. 
Describes somatic, cognitive , emotional, behavioral and social aspects of FM.  
Presents a checklist for diagnosis.  
Chapter 2. Management and treatment strategies. 
Describes the concept of somatisation and appropriate interventions e.g. reattribution, 
symptom registration.  
Describes elements of good quality care: 
- to give information and education;  
- to support healthy movement, e.g. graded activity;  
- psychological support;  
- system support. 
Describes complexity profiles and appropriate interventions per profile:  
- complexity profile 1. Information about FM and lifestyle advices; 
- complexity profile 2. As 1 + patient education/ training program; 
- complexity profile 3. As 2 + intensive support for behavioral change; 
- complexity profile 4. As 3 + system treatment; 
- complexity profile 5. Individual psychiatric treatment. 
Chapter 3. Participation.  
Describes the importance of social participation and employment from a patients’ and a societal  
perspective. 
Describes regulations for sickness absence and work disability. 
Chapter 4. Preconditions for good quality care.  
Describes criteria for referral, financial regulations and incentives, coordination of care and  
education for professionals. 
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In order to support targeted interventions, five complexity profiles were introduced, 
following the work of the Dutch Working Group for Pain Rehabilitation [18]. The profiles 
are based on the level of the patient’s perceived limitations, attitude towards self-
management, and insight in his or her own problems (see Box 5.2).  
 
To support appropriate referral, a checklist was developed. The checklist was based on a 
biopsychosocial approach with the aim of supporting professionals and patients to jointly 
explore perceived problems and dysfunction. The wording was linked to the guideline. As 
FM is often accompanied by depression and anxiety, key questions with regard to these 
comorbidities, based on the Dutch Standards for GPs, were incorporated in the checklist 
(see Box 5.3) [19, 20]. The patient’s understanding and motivation are considered pivotal 
for treatment success and should be assessed. The checklist should result in a decision 
about the complexity profile. This profile, the patient’s preference, and the availability of 
interventions in the region, should determine the referral to an optimal treatment.  
 
 
 
 
 
Box 5.2 Complexity profiles 
 
CP 1 Generalised musculoskeletal pain; 
 Pain > 3 months; 
 No indication for further somatic diagnostic procedures; 
 Patient perceives limited slight limitations in daily functioning; 
 Patient has active attitude in solving the problem; 
 Patient is capable to understand and apply information en instruction; 
 No maintaining biopsychosocial factors; 
 Attention for overuse and ergonomics. 
CP 2 As 1 but 
Limitations in daily functioning;   
Patient has insight in bottlenecks for functioning so self-regulation can be supported; 
Patient has dysfunctional ideas about the disorder;  
Sickness behaviour is present but can be corrected by information. 
 CP 3 As 2 but 
Intensive support is needed for behavioral change, information and education are not sufficient; 
Undesirable psychosocial consequences of the pain problem are present (with regard to daily  
activities, relationships, employment, social role); 
Complex mental and social problems play an important maintaining role. 
CP 4 As 3 but 
Mental and social problems are of major importance in maintaining psychosocial factors; 
Treatment of the total system seems necessary; 
The patient has the potential to develop insight in bottlenecks for dysfunctioning. 
CP 5     As 4 but 
Psychopathological problems; 
Individual treatment necessary.  
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Box 5. 3 Checklist for referral 
 
Item 
 
 
Answer: consequence 
1.Depression or anxiety  
(Key questions based on the Dutch Standards for GPs) 
Yes: treatment according to Standards 
No: continue 
2.Multidimensional exploration of symptoms 
a) somatic       Is this chronic widespread musculoskeletal pain 
and is no further somatic diagnostic procedure 
needed (see checklist for diagnosis) 
b) cognition    Does the patient understand bottlenecks for 
functioning and is there a belief to be able to 
contribute to a solution                
                          Is the patient motivated (stages of behavioral  
                           change)               
c) emotional   Are emotions such as fear, helplessness or  
                          anger present       
d) behaviour  Is there any avoidance behaviour                                                     
 
e) social           Influence on daily living (at home, work,  
                          relationships)      
 
No: further examination 
Yes: continue 
 
No: reattribution and symptom 
registration 
Yes: continue 
No: motivational interviewing 
Yes: continue 
Yes, further exploration 
 
No: risk for overuse  
Yes: fear of movement 
Importance for patient 
3.Maintaining psychosocial factors  
     
     
No: complexity profiles 1 of 2 
Yes: complexity profiles 3 en 4 
Psychopathic: complexity profile 5 
4.Patient’s preference for intervention 
 
Determines kind of  intervention and 
intensity of intervention 
5.Availability of relevant treatment options in the region Inform patient 
 
Measurements 
The guideline and the checklist for referral were introduced to the educational program. 
After completion of the program, the practice teams were asked to test the guideline and 
the checklist for referral in daily practice over six months. Before and after the 6-month 
test period, an adapted version of the Assessment Chronic Illness Care (ACIC) 
questionnaire was applied in interviews with the practice teams [21]. The ACIC evaluates 
team opinions about the level and nature of improvements that are made in response to 
quality improvement interventions. In the interviews, the practice teams discussed the 
questions under the guidance of the first author (YvE-H) and tried to achieve a consensus 
score. If they could not achieve consensus, separate scores were recorded.  
The adapted version of the ACIC consists of the care elements ‘self-management support’ 
(4 items), ‘decision support’ (4 items), ‘delivery system design’ (6 items), and ‘information 
systems’ (5 items). All items were to be scored on a 0-11 point scale. Higher scores 
indicated more optimal support for chronic illness care. A score from 0 to 2 represented  
limited support whereas a score from 3 to 5 represented basic support, a score from 6 to 8  
Chapter 5 
80 
 
indicated reasonably good support and a score from 9 to 11 confirmed fully developed 
chronic illness care. 
 
Statistical analyses 
Descriptive statistics were used to calculate means and standard deviations (SD) for each 
element and item. Paired sample T-tests were used to calculate differences and 95% 
confidence intervals (CI) between the measurements before and after the 6-month test 
period. In order to be able to include all results in the analyses, a mean score was 
calculated for items without a consensus statement, representing the mean of the GP 
score and the physiotherapist score. Two practice teams were not willing to participate in 
the measurement after the test period. For these teams, data from the measurement 
before the test period were imputed. Data were analysed using SPSS version 16.0 (SPSS 
Inc., Chicago, IL). 
 
Results 
A total of 35 health care professionals, 12 GPs and 23 physiotherapists, participated in the 
project, forming 12 practice teams. All 23 physiotherapists and 9 GPs participated in the 
educational program.  
After the 6-month test period, the ACIC showed statistically significant improvements with 
regard to the care elements ‘self-management support’ (+1.3, CI 0.1 to 2.5), ‘decision 
support’ (+2.3, CI 1.1 to 3.6), ‘delivery system design’ (+1.8, CI 0.4 to 3.2), and ‘information 
systems’ (+1.7, CI 0.2 to 3.3) as is shown in Figure 5.2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Changes in care as perceived by professionals 
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Detailed results on the ACIC are presented in Table 5.1. With regard to the care element 
‘self-management support’, the practice teams perceived a statistically significant 
improvement in addressing patients’ and relatives’ concerns (+1.1, CI 0.3 to 1.9). Scores 
from 6.0 to 7.9, representing reasonably good support for chronic illness care, were 
achieved. With regard to the care element ‘decision support’, the practice teams 
perceived a statistically significantly improved availability of evidence-based guidelines 
(+2.4, CI 0.8 to 4.0), involvement of specialists with regard to FM in their practice teams 
(+3.6, CI 1.3 to 6.0) and informing patients about guidelines (+2.1, CI 0.7 to 3.5). With 
regard to the care element ‘delivery system design’, the practice teams perceived 
statistically significantly improved practice team functioning (+2.5, CI 1.0 to 4.0), clarity 
about leadership (+2.1, CI 0.1 to 4.1), planning of follow-up care (+1.8, CI 0.2 to 3.5), and 
continuity of care (+2.0, CI 0.2 to 3.9). With regard to the care element ‘information 
systems’, health care professionals perceived a statistically significant improved feedback 
(+2.4, CI 0.6 to 4.2). The results on all other items of the ACIC also showed improvement.  
Table 5.1 Detailed results on the adapted Assessment Chronic Illness Care questionnaire 
Care element (range 0-11) Before 
mean (SD) 
After 
Mean (SD) 
Difference  
(95% CI) 
Self-management support 
Assessment and documentation of needs 
Self-management support 
Addressing concerns patients and 
relatives 
Availability effective interventions  
 
5.2 (2.4) 
5.0 (2.2) 
6.1 (1.3) 
 
6.5 (2.8) 
 
6.0 (2.6) 
6.7 (2.7) 
7.2 (1.7) 
 
7.9 (2.2) 
 
+ 0.8 (-0.5, 2.2) 
+ 1.7 (0.0, 3.5) 
+ 1.1 (0.3, 1.9)* 
 
+ 1.4 (-0.8, 3.5) 
Decision support 
Availability evidence-based guidelines 
Involvement of specialists 
Provider education 
Informing patients about guidelines  
 
3.3 (2.7) 
2.9 (2.2) 
3.3 (1.7) 
2.7 (2.2) 
 
5.7 (2.9) 
6.5 (3.4) 
4.6 (2.4) 
4.8 (2.7) 
 
+ 2.4 (0.8, 4.0)* 
+ 3.6 (1.3, 6.0)* 
+ 1.3 (-0.6, 3.1) 
+ 2.1 (0.7, 3.5)* 
Delivery system design 
Practice team functioning 
Leadership 
Appointment system 
Schedule follow-up 
Use of planned visits 
Continuity of care  
 
2.4 (2.3) 
1.8 (2.3) 
1.4 (1.8) 
3.0 (2.2) 
4.2 (3.4) 
4.5 (2.0) 
 
4.9 (3.0) 
3.9 (2.5) 
2.5 (2.9) 
4.8 (3.0) 
5.5 (2.6) 
6.5 (1.8) 
 
+ 2.5 (1.0, 4.0)* 
+ 2.1 (0.1, 4.1)* 
+ 1.1 (-1.0, 3.1) 
+ 1.8 (0.2, 3.5)* 
+ 1.3 (-0.6, 3,2) 
+ 2.0 (0.2, 3.9)* 
Information systems 
Registry 
Reminders to providers 
Feedback 
Information about patient needs 
Patient treatment plans  
 
1.4 (1.6) 
0.6 (1.5) 
2.4 (1.9) 
2.4 (2.3) 
4.5 (2.7) 
 
2.4 (2.8) 
2.0 (2.3) 
4.8 (2.7) 
4.4 (3.2) 
6.4 (3.2) 
 
+ 1.0 (-0.7, 2.8) 
+ 1.4 (-0.3, 3.0) 
+ 2.4 (0.6, 4.2)* 
+ 2.0 (-0.2, 4.2) 
+ 1.9 (-0.1, 3.9) 
* statistically significant p < 0.05  
0-2 limited support for chronic illness care, 3-5 basic support for chronic illness care, 6-8 reasonably good 
support for chronic illness care, 9-11 fully developed chronic illness care 
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During the test period, the practice teams assessed feasibility of the guideline and the 
checklist for referral. In the interviews they approved with the contents of the guideline, 
but adherence in daily practice depends on the availability of interventions. 
Implementation of the checklist for referral in daily practice will demand further 
adjustments of daily routine. A multidimensional exploration of symptoms will require 
extra time in consultations, which is often not available. 
 
Discussion 
The project described in this article aimed to improve quality and person-centredness of 
FM management in primary care through support for health care professionals. Practice 
teams of GPs and physiotherapists attended an educational program and tested a 
multidisciplinary guideline and a checklist for referral in daily practice. The practice teams 
reported feasibility of the guideline and the checklist for referral, and improvements with 
regard to all care elements of the ACIC after the 6-month test period.  
All participants had confirmed to be interested in FM care which may have influenced the 
results positively. On the other hand, measurement at baseline was performed after the 
educational program in which GPs and physiotherapists worked together in small groups. 
Fine tuning between them and awareness of usual care may have improved even before 
the test period and therefore the magnitude of the found improvement may be an 
underestimation of the results. 
Appropriate knowledge and skills about early recognition of FM in primary care is required 
[22]. According to the practice teams, the educational program contributed to increased 
knowledge and skills, but this was not assessed in this project. The contents of the 
guideline are in accordance with existing international guidelines with regard to treatment 
strategies [23] and feasibility was confirmed. In the near future, the guideline will be 
further discussed within the professional organisations of GPs and physiotherapists, and 
adapted if necessary. The implementation of the checklist for referral in daily practice 
demands adjustments of daily routine. This problem may be solved by further redesign, 
for example, substitution of tasks from GPs to other professionals, such as nurses [24].  
The willingness to participate in the project among GPs was limited and reasons were 
mainly ‘not interested’ or ‘too busy’. As GPs have an important role to play in the early 
recognition of FM, the limited interest in FM care may contribute to a delay in diagnosing 
FM and delivering appropriate treatment. This may increase the risk of chronicity, which is 
considered a negative predictor of treatment outcome [25]. Another point of concern is 
the ongoing discrepancy between primary and secondary care with regard to a diagnosis 
of FM. A mutual agreement about name and treatment strategies may enhance 
communication and collaboration between both, and may contribute to defragmentation 
of care.  
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The generalisablity of findings has to be examined in future research. An experimental 
design is required to assess the impact of the interventions on professionals’ knowledge 
and behaviour. Ongoing research will examine the patient’s perceived quality of FM care.  
Following the multiple intervention consisting of an educational program, a 
multidisciplinary guideline and a checklist for referral, GPs and physiotherapists reported 
improved management of FM, but also faced difficulties in daily practice. Additional 
quality improvement activities are needed to improve the quality and person-centredness 
of clinical care.  
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Part II 
Improving care for patients with chronic 
                         inflammatory arthritis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pierre-Auguste Renoir (1841–1919), French impressionist 
 
Pierre-Auguste Renoir suffered from severe rheumatoid arthritis for the last 25 years of 
his life. ‘Renoir did not humbled himself and painted more than 400 pictures with an 
incessant activity until the end of his life. The day he died he had spent several hours 
painting a still life and said to his assistant: I think I am beginning to know something 
about painting.’ 
 
Boonen A, van de Rest J, Dequeker J, van der Linden S. How Renoir coped with rheumatoid 
arthritis. BMJ 1997;315:1704-1708  
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Abstract 
Objective. The authors aim to develop European League Against Rheumatism 
recommendations for the role of the nurse in the management of patients with chronic 
inflammatory arthritis, to identify a research agenda and to determine an educational 
agenda. 
Methods. A task force made up of a multidisciplinary expert panel including nurses, 
rheumatologists, occupational therapist, physiotherapist, psychologist, epidemiologist and 
patient representatives, representing 14 European countries, carried out the development 
of the recommendations, following the European League Against Rheumatism 
standardised operating procedures. 
The task force met twice. In the first meeting the aims of the task force were defined, and 
eight research questions were developed. This was followed by a comprehensive, 
systematic literature search. In the second meeting, the results from the literature review 
were presented to the task force that subsequently formulated the recommendations, 
research agenda, and educational agenda. 
Results. In total, 10 recommendations were formulated. Seven recommendations covered 
the contribution of nurses to care and management: education, satisfaction with care, 
access to care, disease management, psychosocial support, self-management, and 
efficiency of care. Three recommendations focused on professional support for nurses: 
availability of guidelines or protocols, access to education, and encouragement to 
undertake extended roles. The strength of the recommendations varied from A to C, 
dependent on category of evidence (1A-3), and a high level of agreement was achieved. 
Additionally, the task force agreed upon 10 topics for future research and an educational 
agenda. 
Conclusion. 10 recommendations for the role of the nurse in the management of chronic 
inflammatory arthritis were developed, using a combination of evidence-based and expert 
consensus approach.  
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Introduction 
In rheumatology, registered nurses often act as the interface between patients and other 
members of the multidisciplinary team. As a result of new treatment regimens and 
organisational developments, the role of the nurse is undergoing great change. However, 
there are large differences across countries and regions. In several European countries, 
rheumatology as a nursing specialty does not exist, whereas in other countries, it has 
developed into a recognised specialty with nurses undertaking advanced and extended 
roles [1]. These include self-management support, patient education and counselling, 
intra-articular injections, recommendation for and the prescription of drug treatments, 
referral to other health professionals, hospital admission of patients, manning telephone 
advice lines, and monitoring disease-modifying and biologic treatments [2-8]. Nurse-led 
clinics have been established, and their effectiveness has been shown to bring added 
value to patients’ outcomes [9-11] at a lower cost [12]. While some countries have 
accepted that interventions undertaken by nurses are essential to effectively tackle the 
challenges of chronic illness in an economic and integrated fashion, this concept has not 
developed everywhere.  
The aim of the present study was to evaluate the currently available literature according 
to the European League Against Rheumatism (EULAR) standardised operating procedures 
in order to provide recommendations for the role of the nurse in the management of 
chronic inflammatory arthritis (CIA) [13]. This evidence-based approach was 
complemented by an expert consensus approach.  
 
Methods 
A multidisciplinary task force made up of 15 nurses, a rheumatologist, an occupational 
therapist, a psychologist, a physiotherapist, two patient representatives and a research 
fellow, representing several European countries, met twice under the leadership of two 
conveners and a rheumatologist/clinical epidemiologist. During the first meeting, the task 
force formulated eight research questions. These questions served as a guide to the 
systematic literature review (SLR) and subsequently as the basis for the recommendations. 
The term ‘CIA’ was confined to rheumatoid arthritis (RA), ankylosing spondylitis and 
psoriatic arthritis, thereby excluding other systemic inflammatory conditions (e.g. systemic 
lupus erythematosus) and non-inflammatory disorders (e.g. fibromyalgia).  
The target population for the recommendations was chosen to be health care 
professionals working in the field of rheumatology (rheumatologists, nurses and other 
disciplines), patients and policy makers. 
After translation of the research questions into relevant search terms, an extensive SLR of 
MEDLINE, Embase, Cochrane CENTRAL, Cumulative Index for Nursing and Allied Health 
Literature (CINAHL) and PsycINFO was performed in August 2010. Two main search terms 
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- ‘inflammatory arthritis’ and ‘nurse’ - were searched for in titles, key words, or full texts 
using Medical Subject Headings (MeSH), subheadings, thesaurus or free text words and 
truncation symbols. No limitations with regard to publication type, research type, 
language or time period were applied. Selected titles and abstracts were screened 
independently for eligibility by AvT and YvE-H. Eligibility criteria were ‘inflammatory 
arthritis’, ‘interventions undertaken by nurses’ and ‘relevant outcomes to answer the 
research questions’. The selection was shared with the other members of the task force, 
and suggestions and comments by the experts complemented the result of the SLR. 
Additionally, abstracts from American College of Rheumatology (ACR) and EULAR 
meetings (2008-2010) were searched (selection procedure is shown in Figure 6.1). 
 
Figure 6.1 Flowchart results of the systematic literature review: 10-13 August 2010 
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During the second meeting, the formulation of the recommendations was discussed by 
the entire group until consensus was reached. The recommendations were graded based 
on the level of evidence of the literature found (Table 6.1 and 6.2) [13]. This was sent to 
each participant for final approval and voting on a scale from 0 to 10. Finally, the task 
force agreed upon the formulation of a research agenda and an educational agenda. 
Table 6.1 Determination of level of evidence 
Category  Evidence 
1A From meta-analysis of randomised controlled trials 
1B From at least one randomised controlled trial 
2A From at least one controlled study without randomisation 
2B From at least one type of quasi-experimental study 
3 From descriptive studies, such as comparative studies, correlation studies, or case control 
studies 
4 From expert committee reports or opinions and/or clinical experience of respected 
authorities 
 
Table 6.2 Strength of recommendation  
Strength  Directly based on 
A Category 1 evidence 
B Category 2 evidence or extrapolated recommendations from Category 1 evidence 
C Category 3 evidence or extrapolated recommendations from Category 1 or 2 evidence 
D Category 4 evidence or extrapolated recommendations from Category 2 or 3 evidence 
 
Results 
In total, 54 studies met the inclusion criteria. The selection comprised 1 meta-analysis, 8 
randomised controlled trials (RCTs), 2 controlled clinical trials, 9 quasi-experimental 
studies, and 34 descriptive studies. As the majority of the studies were descriptive, it was 
acknowledged that there was a high risk of bias.  
Table 1 shows the 10 recommendations with a level of evidence ranging from 1A to 3. The 
strength of recommendations varied from A to C and a high level of expert agreement was 
achieved.  
 
Recommendations 
All recommendations relate to care delivered by registered nurses with a specific training 
in rheumatology. This care includes monitoring of disease consequences on the level of 
daily activities, participation and psychosocial consequences and, increasingly, the 
monitoring of disease activity, drug treatment, and drug side effects. 
The task force judged that the level of evidence for the role of the nurse is far greater in 
the management of RA than in the management of ankylosing spondylitis and psoriatic 
arthritis, and therefore, the recommendations should be regarded as points to consider 
for patients with these conditions.  
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The order of the recommendations follows the discussion in the task force. The first three 
recommendations are formulated from the patient’s perspective, the other 
recommendations are formulated from the nurse’s perspective (see Table 6.3). 
Table 6.3 Recommendations for rheumatology nursing management of CIA [relevant references] 
  Recommendations Category  
of 
evidence 
Strength  
recommen
dation 
Agreement 
(0-10 
mean (SD)) 
  1 Patients should have access to a nurse for education to 
improve knowledge of CIA and its management throughout the 
course of their disease [9,10,16-18] 
1B A 9.9 (0.2) 
  2 Patients should have access to nurse consultations in order to 
experience improved communication, continuity and 
satisfaction with care [9,10,22-31] 
1B A 9.1 (0.6) 
  3 Patients should have access to nurse-led telephone services to 
enhance continuity of care and to provide ongoing support [32-
36] 
3 C 9.2 (0.8) 
  4 Nurses should participate in comprehensive disease 
management to control disease activity, to reduce symptoms 
and to improve patient-preferred outcomes [9-11,23,31,37-42] 
1A A 9.4 (0.8) 
  5 Nurses should identify, assess and address psychosocial issues 
to minimise the chance of patients’ anxiety and depression 
[9,10,30,31,37,39,45-47] 
1B A 9.4 (0.7) 
  6 Nurses should promote self-management skills in order that 
patients might achieve a greater sense of control, self-efficacy 
and empowerment [11,37,45,49-54] 
3 C 9.7 (0.5) 
  7 Nurses should provide care that is based on protocols and 
guidelines according to national and local contexts [41,42,57-
61] 
3 C 8.4 (1.0) 
  8 Nurses should have access to and undertake continuous 
education in order to improve and maintain knowledge and 
skills [62,65,66,70-73] 
3 C 9.7 (0.5) 
  9 Nurses should be encouraged to undertake extended roles 
after specialised training and according to national regulations 
[9-12,26,27,29,42,62] 
3 C 9.5 (0.8) 
10 Nurses should carry out interventions and monitoring as part of 
comprehensive disease management in order to achieve cost 
savings [9,12,30,32-34,36,42,49,54,61,69] 
1B C 8.8 (1.3) 
CIA: chronic inflammatory arthritis 
1. Patients should have access to a nurse for education to improve knowledge of CIA and 
its management throughout the course of their disease.  
Patient education is defined as a planned process aiming to improve coping strategies and 
increase self-care abilities [14, 15]. A statistically significant increase in the patient’s 
knowledge of the disease process, treatment strategies (e.g. drug therapy), physiotherapy, 
and self-management strategies, (e.g. joint protection techniques) was found in patients 
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with RA who were educated during monitoring [10], or who received a specific 
educational program from nurses [16-18]. Moreover, statistically significant greater levels 
of knowledge were found in patients monitored and educated by a nurse compared to 
patients monitored by doctors [9].  
Involvement in disease management allows nurses to offer timely education to newly 
diagnosed and established patients. In addition to information about their disease and 
treatments, education should address risk factors for comorbidities, such as cardio-
vascular problems [19]. Nurses can also play an important role in educating patients about 
the principles of ‘treat to target’ [20] in order to enhance adherence. Overall, the 
literature demonstrates that education by nurses improves patients’ knowledge of their 
disease and disease-related issues. 
 
2. Patients should have access to nurse consultations in order to experience improved 
communication, continuity and satisfaction with care.  
Satisfaction with care is considered an indicator of the quality of care [21]. The majority of 
the studies showed statistically significant increased satisfaction with information, 
empathy, technical quality and attitude of the professional, as well as access to care in 
patients with RA when monitored by a nurse compared to monitoring by doctors or other 
health professionals [9, 10, 22-24]. There were no differences in patient satisfaction after 
intra-articular injections given by either a nurse or a doctor [25]. Patients valued nurses’ 
communication skills and nursing care in terms of advice to use assistive devices, referral 
to other members of the multidisciplinary team and education [26, 27]. Quality and 
continuity of care in nurse-led clinics were perceived as good [28]. Holistic care and 
patient-centred information were found to contribute to patient satisfaction [29].  
However, some studies report conflicting evidence. One study did not find statistically 
significant changes in patients’ satisfaction after monitoring by a nurse practitioner [30]. In 
another study, patients’ satisfaction with multidisciplinary team care was found to be 
significantly higher than care coordinated by a clinical nurse specialist [31].  
Nurses tend to be accessible to patients and can facilitate access to services. Continuity of 
care provides the opportunity to establish a confidential and longstanding patient-
professional relationship that is to be considered important by patients. Despite some 
conflicting evidence, the task force concluded that disease monitoring or follow-up care by 
nurses enhances patients’ perceptions of care.  
 
3. Patients should have access to nurse-led telephone services to enhance continuity of 
care and to provide ongoing support. 
The unpredictable, fluctuating nature of rheumatic diseases means that rapid access to 
advice is of utmost importance for patients. Telephone helplines were found to support 
accessibility to care [32]. Patients perceived that telephone helplines support enhanced 
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continuity of care and provided them with access to a knowledgeable practitioner who 
would often be the first point of contact at times of need. Mostly, patients stated that 
they would call again if needed [32-35]. The contents of the service that was offered by 
the helplines was not clearly described in all studies, and its focus varied. Some services 
provided regular follow-up [33], while others focussed on support by answering disease-
related questions or worries that might avoid unnecessary consultations with general 
practitioners [32]. There were also examples of helplines that focused specifically on 
triage to identify patients that required fast-track clinical assessment [36]. In countries 
where telephone services are not available, information and support is sometimes given 
by email. In general, both means of support contribute to enabling patient accessibility 
and appropriate care.  
 
4. Nurses should participate in comprehensive disease management to control disease 
activity, to reduce symptoms and to improve patient-preferred outcomes. 
Nurses have increasingly combined providing support to patients in a broad spectrum of 
disease-related problems, such as psychosocial problems and limitations in participation, 
with disease monitoring. Several studies showed that nurse-led care results in equivalent 
suppression of disease activity in patients with RA, in comparison with medical care [9-11, 
23, 31, 37-39]. Moreover, appropriately trained nurses were able to detect early arthritis 
[40], make referrals, determine necessary interventions, and change medications [41, 42]. 
Patients with RA also perceived statistically significant less pain [9] and fatigue when 
monitored by nurses, compared to doctors [10]. Research showed that these symptoms 
contribute to patients’ perceptions of disease impact, and therefore, patients consider 
them as preferred outcomes in clinical trials [43].  
There is evidence that nurses can manage CIA appropriately, that they can contribute to 
symptom control, and that they can play a role in the early detection of arthritis.  
 
5. Nurses should identify, assess and address psychosocial issues to minimise the chance of 
patients’ anxiety and depression. 
The psychosocial impact of CIA is considerable, and anxiety and depression are both well-
known comorbidities in RA [44]. One study found a statistically significant reduction in 
anxiety and depression in patients with RA after monitoring by a nurse [9]. Others showed 
equivalent reductions in anxiety and depression in patients receiving nurse-led or medical 
care [10, 37].  
It has been shown that cognitive-behavioral interventions provided by a nurse can 
statistically significant improve the emotional well-being in patients with RA [45]. 
Moreover, quality of life was comparable between patients receiving either nurse-led or 
multidisciplinary team care [30, 31, 39]. Psychosocial adjustment, which is considered as 
overall adaptation to the impact of RA, was comparable in patients monitored by either a 
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nurse or a doctor, but patients monitored by a nurse reported supplementary increased 
social activities [46]. Patients valued the opportunity to discuss the wider implications of 
their condition with a nurse [47]. Counselling in psychological issues is considered 
important, but undertaking this role depends strongly on the level of the problems, the 
skills of the nurse and the ability to access other sources of support when required - for 
example, the availability of psychologists in assisting with these tasks. Therefore, the task 
force considered identifying problems and referring to other professionals when needed 
as key components of nursing care.  
 
6. Nurses should promote self-management skills in order that patients might achieve a 
greater sense of control, self-efficacy and empowerment. 
Self-efficacy refers to the belief that one can successfully execute the behaviour required 
to attain certain goals and, thus, to feel in control [48]. Research shows that nurses are 
likely to contribute to increased perceived control, levels of self-efficacy and 
empowerment. Patients reviewed by a clinical nurse specialist in a drug-monitoring clinic 
perceived clinically relevant increased perception of control [11]. After a cognitive-
behavioral intervention provided by nurses, patients demonstrated a statistically 
significant increase in personal coping resources, such as competency beliefs and decrease 
of helplessness [45]. Nurse-led management, information and support have been shown 
to increase self-efficacy beliefs and self-reliance of patients [49, 50] as well as to 
contribute to patient empowerment [50-52].  
However, some studies were unable to demonstrate any changes in lifestyle, self-
management behaviour or self-efficacy after interventions undertaken by nurses [37, 53, 
54].  
Support with regard to self-management comprises all actions that encourage patients to 
manage their own disease, and this is a task for all members of the multidisciplinary team. 
As self-management support is multifaceted, the task force considered this as an 
important role of the nurse, rather than a single intervention undertaken by nurses.  
 
7. Nurses should provide care that is based on protocols and guidelines according to 
national and local contexts. 
Guidelines provide research-based options for decisions whereas protocols describe steps 
to be taken to reduce variation in the treatment of patients [55]. Guidelines and protocols 
are essential for all health care professionals to ensure safe and high-quality care. Often 
these guidelines and protocols will be adapted to a national or local context [56]. 
It has been demonstrated that structured implementation material supported nurses in 
the guidance of patients with a complex treatment regimen. Furthermore, nurses’ 
perceived capability for guidance increased statistically significant after an educational 
session [57]. Guidelines have been found to support nurses’ clinical decision-making skills 
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with regard to assessment and treatment [58], referral [42], supplementary prescription 
[41], and therefore contribute to evidence-based nursing [59] and holistic care [41, 58]. 
Protocols have been found to support continuity and safety of care in terms of immediate 
and appropriate adjustments of treatment [41, 42, 60] and enabled nurses to discriminate 
between early arthritis and other conditions [61].  
However, standardised care should be implemented alongside national and regional 
regulations yet enable an individualised, patient-centred approach. Overall, guidelines and 
protocols are likely to support nurses in providing evidence-based care. 
 
8. Nurses should have access to and undertake continuous education in order to improve 
and maintain knowledge and skills.  
The literature demonstrates that nurses undertake a wide variety of interventions, 
including self-management support, education, counselling, drug monitoring, drug 
prescription and administration of intra-articular injections [62-69]. In a survey 
undertaken in the UK, the majority of the nurses felt confident in their abilities to 
undertake these tasks [65]. The self-confidence of nurses is supported by knowledge of 
rheumatic diseases and their treatment, skills in relation to education, counselling and 
training, collaboration with other health professionals, and manual skills [70]. 
Furthermore, nurse education needs to be tailored to reflect research findings if nurses 
are to maintain and enhance their knowledge and skills appropriately [62, 70]. Studies 
have demonstrated that the contents of consultations and issues for patient education 
and counselling are dependent on the educational level of nurses [71-73]. However, it has 
been reported that knowledge and skills do not appear to be sufficiently covered by basic 
and advanced training at present [66]. 
Educational opportunities in nursing vary to a large extent if an educational curriculum is 
not defined accurately. Given the complexity of the tasks and activities that are performed 
by nurses, ongoing access to well defined education on a basic, advanced and extended 
level is needed.  
 
9. Nurses should be encouraged to undertake extended roles after specialised training and 
according to national regulations. 
Increasingly, nursing care expands from a more basic level to an advanced or an extended 
level. The rationale for these developments comes from several perspectives. From the 
patient’s perspective, holistic care, patient-centred information and communication skills 
of nurses are appreciated, and improved outcomes such as knowledge, satisfaction, 
physical and psychological symptoms, were found [9-11, 26, 27, 29, 42]. From the 
professional’s perspective, job satisfaction is enhanced by greater autonomy and by 
optimal use of nurses’ qualities and skills [42, 62]. From an organisational perspective, 
advanced and extended roles may prevent fragmentation of care and promote efficiency 
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and accessibility [12, 62]. Key components for achieving extended roles include 
performing outpatient procedures, prescribing drugs and treatment, and taking a lead in 
the organisation of local health services [62].  
However, some concerns about extended nursing roles have been raised among members 
of the medical and the nursing professions about being ‘placebo-doctors’ or ‘second-rate 
doctors’ [26, 62]. If role development is patient-focused, aiming to meet patients’ 
identified needs and to improve overall patient care, the extended role of the nurse 
should be regarded as a complement to the medical role and not only as a substitution of 
medical tasks. 
The competencies and skills of the nurse should be considered and optimised to further 
improve patient care, to enhance and mobilise nursing competency, and to improve 
efficiency of care.  
 
10. Nurses should carry out interventions and monitoring as part of comprehensive disease 
management in order to achieve cost savings. 
Innovative nurse-led care has advanced to increase efficiency of care. Coordinated care by 
a clinical nurse specialist was shown to be statistically significantly cost-effective, 
compared with multidisciplinary inpatient or day-patient care [12]. Additional costs for a 
nurse practitioner to a medical team were found to be partially compensated by taking 
over tasks from other team members [30]. Moreover, nurse-led monitoring led to 
decreased medical referrals [42] or decreased the length of stay in a rehabilitation 
program for patients with RA [49], all pointing to cost savings. Furthermore, rheumatology 
telephone helplines are likely to contribute to cost savings by decreasing the number of 
unnecessary doctor consultations [32, 34, 36] and by reducing follow-up waiting time [33]. 
Accessibility of care also improved with the nurse being able to discriminate different 
categories of early arthritis [61]. Recent preliminary data suggest a positive cost-benefit of 
the role of nurse specialists by preventing unscheduled care and hospital admissions [69].  
However, compared to usual care from a rheumatologist, patients seen by a nurse were 
more frequently referred to occupational therapists, and this difference was statistically 
significant [9, 54]. It is arguable whether this phenomenon is a consequence of the greater 
emphasis that nurses placed on joint protection and improving functioning in daily living 
[9] and, therefore, could be considered as quality improvement of care rather than 
increase in costs [54]. There is need for high-quality economic analyses in future research. 
 
Research agenda 
In addition to the developed recommendations, a research agenda and an educational 
agenda were formulated. The research agenda highlights where there is weak or lacking 
evidence to further optimise the role of the nurse in the management of CIA and is shown 
in Box 6.1.  
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Educational agenda 
The educational agenda was defined to support educational opportunities for nurses and 
to guarantee quality in nursing care (shown in Box 6.2). 
 
Discussion 
Nurses are the largest group of health care professionals, and their role development in 
the provision of team care for patients with rheumatic diseases follows a worldwide 
tendency to more proactive, evidence-based care for patients with chronic disorders with 
nurses fulfilling extended roles [74, 75]. The role of nurses in the management of CIA 
appeared to differ greatly between countries and across regions due to their educational 
level, training and expertise, as well as to national and regional regulations and contexts, 
and funding issues related to overall health care provision.  
Evidence for the additional value of nurses was most obvious when disease monitoring by 
nurses was combined with support for patients in a broad spectrum of disease-related 
problems [9-11]. However, role, tasks, and qualifications should be clearly described in 
frameworks to practice that include protocols and guidelines.  
Nurses tend to be accessible for patients. Given their qualities and skills with regard to 
coordination of care [31, 39], they may facilitate increased access to multidisciplinary 
team care. In practice, however, some tasks may be provided by other health 
professionals, depending on local accessibility and competency. It is arguable whether 
Box 6.1 Research agenda 
 
1. To study the contribution of the nurse in improving access to care and in facilitating the effective 
utilisation of care provided by members of the multidisciplinary team 
2. To study the role of nurses in optimising ‘treat to target’ in early disease 
3. To study the contribution of the nurse in improving patient-preferred outcomes 
4. To compare the different components of nursing care in each European country in relation to 
knowledge and competencies 
5. To perform cost-effectiveness studies across different European countries, on the role of the 
nurse in basic and advanced practice  
6. To study the long-term effects of interventions by a nurse on quality of life, psychosocial and 
general well-being 
7. To study the contribution of the nurse in improving self-management and self-efficacy 
8. To study the impact of interventions by a nurse on the patient’s employment status and social 
participation 
9. To define the contribution of the nurse in the prevention of comorbidities 
10. To study the recommendations in different patient populations including ankylosing spondylitis 
and psoriatic arthritis  
 
Box 6.2 Educational agenda 
 
1. To develop a competency framework for nurses 
2. To develop educational nursing programs at the basic and advanced level 
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these tasks have the same quality when provided by different health professionals. This 
study explicitly deals with nurses, because this profession is often not clearly visible in 
multidisciplinary team care, but their role should be considered in the context of care 
delivery of other health care providers and an active role of patients. By their continuous 
presence, nurses can identify and communicate specific areas that can be addressed by 
other members of the multidisciplinary team. 
Ten recommendations for the role of the nurse in the management of patients with CIA 
were developed. There are some limitations to these recommendations that need to be 
addressed. First, the task force decided to include all types of studies that could give 
insight in nursing care, as only a limited number of RCTs exist and RCTs alone may not 
adequately cover the topic [76, 77]. Qualitative studies provide important insight in 
patients’ individual needs, functional limitations, and the extent to which different types 
of care meet those needs [78], all of which may improve quality of care [21, 28, 79]. 
However, these studies are rated with a lower level of evidence than RCTs, and 
subsequently, there is a high risk of bias. By including the additional and clinically relevant 
information retrieved from these non-controlled studies and combining this with a 
consensus approach, the task force considered that this has ultimately led to more 
inclusive recommendations. Second, the task force intended to formulate strong 
statements that were useful in emphasising the role of the rheumatology nurse 
throughout Europe. The opinion of the task force members, all representatives from 
nurses as well as other relevant parties, was considered of additional value in deciding on 
the strength of the recommendations. This may have contributed to an overestimation of 
the strength of recommendations. However, the high level of agreement within the task 
force supported the method used. Agreement with the recommendations by nurses, 
rheumatologists, health care professionals in daily practice, but also patients will soon be 
validated simultaneously with dissemination of the recommendations.  
The research agenda will support future directions of nursing research, and it is important 
that high-quality studies, with clear descriptions of nursing roles and interventions, will be 
conducted as the role of the nurse in care is currently often not clearly stated in studies 
[80]. Given the research issues and themes of importance, qualitative and quantitative 
insights into nursing care are needed.  
The educational agenda will support access to high-quality education for nurses, will 
enhance clarity about knowledge, skills and competencies required by nurses, and will 
reduce diversity of the nursing role within and between countries. 
The dissemination and implementation of the recommendations will need overall support 
from EULAR. Implementing these recommendations, including education, demands a clear 
implementation strategy in which barriers will need to be assessed. The extent to which 
such barriers can be addressed will be influenced by national and local regulations. 
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In conclusion, this study provides 10 evidence-based and expert opinion-based 
recommendations on the role of the nurse in the management of CIA. These 
recommendations provide a basis for emphasising and optimising rheumatology nursing 
care in order to contribute to a more standardised level of professional nursing across 
Europe. 
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Abstract 
Objective. To a) disseminate-, b) assess agreement with-, c) assess application of-, and d) 
identify potential barriers for implementation of the European League Against 
Rheumatism (EULAR) recommendations for the role of the nurse in the management of 
chronic inflammatory arthritis (CIA) among nurses, rheumatologists and patients. 
Methods. A web-based survey was distributed across Europe and the United States of 
America (USA) using snowball sampling. Levels of agreement and application were 
assessed using a 0-10 rating scale (0: none, 10: full agreement/application). Reasons for 
disagreement and potential barriers to application of each recommendation were sought. 
Regional differences with respect to agreement and application were explored. 
Results. In total, 967 nurses, 548 rheumatologists and 2,034 patients from 23 countries 
participated. Median level of agreement was high in all three groups ranging from 8 to 10 
per recommendation. Median level of application was substantially lower ranging from 0 
to 8 per recommendation. Agreement and application were lowest in Eastern- and Central 
Europe. The most commonly reported reasons for incomplete agreement were ‘too many 
other responsibilities’ (nurses), ‘doubts about knowledge of the nurse’ (rheumatologists) 
and ‘fear of losing contact with the rheumatologist’ (patients). The most commonly 
reported barriers to the application were time constraints and unavailability of service. 
Rheumatologists’ responses suggested that nurses had insufficient knowledge to provide 
the recommended care.  
Conclusion. The EULAR recommendations for the role of the nurse in the management of 
CIA have been disseminated among nurses, rheumatologists and patients across Europe 
and USA. Agreement with these recommendations is high, but application is lower and 
differed across regions. 
 
                           Dissemination and evaluation of the EULAR recommendations 
109 
 
Introduction  
Recently, 10 European League Against Rheumatism (EULAR) recommendations for the role 
of the nurse in the management of chronic inflammatory arthritis (CIA) have been 
developed [1]. The recommendations cover the contribution of rheumatology nurses to 
the care and management of patients with CIA, and additionally cover requirements for 
the professional performance of nurses working in the field of rheumatology (see Box 7.1). 
 
The recommendations aim to achieve a more standardised level of professional 
rheumatology nursing care. However, a successful change of clinical practice, in 
accordance with these recommendations, requires an effective implementation strategy 
[2]. Knowledge of the recommendations and adoption by the major stakeholders of care, 
i.e. nurses, rheumatologists and patients, is a prerequisite but is not sufficient on its own 
[3]. Additional interventions are necessary and may include techniques such as involving 
key opinion leaders, organising education and training for professionals, providing 
feedback, sending reminders, and providing incentives. However, evidence about effective 
single interventions is limited [4-6]. A multifaceted and broader approach on several levels 
(e.g. health professionals and patients, social context, organisations, and political and 
economic contexts) is recommended [7]. In order to develop tailored interventions that 
can support implementation, knowledge about potential barriers for acceptance and 
application of the recommendations in daily practice is essential [3, 7-9]. 
The objectives of the present study were to: a) disseminate-,b) assess agreement with-, c) 
assess application of-, and d) identify potential barriers for implementation of the EULAR 
Box 7.1 EULAR recommendations for the role of the nurse 
 
1. Patients should have access to a nurse for education to improve knowledge of CIA and its 
management throughout the course of their disease 
2. Patients should have access to nurse consultations in order to experience improved communication, 
continuity and satisfaction with care 
3. Patients should have access to nurse-led telephone services to enhance continuity of care and to 
provide on-going support 
4. Nurses should participate in comprehensive disease management to control disease activity, to 
reduce symptoms and to improve patient preferred outcomes 
5. Nurses should identify, assess and address psychosocial issues to minimise the chance of patients’ 
anxiety and depression 
6. Nurses should promote self-management skills in order that patients might achieve a greater sense 
of control, self-efficacy and empowerment 
7. Nurses should provide care that is based on protocols and guidelines according to national and local 
contexts 
8. Nurses should have access to and undertake continuous education in order to improve and maintain 
knowledge and skills 
9. Nurses should be encouraged to undertake extended roles after specialised training and according 
to national regulations  
10. Nurses should carry out interventions and monitoring as part of comprehensive disease 
management, in order to achieve cost savings 
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recommendations for the role of the nurse in the management of CIA among nurses, 
rheumatologists and patients.  
 
Methods 
The study was performed by means of a cross-sectional survey among the target 
population across Europe and the United States of America (USA).  
A steering committee, comprising eight experts in rheumatology nursing, a patient 
representative, and a rheumatologist/clinical epidemiologist, from the United Kingdom 
(UK), France, Spain, Italy, Germany, and the Netherlands, was responsible for designing 
and carrying out the study. The committee met once after completion of the survey to 
discuss the results.  
 
Development of questionnaires 
The survey was developed with three slightly different English versions of the 
questionnaire for nurses, rheumatologists, and patients. The questionnaire consisted of 
demographic variables, followed by the text of each of the recommendations with 
questions on the level of agreement and application per recommendation. For each 
recommendation, responses were rated on a 0-10 scale, with 10 being the highest level of 
agreement or the highest level of care provision in accordance with the 
recommendations. Additionally, reasons for incomplete agreement or barriers to the 
provision of care in accordance with the recommendations were sought. For respondents’ 
convenience, potential reasons or barriers, based on the findings of a previous EULAR 
health professional survey [10], and on clinical experience from the members of the 
steering committee, were offered, with the opportunity for respondents to add items. The 
questionnaires were piloted on three groups: 1) the members of the EULAR nursing task 
force involved in the development of the recommendations, 2) a convenience sample of 
nurses, rheumatologists and patients invited by the former task force members, and 3) a 
small group of health professionals, active within EULAR. In total, 46 persons (18 nurses, 9 
rheumatologists, 15 patients and 4 other health professionals) participated in the pilot 
study. Their comments were used to refine the final versions of  the questionnaires.  
 
Distribution of the questionnaires 
For as many European countries as possible and in the USA, a national principal 
investigator (PI) and a key leading rheumatologist were appointed. They were jointly 
responsible for deciding upon the most appropriate strategy for dissemination of the 
questionnaires in their country. This often included emailing professional and patient 
support groups with the details and link to the survey. In the non-English speaking 
countries, they were also responsible for the translation of the questionnaires into their 
own language. During the survey period, PIs and key leaders were informed twice about 
                           Dissemination and evaluation of the EULAR recommendations 
111 
 
the actual number of responses in their country and were asked to further stimulate the 
dissemination of the questionnaires. 
The questionnaires were transformed into a web-based format and for each target group, 
a link to the survey, with an option to choose from 17 languages, was available between 
June and August 2012. The participants were asked to send the web link of this 
questionnaire to their colleagues within and outside the hospital or to fellow patients 
(snowball sampling technique) [11]. Sample size followed convenience sampling and as 
many participants as possible were included. Possible reasons for not participating were 
communicated by the PIs after the survey. 
 
Statistical analysis 
Descriptive analyses were used to calculate the key outcomes: conceptual agreement 
with-, application of-, reasons for incomplete agreement with- and barriers to the 
application of each recommendation.  
Possible regional differences were explored. First, the participating countries were 
grouped into 6 regions: Northern-, Western-, Southern-, Eastern- and Central Europa, and 
the USA. Subsequently, differences in level of agreement and level of application between 
the regions were assessed using non-parametric Kruskal-Wallis tests within the group of 
nurses, rheumatologists and patients, respectively.  
All analyses were performed using IBM SPSS Statistics 20.0. 
 
Results 
Population  
In total, 3,594 persons responded: 967 nurses, 548 rheumatologists and 2,034 patients, 
from 23 countries. Characteristics of the study population are presented in Table 7.1. The 
nurses had a mean (SD) of 10.4 (8.0) years of clinical experience in rheumatology, for the 
rheumatologists this was 16.4 (9.7) years. The majority of the patients had rheumatoid 
arthritis with a mean (SD) disease duration of 14.4 (11.9) years.  
Table 7.2 presents an overview of the number of respondents per country. The largest 
number of nurse respondents were from the USA (n=142) while the largest number of 
rheumatologist (n=65) and patient (n=384) respondents were from France. The proportion 
of patients with access to nursing care varied widely across countries, from 5.1% in Cyprus 
to 88.9% in the UK.  
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Table 7.1 Characteristics of the study population 
RA: rheumatoid arthritis, AS: ankylosing spondylitis, PsA: psoriatic arthritis 
-: not applicable 
 
Table 7.2 Responses per country 
Region/country 
 
Nurses 
n=967 
Rheumatologists 
n= 548 
Patients 
n=2,034 
Access to nursing 
care as stated by the 
patients (%yes) 
Northern Europe 
Norway  33  19 82  48.1 
Sweden  91 38  139 63.6 
Finland  38  22  318  66.7 
Denmark  83  37  131 64.6 
Western Europe 
United Kingdom 46  12  261  88.9 
Ireland  15  8  41  56.1 
Netherlands 88  25  72  84.3 
Belgium  35  18  71  53.6 
France  104 65  384 22.3 
Southern Europe 
Spain  19  38  8  37.5 
Portugal  18  24  14  78.6 
Italy  71 56  63 28.6 
Greece  3  25  25  44.0 
Cyprus 3  2  39  5.1 
Turkey  4  24  54 13.0 
Eastern Europe 
Russia   28  28  167 12.0 
Romania  38  59  23  21.7 
CzechRepublic 20  1  3  66.7  
Slovenia  15  3  9  22.2 
Central Europe 
Germany  69 8  107 16.0 
Austria  1  13  0  Unknown 
Switzerland 3  11  4  25.0 
USA 142 12 19 36.8 
 
 Nurses 
(n=967) 
Rheumatologists 
(n=548) 
Patients 
(n=2,034) 
Age, mean (SD), years 45.6 (9.9) 46.2 (10.6) 49.2 (14.1) 
Clinical experience in rheumatology, mean (SD), years 10.4 (8.0) 16.4 (9.7) - 
Disease RA:AS:PsA, % - - 62.8:24.8:12.4 
Disease duration, mean (SD), years - - 14.4 (11.9) 
Highest level of education, %  
         Low 
         Medium 
         High (university or higher vocational education) 
 
- 
52.1 
47.9 
 
- 
- 
100 
 
29.0 
33.2 
37.8 
Hospital, %  
         Academic 
         General 
         Not hospital (primary care, private practice) 
 
44.0 
41.6 
14.4 
 
58.9 
31.2 
9.9 
 
41.6 
40.9 
17.5 
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Level of agreement and level of application 
Figure 7.1 presents the level of agreement and the level of application per 
recommendation, from nurses, rheumatologists and patients, respectively.  
 
Figure 7.1 Level of agreement and level of application (median, spread and interquartile range) per 
recommendation, for nurses, rheumatologists and patients 
Overall, the level of agreement was high in all three groups, median 8 to 10 per 
recommendation. All three groups fully agreed with recommendation 8 (‘Nurses should 
have access to and undertake continuous education’). Among nurses and patients, the 
variation was largest for recommendation 10 (‘Nurses should carry out interventions and 
monitoring in order to achieve cost savings’). In all recommendations, the variation among 
rheumatologists was larger than among nurses or patients.  
In contrast, the level of application was substantially lower, median 0 to 8, and the 
variation was much larger in each group and for each recommendation. In the three 
groups, the lowest level of application was found for recommendation 9 (‘Nurses should 
be encouraged to undertake extended roles’). Additionally, a low level of application was 
reported by nurses and rheumatologists for recommendation 4 (‘Nurses should 
participate in comprehensive disease management‘) and recommendation 10 (‘Nurses 
should carry out interventions and monitoring in order to achieve cost savings’). A low 
level of application was also reported by nurses and patients for recommendation 5 
(‘Nurses should identify, assess and address psychosocial issues ‘). 
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Reasons for incomplete agreement 
Participants who did not fully agree with a recommendation, i.e. indicated a level of 
agreement of < 10, identified their reasons for this. The two most frequently reported 
reasons per group and per region are presented in Table 7.3. The most frequently 
reported reasons for incomplete agreement were ‘having too many other responsibilities’ 
(nurses), ‘doubts about knowledge of the nurse’ (rheumatologists) and ‘fear of losing 
contact with the rheumatologist’ (patients). 
 
Barriers to the application 
If a recommendation was not fully applied, i.e. the level of application was < 10, 
participants identified barriers to the application of the recommendation. Table 7.4 
presents the two most frequently reported barriers per group and per region. The most 
frequently reported barriers were ‘lack of time’ (nurses), ‘insufficient number of nurses’ 
(rheumatologists), and ‘the service is not offered’ or ‘no nurse available’ (patients). In 
addition, ‘lack of economic resources’ was reported by nurses and rheumatologists, 
whereas rheumatologists also reported ‘insufficient knowledge of the nurses to provide 
care as stated in the recommendations’.  
 
Regional differences 
Regional differences with respect to the level of agreement and the level of application 
were explored for each recommendation and in the three groups.  
The median level of agreement was high in each region and varied from 6 to 10 among 
nurses, from 5 to 10 among rheumatologists and from 8 to 10 among patients. In the 
three groups, regional differences for the level of agreement were statistically significant 
for most recommendations. Exceptions were recommendation 8 (‘Nurses should have 
access to and undertake continuous education’) which was not statistically significant 
among nurses and patients from the different regions; recommendation 5 (‘Nurses should 
identify, assess and address psychosocial issues ‘) and recommendation 9 (‘Nurses should 
be encouraged to undertake extended roles’) which were not statistically significant 
among rheumatologists from the different regions; and recommendation 10 (‘Nurses 
should carry out interventions and monitoring in order to achieve cost savings’) which was 
not statistically significant among patients from the different regions. 
The lowest levels of agreement were found in Eastern- and Central Europe for all 
recommendations, except for recommendation 6 (‘Nurses should promote self-
management skills’), where the rheumatologists’ level of agreement was lowest in 
Southern- and Central Europe; recommendation 7 (‘Nurses should provide care that is 
based on protocols and guidelines’) where the rheumatologists’ and patients’ level of 
agreement was lowest in Central Europe and in the USA; and recommendation 9 (‘Nurses 
should be encouraged to undertake extended roles’) where the rheumatologists’ level of  
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agreement was lowest in Western- and Southern Europe.  
The median level of application of the recommendations was substantially lower in each 
region and varied from 3 to 9 among nurses, from 0 to 10 among rheumatologists and 
from 0 to 8 among patients. Regional differences in the level of application were 
statistically significant for all recommendations and in each of the three groups.  
The level of application was lowest in Southern-, Eastern- and Central Europe for all 
recommendations, except for recommendation 8 (‘Nurses should have access to and 
undertake continuous education’) where the nurses’ level of application was lowest in 
Northern-, Southern-, and Eastern Europe.  
Acceptance of the nurse to perform specific roles as stated in the recommendations, was 
frequently reported as a reason for incomplete agreement with the recommendations by 
rheumatologists and patients from Eastern- and Central Europe.  
In Eastern Europe, insufficient number of nurses’, ‘insufficient knowledge of nurses’ and 
‘no nurse available’ were more frequently reported as the main reason for not fully 
applying the recommendations by nurses, rheumatologists, and patients respectively. 
 
Tables 7.5 and 7.6 present level of agreement and level of application per 
recommendation, for each group and region, and the results regarding regional 
differences between North- (i.e. Northern Europe: Norway, Sweden, Finland, Denmark, 
respondents nurses n=245, rheumatologists n=116, patients n=670), West- (i.e. Western 
Europe: UK, Ireland, Netherlands, Belgium, France, respondents nurses n=288, 
rheumatologists n=128, patients n=829), South- (i.e. Southern Europe: Spain, Portugal, 
Italy, Greece, Cyprus, Turkey, respondents nurses n=118, rheumatologists n=169, patients 
n=203), East- (i.e. Eastern Europe: Russia, Romania, Czech republic, Slovenia, respondents 
nurses n=101, rheumatologists n=91, patients n=202), Central (i.e. Central Europe: 
Germany, Austria, Switzerland, respondents nurses n=73, rheumatologists n=32, patients 
n=111) and the USA (respondents nurses n=142, rheumatologists n=12, patients n=19). 
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Discussion 
A large number of nurses, rheumatologists and patients participated in this survey that 
evaluated agreement with- and application of the EULAR recommendations for the role of 
the nurse in the management of CIA. The survey achieved a good range of participants 
across Europe and the USA, although the highest number of responses was from 
Northern- and Western Europe. The level of agreement was high for the 
recommendations, but the level of application was substantially lower. Many barriers for 
acceptance and application were reported and regional differences were explored. 
The level of agreement was highest among nurses. The main reason nurses gave for 
incomplete agreement was having ‘too many other responsibilities’, which provides an 
indication of their perceived workload. The use of protocols and guidelines has been 
found to increase efficiency and therefore may reduce workload [12, 13]. However, lack of 
appropriate protocols was frequently reported by nurses and rheumatologists. Across 
countries, a wide variation in the role of the nurse was found. Agreement among 
rheumatologists and patients was highest in regions where rheumatology nursing care on 
an extended level is well-established which has been shown to result in confidence and 
satisfaction of patients in earlier studies [14, 15]. 
Many barriers to the application of the recommendations were identified. All three groups 
mentioned ‘lack of time’, ‘lack of sufficient number of nurses’ or ‘lack of resources’, which 
all refer to the financial investments that are required if a minimum standard for 
rheumatology nursing care is to be implemented. The high level of agreement with the 
recommendations demonstrated within this survey, as well as the level of evidence for 
effectiveness of nurse-led care [16-19] justifies investments in education and training of 
nurses.  
Further research is needed to develop targeted interventions for implementation and to 
evaluate their effectiveness. Interventions may be focussed on hindering factors at the 
level of the health professionals (e.g. knowledge of nurses), the social context (e.g. 
acceptance of rheumatology nursing care), the organisation (e.g. the position of 
specialised nurses), and economical and political context (e.g. availability of economic 
resources, policy with regard to task shifting) [9]. Specific interventions for 
implementation of the recommendations will likely differ per region and for the 
subgroups, and should be governed by the barriers identified. On a national level, key 
opinion leaders can play an important role in serving as a role model, in questioning 
existing values, and in encouraging best practices [3]. They could also contribute to 
defining specific interventions for further implementation in their countries. In addition, 
interventions are required on an international level.  
Access to continuous education is one of the EULAR recommendations for the role of the 
nurse [1]. The high level of agreement with this recommendation shows that the 
knowledge base of nurses is considered important by nurses, rheumatologists and 
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patients in all countries. Standardisation of education would improve knowledge and self-
confidence of nurses, and contribute to the development of nursing skills in order to 
achieve high quality care. Further, transparency and understanding of the objectives and 
content of nurses’ curricula might improve confidence from rheumatologists and patients. 
Easy access to affordable and clinically relevant courses on basic and advanced levels in 
rheumatology nursing is required in order to guarantee appropriately trained 
rheumatology nurses. Availability of education in an individual’s own language may be 
important to increase access and uptake of education.  
Minimum standards of care have been formulated in the recommendations, but they 
need further definition and refinement. Several initiatives to support excellent 
rheumatology nursing and multidisciplinary collaboration regarding these issues have 
already been undertaken by the members of the former EULAR nursing task force. EULAR 
can play an active role in encouraging and supporting the further implementation of 
rheumatology nursing care. A follow-up of the survey in five years is recommended to 
evaluate if the intended strategies for implementation have the desired effects.  
Several limitations to the survey should be addressed. While the intention was to include 
as many EULAR countries as possible, not all participated in the survey. All countries in 
which rheumatology nursing is well established participated, and fortunately we were also 
able to include several countries in which rheumatology nursing has only started to 
develop. Less than 50% of the participating patients indicated that they had access to 
rheumatology nursing care. Nevertheless, all participants gave their critical comments and 
provided important information with respect to barriers for the acceptance and 
application of rheumatology nursing care, which can be used in defining further 
implementation strategies.  
Also, responses varied widely across countries and regions. Given the number of 
responses that were received, it is likely that many eligible people did not fill in the survey. 
As snowball sampling was used to disseminate the link to the survey, it is not possible to 
estimate a response rate. Selection bias may have occurred [11]. Possible reasons for not 
participating were communicated by the PIs. These included unequal access to the 
internet, the time period in which the survey was available coincided with summer 
holidays, no access to or experience with nursing care, a EULAR project instead of a 
project from a national association, substantial time required to obtain formal approval 
from medical ethical committees, and unwillingness of national associations to 
disseminate the link to their members.  
Finally, the formal ‘forward-backward’ translation approach was not used in translating 
the questionnaires from English to target languages [20]. Nevertheless, the questionnaires 
were translated by the PIs and local rheumatologists in the participating countries as 
accurately as possible. 
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In conclusion, with this survey the EULAR recommendations on the role of the nurse in the 
management of CIA have been disseminated among nurses, rheumatologists, and patients 
across Europe and the USA. The level of agreement was high in all three groups, but the 
level of application was substantially lower. Agreement and application differed between 
regions and were lowest in Eastern- and Central Europe.  
Topics were identified that can be used to develop tailored strategies supporting further 
implementation of rheumatology nursing care. 
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Abstract 
Objective. The contribution of rheumatology nurses to improved patient outcomes is 
increasingly recognised, but more research is needed about the effects of interventions. 
The patient’s role in deciding about health care quality is considered pivotal and therefore 
patients’ opinions and expectations should be directional in defining priorities for a 
research agenda. The objective of this study was to explore needs and expectations with 
regard to rheumatology nursing care in patients with chronic inflammatory arthritis (CIA). 
Methods. Patients aged 18-90 years from three medical clinics in different regions in the 
Netherlands were invited to participate in focus group interviews. The interviews were 
transcribed verbatim and independently analysed by the authors. In a consensus meeting 
the emerging subjects were categorised into themes which were verified in a fourth 
interview. 
Results. In total, 20 patients, mean age 57 years old, participated in the focus group 
interviews. The majority had rheumatoid arthritis and mean disease duration was 15 
years. The focus group interviews revealed 12 subthemes that were organised into four 
main themes: education, self-management support, emotional support and well organised 
care. Additionally, patients considered opinions about ‘the personality of the nurse’ (e.g. 
easy to talk to) to be important.  
Conclusion. Patients with CIA mentioned that many problems have to be addressed when 
one is faced with having a rheumatic disease. The focus group interviews yielded valuable 
information about the care these patients need and expect. This information will direct 
future research with regard to rheumatology nursing care.  
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Introduction 
Chronic Inflammatory arthritis (CIA), more specifically rheumatoid arthritis (RA), 
ankylosing spondylitis (AS) and psoriatic arthritis (PsA), are characterised by inflammation, 
with a pattern of flares and low disease activity, and apart from pain and stiffness, 
patients can experience symptoms of severe fatigue [1]. Increasingly, treatment focuses 
on remission or, if that is not possible, low disease activity [2]. New treatment regimens 
have contributed to better outcomes, but many patients still perceive an impact of CIA on 
their daily life [2-5].  
Apart from rheumatologists, other health care professionals, such as physiotherapists, 
occupational therapists and nurse specialists, are involved in the treatment and support of 
patients with CIA [6]. The contribution of nurses to improved patient outcome in 
rheumatology is recognised, as reflected in the ‘EULAR recommendations for the role of 
the nurse in the management of CIA’ [7]. In the study of van Eijk-Hustings et al, 10 
recommendations were formulated, seven of which focused on the contribution of nurses 
to care and management. This care includes monitoring of disease consequences on the 
level of daily activities, participation and psychosocial consequences, and in some 
countries monitoring disease activity, drug treatment and drug side effects. Apart from 
the recommendations, the study also presents a research agenda focusing on weak or lack 
of evidence about the contribution of nurses to outcome and the effects of nursing 
interventions in the short and long term [7].  
A patient-centred approach is increasingly considered an important precondition for 
delivering high-quality care and is considered a quality dimension [8, 9]. Many definitions 
exist but, in general, patient-centred care is tailored to the individual’s needs and 
preferences [9]. The patient’s perspective is considered pivotal in determining the 
required content and organisation of care, and also in decisions about quality of care. The 
increased focus on patient-centredness reflects a revision of current epistemology ‘from 
evidence based to an evidence informed way of thinking and doing’ [10]. 
Rheumatology nursing is common in the Netherlands, but the procedure for referral to 
the rheumatology nurse differs in different centres. Consequently, not all patients visiting 
the outpatient clinic will receive nursing care. A project group from V&VN Dutch Nurses' 
Association, unit Rheumatology, was set up with the intention to formulate a national 
research agenda regarding the extent to which nurses contribute to the quality of care in 
rheumatology. Patient research partners were invited into the project group from the 
start, and were asked to bring their expertise and thoughts [11, 12]. Based on 
contributions from the patient research partners, it was decided that patients’ opinions 
about priorities for quality improvement should be the starting point and that patients 
should be directional in defining the scope and priorities for the research agenda.  
Although the patient’s perspective has been incorporated into the EULAR 
recommendations, patients’ expectations and needs regarding rheumatology nursing care 
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were not explicitly reflected. The objective of this study was to identify these expectations 
and needs in patients with CIA in the Netherlands.  
 
Patients and methods 
Design  
A qualitative design was chosen to explore the patient’s perspective [13, 14]. To identify 
the main themes for expectations and needs, three focus group interviews were 
organised. The focus group discussion is a valid qualitative technique where group 
interaction is explicitly used to generate data. Focus groups have proven to be helpful 
because they provide an interactive environment and allow participants’ experiences to 
be elicited in the context of discussion as participants query and clarify one another’s 
statements and opinions [15]. A fourth focus group interview was scheduled to check if 
saturation of the themes had been achieved (i.e. if no additional themes emerged). The 
focus groups were conducted between August and December 2011. 
 
Patient selection  
For the first three focus group interviews, eligible patients were recruited from three large 
outpatient rheumatology clinics in different arias in the Netherlands. All patients were 
considered eligible for participation if they were 1) aged 18-90 years, 2) diagnosed with 
CIA by a rheumatologist, 3) able to speak and read the Dutch language, and 4) in contact 
(or have had contact) with a rheumatology nurse. Consecutive patients, 10 at each clinic, 
were informed about the study by the rheumatology nurse. All patients received a brief 
demographic questionnaire (e.g. age, level of education and disease duration) and an 
information letter explaining the aim of the study. The patient’s consent was obtained by 
filling out the brief demographic questionnaire. Patients for the fourth focus group 
interview were invited by one of the authors (HR-W). 
 
Data collection  
Each focus group session was facilitated by an independent moderator (CV) as well as an 
observer (HR-W), both registered nurses but no longer in practice. To facilitate optimal 
interaction between participants, the moderator mainly posed open questions. A general 
introductory question was asked, followed by the broad question ‘what (nursing) care do 
you need to live your life with a rheumatic disease?’. Each focus group lasted for 
approximately two hours. All interviews were audio taped and conducted in a quiet room 
at the clinics. Participants gave their permission to be tape recorded. The tape recorded 
discussions were transcribed verbatim. Field notes were made during or immediately after 
the interview to record non-verbal communication and interaction allowing for 
contextualising of the data.  
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Data analyses  
Data were analysed using Krueger’s ‘long-table approach’ [15]. This is a structured method 
in which an independent content analysis is followed by consensus meetings of the 
project group. Three of the researchers (YvE-H, JA and HV-N) were appointed at the clinics 
where the first three focus group interviews took place. The written transcripts of the 
focus group meetings were copied and sent to a researcher so that each researcher 
analysed the transcript of an interview from another clinic. After reading the transcripts 
and assessing the whole scope of the interviews, the statements that provided 
information for the central research question were marked. The observer (HR-W) analysed 
all of the interviews using the same marking method. Subsequently, the project group 
evaluated and discussed the selected statements. If consensus regarding the importance 
or relevance of a particular statement was not achieved, the statement was omitted from 
further analysis. In a follow-up meeting, the statements were discussed by the project 
group and were organised into subthemes. After this discussion, the group decided on the 
main themes. The fourth focus group interview was scheduled after data analysis. The 
procedure for the interview was similar to the first three interviews. 
The study was submitted for approval to the Medical Ethical Committee of Maastricht 
University Medical Centre and was considered evaluation of daily practice. No further 
approval was required. 
 
Results 
For each of the first three focus group interviews, four out of 10 invited patients 
consented to participate, whereas all invited patients for the fourth interview (n=8) 
consented. In total, 20 patients participated in the four focus groups, 15 women and five 
men. Main characteristics of the patients are summarised in Table 8.1.  
In the focus group interviews, patients mentioned many problems that have to be 
addressed when faced with having a rheumatic disease. These include physical symptoms, 
such as pain and fatigue, emotions such as sorrow and grief, psychosocial issues and 
insecurities about the future, such as the fear of becoming disabled, choices to be made 
regarding education, work, becoming pregnant and having children, and perceived 
limitations with regard to fulfilling social roles. In response, patients expressed the wish to 
cope with their disease and to be able to manage their own problems. Patients stated that 
they often felt capable of dealing with their disease by themselves. However, flares or 
changes in personal situations may affect their sense of capability, resulting in a need for 
support.  
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Table 8.1 Characteristics of the participants in the focus groups 
 Total group 
(n = 20) 
Centre 1 
(n=4) 
Centre 2 
(n=4) 
Centre 3 
(n=4) 
Centre 4 
(n=8) 
Age, mean (range), years  56.6 (32-76) 63.5 (54-76) 49.5 (45-59) 39.8 (32-56) 65.1 (59-72) 
Gender M:F (n) 5:15 1:3 1:3 1:3 2:6 
Level of education (%) 
Low 
Medium 
High 
 
15.8 
57.9 
26.3 
 
33.3 
33.3 
33.3 
 
25.0 
50.0 
25.0 
 
50.0 
50.0 
0.0 
 
12.5 
50.0 
37.5 
Married/ cohabiting (%) 70.0 50.0 75.0 75.0 75.0. 
Work status 
     Employed (%) 
     Sick leave(%) 
     Work disability (%) 
     Retired (%) 
 
40.0 
10.5 
15.8 
36.8 
 
25.0 
25.0 
25.0 
25.0 
 
66.7 
33.3 
0 
0 
 
50.0 
0 
50.0 
0 
 
12.5 
      0 
0 
75.0 
Disease RA:AS (n) 
Disease duration,  
mean (range), years 
18:2 
14.8 (1.5-42) 
3:1 
24.8 (12-35) 
3:1 
14.5 (3-42) 
4:0 
3.5 (1.5-7) 
8:0 
15.8 (10-30) 
Centers: 1:UMC Utrecht, 2: Maasstad Hospital Rotterdam, 3: UMC+ Maastricht, 4: UMC Nijmegen 
RA: rheumatoid arthritis, AS: ankylosing spondylitis 
They expressed many needs and expectations with regard to care in general, and to 
rheumatology nursing care. In total, 200 statements were extracted from the focus group 
transcripts. In the analyses, 12 subthemes for needs and expectations were defined which 
were then organised into four main themes: education, self-management support, 
emotional support and well organised care. In the fourth focus group interview the main 
themes were verified: no additional themes emerged. The field notes did not reveal 
observations that influenced the results. The distribution of the statements in the themes 
is presented in Figure 8.1.  
Regarding ‘education’, patients expressed their needs for appropriate, tailored and timely 
information about the disease, treatment and potential side effects. They also expressed 
their needs for education about potential self-management strategies, and their needs for 
practical information about assistive devices and health care facilities.  
Regarding ‘self-management support’, patients expressed their needs for advice regarding 
dealing with limitations, and how to communicate with others about these limitations.  
Regarding ‘emotional support’, patients expressed their needs for understanding, a 
listening ear, but also for clear and supportive communication. They stated the value of a 
listening ear from a professional in addition to the support from their relatives and 
friends; patients felt it was more convenient to share their problems with someone 
outside of their social environment. 
  
Figure 8.1 Distribution in % of the extracted statements (n) in the four main themes
In addition to their needs, patients also expressed expectations regarding the care they 
receive for their rheumatic disease
that is easily accessible, in which knowledgeable professionals collaborate and 
communicate with each other. They emphasised the importance of having access to a 
contact person. 
Patients stated that 
they are knowledgeable, work closely with the rheumatologist, have access to relevant 
information, have a relevant network for referral and are easy accessible, but that 
rheumatology nursing c
themes, subthemes and illustrative quotes from patients for each subtheme. 
Some extracted 
further analysis as patients con
opinions about the ‘personality’ of the nurse, for example ‘the nurse is easy to talk to’, 
‘the nurse is empathic’, ‘the nurse considers me as a whole’. An example is expressed in 
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do not know, but I like that and it makes me feel very comfortable’. Female, RA, 56 years 
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Table 8.2 Main themes, subthemes (n statements) and illustrating quotes of patients’ needs and expectations 
regarding rheumatology nursing care  
Main themes Sub themes and illustrating quotes 
Needs 
I) Education  
 
1) Understandable tailored information about the disease and its management 
including information about medications should be given whenever needed 
(35 statements). 
 Quote:’(…….) Information is so important. I felt insecure not knowing what  
 was going on’. Female, RA, 61 years old. 
2) Education to support coping and self-management (17 statements) 
Quote: ‘(…….) I learned how to self-inject my medication, and also how to act 
in case of infection’. Female, RA, 56 years old. 
3) Practical support including information on how to obtain help or assistive     
 devices (16 statements) 
Quote: ‘(……)They had a knife, a kind of saw, and a tin opener. These things 
are helpful, we have to be told about it ‘. Female, RA, 56 years old. 
II) Self-management  
      support 
 
1) Advices on how to deal with the disease (23 statements) 
     Quote: ‘(…….) If you need something, that they can help you, show the way.   
     I think the nurse is very important. Male, AS, 76 years old. 
2) Learn to clearly communicate (22 statements) 
     Quote: ‘(…….) I did not know how to explain my limitations to my colleagues  
     and consequently, I could not address them during work’. Female, RA, 47  
     years old. 
III) Emotional support 
 
1) A listening ear (28 statements) 
    Quote: ‘(…….) People do not understand. I could talk with the nurse about all   
     my problems. That made me feel well. And she has listened very well.  
     Female, RA,  47 years old. 
2) Clear communication (8 statements) 
     Quote: ‘(…….) Trust. I think somebody should be clear, not too soft. You  
     know I value the adequate communication. And as I say: it doesn’t have to  
    be too soft, it has to be pure and simple’. Female, RA, 59 years old. 
Expectations 
IV) Well organised  care 
1) Accessibility of care (13 statements) 
     Quote:’(…….) It is so important that someone is easy accessible, to just give 
     that advice or support’. Female, RA, 54 years old. 
2) Knowledgeable professionals (13 statements) 
     Quote:’(…….) Other specialists and my GP do not know what biologicals are 
      so you cannot ask even very simple questions’. Female, RA, 32 years old. 
3) Collaborating health care professionals (6 statements) 
    Quote:’(…….) I think that the nurse is in line with the rheumatologist’  
     Female, RA, 47 years old. 
4) Coordinated care (5 statements) 
    Quote:’(…….) He takes the phone and makes arrangements. The doctor does  
    not have time for that’. Male, RA, 39 years old. 
5) Contact person (6 statements) 
     Quote:’(…….) To know that I can call whenever that is needed makes me feel  
     reassured’. Female, RA, 32 years old. 
 
Discussion 
In this study we identified patients’ expectations and needs with regard to rheumatology 
nursing care in focus group interviews. We decided to start with this first step based on 
the advices of the patient research partners in the project group.  
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Participants in the focus group interviews discussed the many needs they perceived during 
their journey to live with a rheumatic disease, which were organised in three main 
themes: education, self-management support and emotional support. They also expressed 
what they expected from health care resulting in a fourth theme -well organised care. 
Participants stated that rheumatology nurses can address their needs and can meet their 
expectations. 
In our study, the need for education was most prominent. Patient education is a planned 
process aiming to improve coping strategies and increase self-care abilities [16, 17]. 
Patients expressed the need for reassurance, which can be addressed by tailored 
information. Feeling insecure, feeling confused, fear of losing independence and feeling 
anxious because of potential risks all have an impact on daily life [18, 19]. Rheumatology 
nurses have been found to contribute to increased knowledge of the disease and the 
treatment [20] which may contribute to reassurance, but may also play an important role 
in improving self-management [21, 22].  
Self-management support appeared to be important for patients. Patients explicitly 
expressed the desire to manage their own problems. Self-management support comprises 
many interventions, performed by many health professionals. It usually includes 
education, but interaction with psychosocial factors, such as coping strategies and 
motivation, should be taken into account [23]. A variety of rheumatology nursing 
interventions focus on improving well-being, coping skills and self-efficacy. The literature 
has shown that rheumatology nurses are likely to contribute to self-efficacy and to 
perceived control [24. 25].  
Statements with regard to emotional support were also extracted from the focus group 
interviews. The psychosocial impact of rheumatic diseases is recognised [26]. The patients 
in our study described emotional support such as understanding, a listening ear and 
supportive communication. They distinguished between social companionship from 
relatives and friends, and emotional support from health care providers which are both 
associated with lower psychological distress [27, 28]. In our study, patients valued 
emotional support from a rheumatology nurse so that they did not overburden their 
relatives and friends.  
Patients stated their expectations regarding the organisation of care. Knowledgeable 
professionals, important information, guidance, access to care, and collaboration of 
professionals are indicators of quality of care from a patient’s perspective [29]. The 
contribution of rheumatology nurses to quality and continuity of care has been described 
before [30].  
A strength of our study was the participation of the target population -patients with CIA- 
in all parts of the study. The contribution of the patient research partners was directional 
for the design and validated the results of the data analyses. Furthermore, each focus 
group interview started with an open question that elicited a broad discussion among the 
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participants. We think that this contributed to an optimal exploration of patients’ needs 
and expectations.  
Some limitations need to be addressed. Although 10 patients per clinic were invited for 
the first three focus group interviews, only four patients per clinic decided to participate. 
The reasons for not consenting are not known. Despite the small number of participants, 
there was a wide variation in age and disease duration, but we cannot exclude the fact 
that our findings may be limited. However, in the fourth focus group interview, the 
subthemes were verified and no other themes emerged, which suggests that saturation 
had been achieved. The inclusion criteria limited recruitment of participants to those 
patients that had contact with a rheumatology nurse. Access to rheumatology nursing 
care is not equally available in all countries. Our results may also reflect the opinions of 
patients that do not have access, but this remains unclear. Furthermore, from the 
participants in the focus groups, 18 patients had RA. Although education, self-
management support, emotional support and well organised care may also be important 
themes for patients with inflammatory diseases other than RA, we do not know if the 
results would have been different if patients with other diseases had participated in our 
study.  
The findings of this study will direct further research that will show if the themes that have 
been identified in the focus group interviews also represent the opinions of a larger group 
of patients. Disease specific components may be of special interest as well as a 
comparison of the opinions of patients that have access to rheumatology nurses with the 
opinions of the patients who do not have access. Further research may focus on disease 
specific components in different European countries. Subsequently, the results will be 
used to assess if the care that is currently provided meets the needs and expectations of 
patients that may result in patient-centred care improvement strategies.  
In summary, the focus group interviews yielded valuable information and provided a 
structured overview about the care that patients with CIA in the Netherlands need and 
expect. This is a first step in defining patients’ priorities for rheumatology nursing care that 
can direct future research towards issues which are most relevant for patients.  
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Summary of the content and main findings 
Chronic rheumatic conditions, such as fibromyalgia (FM), i.e. chronic, widespread, 
unexplained pain, and chronic inflammatory arthritis (CIA), have a high impact on the 
patient’s daily life. Despite undeniable progress in the treatment and care of rheumatic 
diseases, there is still room for improvement. Different aspects of care delivered to 
patients should be addressed and more importantly, a well-coordinated approach is 
needed to integrate the new insights into current practice. Redesigning health care, 
however, is no sinecure. This thesis describes several studies addressing different aspects 
of care improvement and attempts to integrate the different findings into a holistic view 
on health care for patients with rheumatic diseases. Chapter 1 describes that efforts to 
improve health care should i) focus on the development of effective interventions that 
support self-management of patients, ii) include a clear definition of roles for all health 
care providers that are involved, even beyond traditional tasks, iii) offer appropriate 
training and education for all to fulfil these roles, iv) provide decision support for health 
care providers and for policy makers, and v) emphasise fine tuning between professionals 
and available resources.  
Following the introductory Chapter of the thesis, two main parts are distinguished. The 
first focusses on care improvement for patients with FM by evaluating the results from a 
multidisciplinary intervention and by developing a proposal for stepped care to support 
primary care health professionals in the management of FM. The second part focusses on 
care improvement for patients with CIA by emphasising the role of the rheumatology 
nurse in this care. 
 
In order to understand whether a timely and multicomponent intervention contributes to 
improved health care for patients with FM, an intensive multidisciplinary program with 
aftercare (MD) was developed and compared with aerobic exercise (AE) and with usual 
care (UC).  
Chapter 2 describes the results of a randomised controlled trial, in which 203 patients, 
recently diagnosed with FM, were assigned to MD (n=108), AE (n=47) and UC (n=48). The 
primary outcomes were health care resource utilisation, participation and quality of life, 
three societal relevant outcomes. Mixed linear model analyses showed that in the MD and 
AE group most outcomes improved over time, but between the three groups differences 
were small. In addition, patients’ willingness to participate in the interventions was 
limited; in total, 68 patients started with MD and 19 patients started with AE. Patients’ 
preferences and expectations about potential treatment results of interventions, but also 
time required for accepting the diagnosis and for learning how to cope with limitations, 
might be decisive in this willingness to participate, but it is conflicting with our aim to offer 
a timely intervention. Based on these findings, we could not conclude about the 
effectiveness of the MD intervention. Notwithstanding, even though no effects on a group 
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level were found, it cannot be excluded that some patients benefitted from the 
interventions. 
In order to provide a more comprehensive view on the course of costs, the resource 
utilisation and costs of patients of the above described cohort were examined from the 
time of referral to the rheumatologists, which was well before the start of the 
interventions. As presented in Chapter 3, the main finding was a clear reduction of health 
care costs in all groups in the period following the diagnostic phase, even before starting 
any intervention. Mixed linear model analyses showed that health care costs (excluding 
the intervention costs) further decreased in the AE group, but remained unchanged in the 
MD group, and increased in the UC group. After the intervention, average health care 
costs increased again in all three groups. In contrast, patient & family costs increased in 
the three groups directly after diagnosis. When comparing the total direct costs, including 
the intervention costs, between the groups, the total costs were highest in MD and AE, 
although differences were not statistically significant. In other words, program costs are 
not offset by subsequent savings in health care costs or patient & family costs. 
Although the previous study did not show differences in effect between groups, there 
were individual patients that showed improvement. In the study described in Chapter 4, 
potential predictors for improved health of the patients in the FM study after two years 
follow-up were assessed using univariate and multivariate linear and logistic regression 
methods. The International Classification of Functioning and Health was used as a model 
to structure the large number of potential predictors and factor analysis was used to 
cluster predictors into distinct factors. Being employed and full participation in an 
intervention (i.e. started and followed > 70% of the scheduled sessions) were 
independently associated with the patient’s global impression of improved health, 
whereas a longer duration of symptoms and higher perceived limitations in physical 
functioning contributed to a worse end-of-study experience of health. The study results 
suggest that the selection for a more intensive and expensive program should be directed 
towards patients with a high perceived impact of FM on their daily life that are showing 
signs of help-seeking behaviour. Further, a proactive approach by encouraging patients to 
participate in an intervention, is supported by our results. Being in full employment and 
motivation to participate in an intervention can be part of treatment indications.  
Since the majority of the patients with FM are managed in primary care, general 
practitioners (GPs) and physiotherapists are the main health care providers. However, 
they often lack sufficient knowledge about FM and there is no consensus about 
appropriate management. Chapter 5 describes a project in which a multidisciplinary 
guideline for management and a checklist for referral to appropriate interventions were 
developed. Both were offered to primary health care professionals in an educational 
program about diagnosis and management of FM. After testing in daily practice during six 
months, the guideline as well as the checklist for referral were considered feasible for 
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application. In interviews using the Assessment Chronic Illness Care questionnaire, 12 
teams of 12 GPs and 23 physiotherapists in total thatalready had some kind of 
collaboration, reported improvements with regard to the care elements ‘self-management 
support’, ‘decision support’, ‘delivery system design’ and ‘information systems’. In 
addition they considered adjustments of daily routine pivotal for implementation of the 
guideline and the checklist for referral in daily practice. 
 
Care for patients with CIA is provided by multidisciplinary teams in which rheumatology 
nurses are increasingly considered important members. However, the role of the 
rheumatology nurse differs across countries and regions. In order to achieve 
standardisation in rheumatology nursing care across Europe, the European League Against 
Rheumatism (EULAR) supported the development of recommendations for the role of the 
nurse in the management of CIA, which is described in Chapter 6. Based on evidence from 
a systematic review of the literature and expert opinions 10 recommendations were 
formulated by a multidisciplinary task force, comprising 25 professionals and patients 
from 14 countries, in a consensus meeting. Seven recommendations cover the role of the 
nurse in care and management, e.g. patient education, patient satisfaction, access to- and 
efficiency of care, disease management, psychosocial and self-management support, 
whereas three recommendations focus on professional support for nurses, e.g. access to 
continuous education, availability of guidelines and protocols, and encouragement to fulfil 
extended roles. In addition, a research and an educational agenda were formulated. 
While the level of agreement with the recommendations within the task force was high, a 
wider adoption among nurses, rheumatologists and patients was considered necessary to 
support implementation. Furthermore, insight in barriers for acceptance and application 
of the recommendations was needed. Chapter 7 describes a web-based survey among 967 
nurses, 548 rheumatologists and 2,034 patients from 22 European countries and the 
United States of America (USA). Agreement with and application of the recommendations 
were asked for on a 0-10 scale (0: none, 10: full agreement/application); additionally, 
reasons for disagreement and potential barriers to application of each recommendation 
were asked for. Regional differences with respect to agreement and application were 
explored. The survey revealed a high level of agreement (median between 8 and 10) with 
all recommendations in all three groups, but a substantially lower level of application 
(median between 0 and 8) in daily practice. Agreement and application were lowest in 
Eastern- and Central Europe. The most commonly reported reasons for disagreement with 
the recommendations by nurses were ‘too many other responsibilities’, by 
rheumatologists ‘doubts about knowledge of the nurse’, and by patients ‘fear of losing 
contact with the rheumatologist’. In the three groups, time constraints and unavailability 
of services were the most commonly reported barriers to the application of the 
recommendations. In addition, rheumatologists reported insufficient knowledge of nurses 
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to fulfil roles as stated in the recommendations. In the survey, topics were identified that 
can be used to develop tailored strategies supporting further implementation of the 
recommendations for rheumatology nursing care. 
An important dimension for quality of care is patient-centredness. Care improvement 
activities should focus on topics that are important for patients. More insight in the quality 
of the care actually offered in rheumatology is needed. A task force from the Dutch Nurses 
Association V&VN, unit Rheumatology, in collaboration with patient research partners, 
decided that patients’ needs and expectations should be directional in defining priorities 
for a research agenda with regard to rheumatology nursing care in the Netherlands. 
Chapter 8 describes a first step in the development of the research agenda. Patients’ 
needs and expectations were explored by 20 patients in focus group interviews in four 
medical clinics. Two hundred statements were extracted from the transcriptions of the 
interviews. In total, 12 subthemes emerged that were organised into four main themes. 
Patients needed ‘education’, ‘self-management support’ and ‘emotional support’, and 
expected ‘well organised care’. The emerged themes will be main issues for future 
patient-centred research on rheumatology nursing. 
 
Methodological considerations 
Apart from the limitations of the studies that were described in the Chapters 2 to 8 of this 
thesis, two overall methodological considerations appeared and are discussed, one being 
the framework to understand the complexity of care improvement, and the second the 
outcomes needed to show if care improved. 
 
Frameworks for care improvement 
Improving care is an ongoing process and comprises many different elements. 
Interventions can focus on multiple dimensions of care. Many models, such as the Plan-
Do-Study-Act iterative Deming cycle, and Donabedian’s structure-process-outcomes 
triangle have been developed and have shown their usefulness in a structured approach 
to achieve improvement, also in the field of health care [1-3]. More recently, frameworks 
such as the Chronic Care Model (CCM) contribute to a more integrative approach. The 
CCM includes an active role for society and for patients, and seems a more suitable 
framework for improvement of chronic illness care [4, 5]. Improvement strategies can 
focus on different elements of care that are interrelated. Although it is necessary to be 
aware of effectiveness of individual interventions, the fine tuning between all elements of 
improvement activities determines the final results.  
In the studies that are presented in this thesis we focus on FM and CIA. Our activities for 
care improvement concern different elements of care, as can be seen in Figure 9.1. 
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Figure 9.1 Activities for care improvement for patients with rheumatic diseases, structured in the CCM 
 
When improving health care, results from activities for one (rheumatic) disease might be 
applicable to other (rheumatic) diseases and may be considered examples which can be 
adapted to other diseases and contexts. However, disease specific components cannot be 
ignored. A nice example is the implementation of cardio-vascular risk management in the 
care for patients with inflammatory rheumatic diseases. Although the attention for cardio-
vascular risk management is considered important within health care in general, and even 
within public health, increasing knowledge about the effects of inflammation on cardio-
vascular risks requires more specific interventions with regard to disease activity control in 
patients with CIA [6]. Also, disease-related aspects need to be addressed within patient 
education towards self-management. Many typical symptoms in rheumatology, such as 
pain, fatigue and stiffness, are highly responsible for perceived limitations in daily 
activities in patients with a wide range of rheumatic diseases. However, in-depth 
education about the potential cause of these symptoms and subsequent appropriate 
strategies for self-management, e.g. graded activity for patients with FM, may require 
disease specific components [7-9].  
Notwithstanding, the results from our activities for care improvement with regard to FM 
and CIA, and the lessons that are learned from our studies might also benefit the care for 
patients with other (rheumatic) diseases. 
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Outcomes for care improvement 
Evaluation of care improvement from several perspectives is complex and requires 
assessment of the connection between all activities [5, 10]. The selection of outcome 
domains and the development of appropriate instruments to measure the different 
aspects of care improvement is another methodological consideration and will depend on 
the perspective. For patients, health but also quality of care may be appropriate 
outcomes; for health care providers, sufficient knowledge, skills and support may be of 
importance; for society, access to care and costs are relevant outcomes. 
In our studies about FM that are described in Chapter 2, 3 and 4, the focus was on 
improved outcomes of societal interest and on medical outcomes on the patient’s level 
that adhered to some extent to the Outcomes in Rheumatology (OMERACT) core set for 
FM [11]. As cure is an unrealistic treatment goal for FM patients, self-management skills, 
mediators for health, are considered of special importance. However, there are no reliable 
instruments available to assess self-management. We assumed that a reduced use of 
health care resources, and improved participation and quality of life was a consequence of 
better self-management, which may be arguable.  
In Chapter 5, the CCM was used as a framework for improving health care. The 
interventions were evaluated on the level of perceived team performance in the health 
care system. We did not assess if the application of the tools resulted in better outcomes 
for patients. Notwithstanding, the improved collaboration, as stated by the health care 
professionals, might contribute to a better care for FM patients.  
With regard to the care for patients with CIA, Chapters 6, 7, and 8, we have focussed on 
the role of the nurse, an increasingly important player in the health care system.  
In doing so, the literature revealed a variety of outcomes [12]. An increasing number of 
studies provide evidence about the contribution of rheumatology nurses to accessible and 
high quality of care for patients with CIA by showing improved patient outcomes in terms 
of knowledge, satisfaction, and self-efficacy, but also societal relevant information with 
regard to cost-effectiveness [13-17]. These findings justify our efforts to promote the role 
of the nurse, but until today there is no agreement upon main outcomes of interest for 
rheumatology nursing care. 
 
Implications for research 
Research with regard to holistic care for patients with FM remains a challenge. A tailored 
approach when offering interventions might contribute to larger effects, but given the 
worldwide and ongoing discussion about phenotyping FM patients, appropriate patient 
selection is no sinecure. Potential biomarkers as well as psychological and environmental 
factors have been taken into account but these efforts have not yet resulted in convincing 
profiles [18-21], nor have been tested in other populations, or may lack feasibility. Both 
appropriateness of criteria for selection and the selection process itself should be 
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scrutinised in the discussion. Considering the different roles and reallocating tasks of the 
health care professionals, such as nurses, in this process might be a valuable topic for 
research [22, 23]. Our studies have shown, that patients’ expectations about potential 
treatment results and preferences for specific interventions should be taken into account. 
Studies that will show improvement of care through the patient’s eye and also provide 
insight in patients’ expectations, in relevant phenotypes, and in economic consequences 
of this care, might require mixed methods designs. Last, but not least, when evidence-
based guidelines are available, research should also study the extent to which guidelines 
have been implemented and appropriate referral takes place [24]. 
 
With regard to the role of the rheumatology nurse, high-quality studies on a national and 
international level, which include clear descriptions of nursing roles and interventions, are 
needed. A research agenda regarding (cost) effectiveness of nursing interventions on 
various outcomes, also in the long term, and regarding international comparisons, has 
been identified already [12]. The agenda provides a list of priorities, but also requires a 
spirit of cooperation among nurses. The large differences between nurses from different 
countries in roles and educational level might hinder a joint approach. To support nursing 
collaboration with regard to research, an international study group, endorsed by EULAR, 
has been founded [25].  
In addition, the implementation of aspects of rheumatology nursing care itself and its 
impact on care for patients with rheumatic diseases should be monitored. Until today, 
research with regard to effects of rheumatology nursing interventions is limited and 
focussed on a variety of outcomes such as patients’ experiences and perceptions, self-
efficacy, self-management and knowledge, and in addition outcomes for disease activity 
[13, 15-17, 26-31]. All these outcome domains are measured with a variety of instruments, 
which hampers comparibility of the studies. The definition of a core set of outcome 
domains and instruments that are sensitive for nursing interventions is necessary. An 
intercontinental study group has been founded that will explore key outcome domains to 
be used in research, and will select and develop valid instruments for measurements. The 
group will be supported by OMERACT [32]. 
 
Implications for practice 
The need to redesign our health care system is emphasised by policy makers in an attempt 
to control cost-of-illness while maintaining and improving health [33]. Also, health care 
professionals and patients in rheumatology recognise limitations in the present system in 
terms of quality of care, specifically patient-centredness, accessibility and efficiency of 
care [34-36]. Sustainable, integrated care is the future aim and this aim should be leading 
when implementing the required changes [37]. 
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With regard to care for patients with FM, a stepped care approach, in which care is 
provided, based on severity of symptoms and dysfunctioning [38], might contribute to 
sustainability of care. This stepped care approach, designed via mutual agreement 
between primary, secondary and tertiary care providers, was already emphasised by a 
small project group in our region [39], but might be generalised. The separate steps and 
the role of each health care provider, adjusted to the local situation, should be clearly 
described. The impact of FM on patients is high [40, 41], and the help-seeking behaviour 
of certain patients raise the question if ongoing self-management during the entire course 
of their disease is a realistic goal for all patients. In addition to a tailored and stepped care 
approach, a structured follow-up such as in disease management programs for diabetes or 
asthma might be considered for these patients [42-44]. Improved training in the diagnosis 
and management of FM is needed for physicians, especially GPs, but also other specialties 
[45]. Health care providers and health insurance companies might consider to collaborate 
in order to improve care that remains accessible at low cost. Monitoring of health care 
utilisation is delicate, but might be considered. 
 
The wider implementation of rheumatology nursing care also fits in the aim to develop a 
care system in which sustainable and integrated care is delivered. However, not all 
patients with a rheumatic disease have access to a rheumatology nurse. Further 
implementation of the recommendations for the role of the nurse will be faced with 
barriers for acceptance and application, which are partially different across regions in 
Europe and in the USA. Targeted strategies are needed that address the specific problems 
in the different countries. However, lack of time, lack of money and lack of sufficient well 
trained nurses were reported as important barriers for implementation, independent from 
country or region. More information about cost-effectiveness of nurse-led care within 
rheumatology might contribute to a discussion about the economic value of rheumatology 
nursing. Appropriate education for rheumatology nurses is a major prerequisite for a high 
quality of care. Roles for national and international multidisciplinary organisations are 
obvious; they are leading in defining a view on care for patients with rheumatic diseases, 
which should include a view on the role of the rheumatology nurse. Following this view, 
national and international standards for education of rheumatology nurses can be defined 
and developed. 
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Overall conclusions 
In this thesis we have presented several initiatives for care improvement in rheumatology. 
Although we could not conclude about MD to be a highly effective intervention for 
patients with recently diagnosed FM, our studies increased understanding of difficulties to 
prove (cost) effectiveness in this patient group. Taking patients’ preferences and 
expectations, as well as the costs into account, a tailored and stepped care approach for 
offering interventions by knowledgeable professionals seems required. A practical 
approach to appropriate training for health care professionals and decision support with 
regard to management and patient selection resulted in a sense of improvement by health 
care professionals. Further research is needed to prove if this results in improved care for 
patients with FM, and such research requires instruments that measure the different 
aspects of the complexity of care improvement. 
 
With regard to the role of the nurse in rheumatology we have contributed to an 
international movement towards a professionalisation of rheumatology nursing care for 
patients with CIA. The evidence-based recommendations that were developed, highlight 
points of particular interest in nursing care and provide a basis for further optimising care. 
The recommendations were widely adopted by nurses, rheumatologists and patients in 
many European countries and in the USA. However, important barriers for 
implementation, such as the availability of sufficient well trained nurses, economic 
resources, and materials for support -e.g. protocols, guidelines- will have to be addressed 
and ongoing support from EULAR and other national and international organisations is 
needed. 
  
                                                           Summary and general discussion 
149 
 
References 
1. Donabedian A. Evaluating the quality of medical care. Milbank Q. 2005;83(4):691-729. 
2. Moran S. Improving palliative care. Nurs Manag (Harrow). 2009;16(2):14-7. 
3. Lawson EF, Yazdany J. Healthcare quality in systemic lupus erythematosus: using Donabedian's 
conceptual framework to understand what we know. Int J Clin Rheumtol. 2012;7(1):95-107. 
4. Coleman K, Austin BT, Brach C, Wagner EH. Evidence On The Chronic Care Model In The New Milennium. 
Health Affairs. 2009;28(1):75-85. 
5. Wagner EH, Austin BT, Von Korff M. Improving outcomes in chronic illness. Manag Care Q. 1996;4(2):12-
25.  
6. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular 
risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann 
Rheum Dis. 2009;69(2):325-31.. 
7. Hoedeman R, Krol B, Blankenstein N, Koopmans PC, Groothoff JW. Severe MUPS in a sick-listed 
population: a cross-sectional study on prevalence, recognition, psychiatric co-morbidity and impairment. 
BMC Public Health. 2009;9:440.  
8. Koch H, van Bokhoven MA, ter Riet G, van der Weijden T, Dinant GJ, Bindels PJ. Demographic 
characteristics and quality of life of patients with unexplained complaints: a descriptive study in general 
practice. Qual Life Res. 2007;16(9):1483-9. 
9. Bijlsma J, Geussens P, Kallenberg C, Tak PP, Jacobs J (CD-rom), editors. Reumatologie en klinische 
inmmunologie: Bohn Stafleu van Loghem Houten; 2004. 
10. Campbell M, Fitzpatrick R, Haines A, et al. Framework for design and evaluation of complex 
interventions to improve health. BMJ. 2000; 321 doi: 10.1136/bmj.321.7262.694. 
11. Mease P, Arnold LM, Choy EH, et al. Fibromyalgia syndrome module at OMERACT 9: domain construct. J 
Rheumatol. 2009;36(10):2318-29.  
12. van Eijk-Hustings Y, van Tubergen A, Boström C, et al. EULAR recommendations for the role of the nurse 
in the management of chronic infl ammatory arthritis. Ann Rheum Dis. 2012;71(1) (13-19). 
13. Koksvik HS, Hagen KB, Rødevand E, Mowinckel P, Kvien TK, Zangi HA. Patient satisfaction with nursing 
consultations in a rheumatology outpatient clinic: a 21-month randomised controlled trial in patients 
with inflammatory arthritides. Ann Rheum Dis. 2013;72(6):836-43. (6):836-43. 
14. Ndosi M, Lewis M, Hale C, et al. The outcome and cost-effectiveness of nurse-led care in people with 
rheumatoid arthritis: a multicentre randomized controlled trial. Ann Rheum Dis. 
2013;doi:10.1136/annrheumdis-2013-203403:1-11. 
15. Ndosi M, Vinall K, Hale C, Bird H, Hill J. The effectiveness of nurse-led care in people with rheumatoid 
arthritis: a systematic review. Int J Nurs Stud. 2011;48(5):642-54. 
16. Primdahl J, Sørensen J, Horn HC, Randi Petersen R, Hørslev-Petersen K. Shared care or nursing 
consultations as an alternative to rheumatologist follow-up for rheumatoid arthritis outpatients with 
low disease activity--patient outcomes from a 2-year, randomised controlled trial. Ann Rheum Dis. 
2013;00:1–8.[Epub ahead of print]. 
17. Zangi H, Mowinckel P, Finset A, et al. A mindfulness-based group intervention to reduce psychological 
distress and fatigue in patients with infl ammatory rheumatic joint diseases: a randomised controlled 
trial. Ann Rheum Dis. 2012;71:911–7. 
18. Giesecke T, Williams DA, Harris RE, et al. Subgrouping of fibromyalgia patients on the basis of pressure-
pain thresholds and psychological factors. Arthritis Rheum. 2003;48(10):2916-22.  
19. Turk DC, Okifuji A, Sinclair JD, Starz TW. Pain, disability, and physical functioning in subgroups of patients 
with fibromyalgia. J Rheumatol. 1996;23:1255-62. 
20. van Koulil S, Kraaimaat FW, van Lankveld W, et al. Screening for pain-persistence and pain-avoidance 
patterns in fibromyalgia. Int J Behav Med. 2008;15(3):211-20.  
21. Xiao Y, Russell IJ, Liu YG. A brain-derived neurotrophic factor polymorphism Val66Met identifies 
fibromyalgia syndrome subgroup with higher body mass index and C-reactive protein. Rheumatol Int. 
2012;32(8):2479-85. 
22. Ryan S, Packham JC, Dawes PT, Jordan KP, T P. The Impact of a Nurse-Led Chronic Musculoskeletal Pain 
Clinic on Healthcare Utilization. Musculoskelet Care. 10. 2012;10:196-201. 
23. Ryan S, Hassell A, Thwaites C, Manley K, Home D. Developing a new model of care for patients with 
chronic musculoskeletal pain. J Nurs Manag. 2007;15(8):825-9. eng. 
Chapter 9 
150 
 
24. Kroese ME, Schulpen GJ, Sonneveld HM, Vrijhoef HJ. Therapeutic approaches to fibromyalgia in the 
Netherlands: a comparison between 1998 and 2005. J Eval Clin Pract. 2008 Apr;14(2):321-5.  
25. www.eular.org. Accessed March 2013 
26. Arvidsson SB, Peterson A, Nilsson I, et al. A nurse-led rheumatology clinic's impact on empowering 
patients with rheumatoid arthritis: A qualitative study. Nursing and Health Sciences. 2006;8 (3):133-9.  
27. D'Arcy Y. Controlling pain. How to treat arthritis pain. Nursing. 2002;32(7):30-1. 
28. Helland Y, Kjeken I, Steen E, Kvien T, Hauge M, Daginfrud H. Rheumatic Diseases and Sexuality: Disease 
Impact and Self-Management Strategies. Arthritis Care & Research. 2011;63(5):743–50. 
29. Primdahl J, Wagner L, Holst R, Horslev-Petersen K. The impact on self-efficacy of different types of 
follow-up care and disease status in patients with rheumatoid arthritis. A randomized trial. Pat Educ 
Counsel. 2012;88:121-8. 
30. Repping-Wuts H, Fransen J, van Achterberg T, Bleijenberg G, van Riel P. Persistent severe fatigue in 
patients with rheumatoid arthritis. J Clin Nurs. 2007;16(11c):377-83. 
31. Ryan S, Hassell A, Dawes P, Kendall S. Perceptions of control in patients with rheumatoid arthritis. Nurs 
Times. 2003 2003;99 (13):36-8.  
32. www.omeract.org. Accessed March 2013 
33. http://www.google.nl/search?q=rijksoverheid+programmatische+zorg&rls=com.microsoft:nl-
NL&ie=UTF-8&oe=UTF-8&startIndex=&startPage=1&redir_esc=&ei=ftxrUcTXEYy1PefIgNAE. Accessed 
March 2013 
34. Choy E, Perrot S, Leon T, et al. A patient survey of the impact of fibromyalgia and the journey to 
diagnosis. BMC Health Serv Res 2010;10:102. 
35. Bombardier C, Mian S. Quality indicators in rheumatoid arthritis care: using measurement to promote 
quality improvement. Ann Rheum Dis. 2013;72 Suppl 2:ii128-ii131. 
36. Briones-Vozmediano E, Vives-Cases C, Ronda-Pérez E, Gil-González D. Patients' and professionals' views 
on managing fibromyalgia. Pain Res Manag. 2013;18(1):19-24. 
37. http://www.rijksoverheid.nl/ministeries/vws/documenten-en-
publicaties/kamerstukken/2013/02/08/kamerbrief-gezamenlijke-agenda-vws-van-systemen-naar-
mensen.html. Accessed March 2013 
38. Schröder A, Fink P, Fjordback L, Frostholm L, Rosendal M. Towards a unified treatment approach for 
functional somatic syndromes and somatization Ugeskr Laeger (Danish). 2010;172(24):1839-42. 
39. van Eijk-Hustings Y, Bessems-Beks M, Kroese M. Samenwerken bij chronische pijn in het 
bewegingsapparaat: regionale multidisciplinaire richtlijn (in Dutch). 2011. Maastricht: Maastricht 
University Medical Centre. 
40. Annemans L, Le Lay K, Taïeb C. Societal and Patient Burden of Fibromyalgia Syndrome. 
Pharmaeconomics. 2009;27(7):547-59. 
41. Arnold LM, Crofford LJ, Mease PJ, et al. Patient perspectives on the impact of fibromyalgia. Patient Educ 
Couns. 2008;73(1):114-20. 
42. Steuten L, Palmer S, Vrijhoef B, et al. Cost-utility of a disease management program for patients with 
asthma. Int J Technol Assess Health Care. 2007;23(2):184-91. 
43. Steuten LM, Vrijhoef HJ, Landewé-Cleuren S, Schaper N, Van Merode GG, Spreeuwenberg C. A disease 
management programme for patients with diabetes mellitus is associated with improved quality of care 
within existing budgets. Diabet Med. 2007;24(10):1112-20. 
44. Elissen AM, Duimel-Peeters IG, Spreeuwenberg C, Spreeuwenberg M, HJ V. Toward tailored disease 
management for type 2 diabetes. Am J Manag Care. 2012;18(10):619-30. 
45. Perrot S, Choy E, Petersel D, Ginovker A, Kramer E. Survey of physician experiences and perceptions 
about the diagnosis and treatment of fibromyalgia. BMC Health Serv Res. 2012;12:356. 
151 
 
  
 152 
 
 
 153 
 
Samenvatting en discussie 
Samenvatting en discussie 
154 
 
Hoofdstuk 1. Introductie 
De zorg voor chronisch zieken is gebaat bij een proactieve benadering. Goed 
gecoördineerde en geplande zorg, gebaseerd op richtlijnen en gericht op het verbeteren 
van zelfmanagement van patiënten, leidt tot het verbeteren van hun gezondheid. Om de 
toegang tot kwalitatief goede zorg in de toekomst te garanderen, zijn nieuwe modellen 
voor zorgverlening noodzakelijk waarin nieuwe rollen voor de professionals, nieuwe 
technologieën en een goede ondersteuning van het zorgproces van belang zijn.  
Reumatische aandoeningen zijn klachten in het bewegingsapparaat die niet kunnen 
worden verklaard door een ongeval of een andere specifieke gebeurtenis. Ze zijn meestal 
chronisch van aard. Ook in de zorg voor reumapatiënten vinden veranderingen plaats: in 
de aard van behandelingen, in de organisatie van de zorg én in veranderende rollen voor 
professionals. De behandeling is meestal multidisciplinair. Naast eventuele 
medicamenteuze behandeling kan zo nodig zorg worden verleend door onder andere de 
fysiotherapeut, de ergotherapeut en de psycholoog.  
In toenemende mate spelen gespecialiseerde verpleegkundigen een belangrijke rol in deze 
zorg. De verpleegkundige zorg beoogt een bijdrage te leveren aan het zelfmanagement 
van patiënten. Ondersteuning van patiënten vindt plaats ten aanzien van een breed scala 
aan ziekte gerelateerde problemen. De rol van verpleegkundigen verandert en zij worden 
steeds meer betrokken bij de geplande controles van groepen patiënten en bij de 
behandeling.  
Uit de geraadpleegde literatuur bleek dat zowel de zorg voor patiënten met fibromyalgie, 
chronische pijn in ‘weke delen’, zoals spieren en pezen, alsook de zorg voor mensen met 
chronisch inflammatoire aandoeningen, aandoeningen gekenmerkt door chronische 
ontstekingen in gewrichten, kan worden verbeterd. Met dat doel zijn verschillende 
projecten ontwikkeld en uitgevoerd die in dit proefschrift worden beschreven.  
 
 
Deel 1. Het verbeteren van de zorg voor mensen met fibromyalgie 
Fibromyalgie komt het meeste voor bij vrouwen. De klachten kunnen al vroeg, rond het 
twintigste- of dertigste levensjaar, ontstaan. Veelal hebben patiënten, naast pijn, ook 
andere klachten, zoals vermoeidheid en problemen met concentreren. De oorzaak van 
fibromyalgie is niet bekend maar het dagelijks functioneren van patiënten kan ernstig 
worden belemmerd. Vaak is sprake van een hoog zorggebruik, veelvuldig en langdurig 
ziekteverzuim en een slechte kwaliteit van leven.  
Omdat genezing vooralsnog niet voorhanden is, richt de behandeling zich op ‘het leren 
omgaan met de klachten’. Volgens de literatuur lijken multidisciplinaire behandelingen het 
beste resultaat te geven, maar de effecten zijn, indien aanwezig, meestal van korte duur. 
Het lijkt van belang om tijdig een behandeling aan te bieden; dit om te voorkomen dat 
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mensen hun leven helemaal inrichten rond hun pijn. In de regio Zuid-Limburg bestond in 
het jaar 2000 geen multidisciplinaire behandeling. Om die reden werd een intensieve 
multidisciplinaire dagbehandeling met nazorg (MD) ontwikkeld, die werd aangeboden aan 
recent gediagnosticeerde patiënten. De behandeling bestond uit een 
combinatieprogramma van fysiotherapie, sociotherapie, psychotherapie en creatieve 
therapie. Gedurende drie maanden werd drie keer per week een dagdeel 
combinatietherapie aangeboden, gevolgd door een vijftal nazorgbijeenkomsten in een 
periode van negen maanden. 
Een ander probleem dat werd gesignaleerd, was de diversiteit van behandelingen die in de 
dagelijkse praktijk werden aangeboden, en het veelvuldig verwijzen van de ene naar de 
andere professional, vaak pas zodra sprake was van ernstig disfunctioneren. Omdat de 
meeste mensen met fibromyalgie worden behandeld door huisartsen en fysiotherapeuten 
leek ondersteuning van deze eerstelijns professionals noodzakelijk om te kunnen komen 
tot beter op elkaar afgestemde zorg. 
 
Hoofdstuk 2. De effecten van multidisciplinaire dagbehandeling 
Allereerst werd onderzocht of MD leidde tot minder zorggebruik, minder ziekteverzuim en 
een betere kwaliteit van leven. Om dit onderzoek uit te voeren, werden patiënten van het 
Maastrichts Universitair Medisch Centrum, het Atrium Ziekenhuis in Heerlen en het Orbis 
Medisch Centrum in Sittard benaderd met de vraag of ze mee wilden doen aan een studie 
naar het natuurlijk verloop van fibromyalgie. Indien patiënten wilden deelnemen, 
ontvingen ze vragenlijsten waarmee, naast algemene gegevens zoals leeftijd, geslacht en 
opleiding, ook gegevens over het zorggebruik, ziekteverzuim en de kwaliteit van leven 
werden verzameld.  
Vervolgens werden de deelnemers aan de studie (n=203) door loting (randomisatie) 
ingedeeld in drie behandelgroepen: MD (n=108), aerobe oefeningen (AE) (n=47), en 
voorlichting en begeleiding zoals gebruikelijk was (UC) (n=48). Daarna werden de 
patiënten, die waren ingeloot voor MD of AE, benaderd met de vraag of ze aan deze 
behandeling wilden deelnemen. Alle deelnemers aan het onderzoek, ook degenen die niet 
aan de behandeling wilden deelnemen, ontvingen de vragenlijsten op drie momenten: na 
afloop van de behandeling, en één jaar en twee jaar na de start van het onderzoek. In 
iedere groep werd bekeken of er verbetering optrad in de loop van de tijd. Daarnaast 
werden de resultaten van de drie groepen aan het einde van de studie onderling 
vergeleken.  
Uiteindelijk wilden 68 patiënten die waren ingeloot voor MD en 19 patiënten die waren 
ingeloot voor AE deelnemen aan de behandeling. Een aantal patiënten, acht in de MD 
groep en 11 in de AE groep, stopten om allerlei redenen vroegtijdig met de behandeling.  
In de drie groepen zagen we een daling in het zorggebruik en in het ziekteverzuim, en een  
  
Samenvatting en discussie 
156 
 
verbetering van de kwaliteit van leven. De verbetering leek het grootste in de MD groep, 
maar de verschillen tussen de drie groepen waren klein aan het einde van de studie. Om 
deze reden én omdat slechts een gering aantal patiënten aan de behandelingen had 
deelgenomen, hebben we geconcludeerd dat we op basis van ons onderzoek geen 
uitspraak konden doen over de effecten van de MD behandeling. Wel droegen de 
resultaten van het onderzoek bij aan inzicht in het verloop van fibromyalgie, onafhankelijk 
van interventies, en aan inzicht in barrières die van belang zijn bij het implementeren van 
zorgprogramma’s.  
 
Hoofdstuk 3. Het verloop van kosten 
Vanwege een hoog zorggebruik zijn de kosten voor de gezondheidszorg bij fibromyalgie 
aanzienlijk. Interventies moeten daarom gepaard gaan met aanvaardbare effectiviteit 
tegen aanvaardbare kosten. In het onderzoek, dat wordt beschreven in dit hoofdstuk, 
hebben we het verloop van kosten over een periode van twee jaar onderzocht in het 
cohort van recent gediagnosticeerde fibromyalgie patiënten (n=203), die deelnamen aan 
de effectstudie uit hoofdstuk 2. 
Zoals al beschreven, werden patiënten na het stellen van de diagnose door loting 
toegewezen aan MD (n=108), AE (n=47) of UC (n=48). Gegevens over kosten voor de 
gezondheidszorg en kosten voor patiënten en hun families werden verzameld door middel 
van tweemaandelijkse vragenlijsten. In de drie groepen werd het verloop van de 
gemiddelde kosten bij aanvang van de studie, in de periode voorafgaand aan de 
behandeling, tijdens de behandeling en in de periode na afloop van de behandeling 
onderzocht. Daarnaast werd onderzocht in hoeverre, op basis van patiënten kenmerken 
bij aanvang van de studie, de kosten voor de gezondheidszorg in de periode na afloop van 
de behandeling konden worden voorspeld. 
De kosten voor de gezondheidszorg namen in de drie groepen af na aanvang van de 
studie, maar dit leek vanzelfsprekend omdat de kosten voor bezoeken aan huisarts en 
medisch specialist, ten behoeve van de diagnostiek, in de eerste meting waren 
meegenomen. Toch was in de AE groep nog een verdere daling te zien, zelfs voordat een 
behandeling was gestart. In de loop van de tijd stegen de kosten weer licht in de drie 
groepen. De kosten voor patiënten en hun familie stegen in de loop der tijd in iedere 
groep. De kosten voor de interventies, met name de MD interventie, maakten substantieel 
deel uit van de totale kosten voor de gezondheidszorg. Patiënten die bij aanvang van de 
studie een grote invloed van fibromyalgie op het dagelijkse leven aangaven, genereerden 
hoge zorgkosten in de periode na afloop van de behandeling. Onze resultaten suggereren 
dat het verloop van de kosten niet voldoende wordt beïnvloed om dure interventies te 
rechtvaardigen. 
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Hoofdstuk 4. Voorspellers van ‘ervaren gezondheid’ 
De impact van fibromyalgie op ervaren gezondheid is groot. Omdat het effect van 
interventies meestal vrij klein is, is een beter inzicht in voorspellers voor ervaren 
verbeterde gezondheid noodzakelijk. In dit onderzoek hebben we voorspellers van ‘door 
de patiënt ervaren verbetering van gezondheid’ en de verandering in 
‘gezondheidstoestand’ onderzocht. We hebben hierbij gebruik gemaakt van een 
biopsychosociaal model voor gezondheid, dat de samenhang tussen een aandoening, het 
functioneren, activiteiten, persoonskenmerken en omgevingsfactoren beschrijft: de 
’International Classification of Functioning, Disability and Health’ (ICF).  
Gegevens van het eerder beschreven cohort van recent gediagnosticeerde fibromyalgie 
patiënten (n=203) werden gebruikt. Patiënten werden door toeval toegewezen aan MD 
(n=108), AE (n=47) of UC (n=48), maar slechts een beperkt aantal patiënten startte een 
interventie (n=86) of was > 70% van de geplande sessies aanwezig (n=68). Patiënten 
vulden bij aanvang van de studie vragenlijsten in, die betrekking hadden op alle 
onderdelen van het ICF-model en op ervaren gezondheidstoestand. Na twee jaar werd 
gevraagd naar ervaren verbetering van de gezondheid ten opzichte van het begin van de 
studie, en daarnaast weer naar ervaren gezondheidstoestand. Vervolgens werd 
onderzocht welke kenmerken van patiënten, gerangschikt volgens het ICF-model, 
verbetering van gezondheid konden voorspellen.  
Het hebben van werk en voldoende aanwezigheid bij een interventie voorspelden door de 
patiënt ervaren verbetering van gezondheid na twee jaar. Een langere duur van de 
klachten en ervaren fysieke beperkingen voorspelden een slechtere gezondheidstoestand 
na twee jaar. Patiënten met grotere fysieke en mentale beperkingen waren meer bereid 
om te starten met een interventie en om daar voldoende aanwezig te zijn. De resultaten 
lijken te wijzen op het belang van een actief aanbod van een interventie, vooral voor 
mensen met ernstige klachten. 
 
Hoofdstuk 5. Het ondersteunen van eerstelijns professionals  
In twee regio's in het zuiden van Nederland werd een project opgezet om eerstelijns 
professionals, vooral huisartsen en fysiotherapeuten, te ondersteunen in het verlenen van 
beter op elkaar afgestemde zorg aan mensen met fibromyalgie. In het project werd het 
Chronic Care Model (CCM) gebruikt als een raamwerk om gecombineerde interventies te 
ontwikkelen. Het CCM beschrijft de samenhang tussen verschillende activiteiten binnen 
de gezondheidszorg en in de maatschappij, die uiteindelijk een bijdrage leveren aan 
verbeterde uitkomsten van patiënten. Voorbeelden van dergelijke activiteiten zijn: het 
aanbieden van effectieve interventies die het zelfmanagement van patiënten verbeteren, 
het ondersteunen van besluitvorming van professionals en een herverdeling van taken 
tussen verschillende disciplines die zijn betrokken in het zorgproces. In het genoemde 
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project werden de volgende gecombineerde interventies ontwikkeld: een 
scholingsprogramma, een multidisciplinaire richtlijn voor behandeling, en een 
verwijsinstrument.  
In totaal namen 12 huisartsen en 23 fysiotherapeuten, die samen 12 praktijkteams - al 
bestaande samenwerkingsverbanden- vormden, deel aan de scholing. Nadat de scholing 
was gevolgd, testten de praktijkteams de richtlijn en het verwijsinstrument gedurende zes 
maanden in de dagelijkse praktijk. Voorafgaand aan- en na afloop van de testperiode 
werden de teams geïnterviewd aan de hand van een vragenlijst, de ‘Assessment Chronic 
Illness Care’ (ACIC) vragenlijst. Deze vragenlijst evalueert teamopvattingen over het niveau 
en de aard van verbeteringen in de zorg als gevolg van interventies.  
Na afloop van de testperiode bleek dat alle elementen van de zorg waren verbeterd. 
Volgens de professionals was het gebruik van de richtlijn en het verwijsinstrument 
haalbaar in de dagelijkse praktijk. Het was echter moeilijk om veranderingen in hun 
praktijk door te voeren. In aanvulling op onze interventies zijn andere activiteiten nodig 
om deze zorg verder te verbeteren. 
 
 
Deel 2. Het verbeteren van de zorg bij chronisch inflammatoire aandoeningen 
Inflammatoire (ontsteking gerelateerde) aandoeningen worden gekenmerkt door een 
abnormale reactie van het afweersysteem. Als gevolg hiervan treden ontstekingen op. Bij 
reumatoïde artritis, chronisch gewrichtsreuma, zien we deze ontstekingen vooral in de 
kleine gewrichten van handen en voeten, maar daarnaast ook in de grotere gewrichten. 
Bij spondyloartritis, een verzamelnaam voor meerdere aandoeningen waaronder de ziekte 
van Bechterew en artritis psoriatica, zijn er ontstekingen in de wervelkolom, waarbij ook 
andere gewrichten betrokken kunnen zijn. Naast gewrichtsontstekingen kunnen ook 
organen zijn aangedaan, vandaar dat we deze aandoeningen systemisch noemen. De 
voornaamste klachten -pijn, stijfheid en vermoeidheid-, kunnen het dagelijks functioneren 
van patiënten ernstig belemmeren. De aandoeningen worden gekenmerkt door perioden 
met hoge en lage ziekteactiviteit. Het patroon waarin deze perioden optreden is  
onvoorspelbaar.  
In de behandeling is de afgelopen decennia veel verbeterd en in toenemende mate wordt 
de abnormale afweerreactie van het immuunsysteem succesvol onderdrukt. Toch kunnen 
patiënten worden beperkt door de klachten. De intensieve behandeling zelf vraagt goede 
controles door professionals én zelfmanagement van patiënten. Gespecialiseerde 
verpleegkundigen spelen hierin een belangrijke rol. Zij verzorgen voorlichting en scholing 
aan patiënten, bieden steun bij het omgaan met de gevolgen van de aandoeningen, 
participeren in de geplande controles en dragen bij aan de toegankelijkheid van de zorg.  
De rol van de reumaverpleegkundige wordt in landen en zelfs in regio’s verschillend 
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 ingevuld. In sommige landen is reumaverpleegkundige zorg niet beschikbaar. De 
European League Against Rheumatism (EULAR), die beoogt een bijdrage te leveren aan 
een gelijkwaardige kwaliteit van de zorg voor alle reumapatiënten, heeft een aantal 
projecten ondersteund ten einde de rol van de reumaverpleegkundige te optimaliseren en 
te standaardiseren. 
 
Hoofdstuk 6. EULAR aanbevelingen voor de rol van de verpleegkundige  
Een multidisciplinair expertpanel van 25 personen uit 14 Europese landen, bestaande uit 
verpleegkundigen, reumatologen, een ergotherapeut, een fysiotherapeut, een 
psycholoog, een epidemioloog en vertegenwoordigers van patiënten, was 
verantwoordelijk voor het ontwikkelen van aanbevelingen voor de rol van de 
verpleegkundige in de behandeling van mensen met chronische inflammatoire 
aandoeningen, in het bijzonder reumatoïde artritis en spondyloartritis.  
Aan de hand van onderzoeksvragen werd een systematisch literatuuronderzoek verricht. 
De resultaten van dit onderzoek werden door het expertpanel besproken en 
bediscussieerd. Op basis van de evidentie uit de literatuur en de mening van de experts 
werden 10 aanbevelingen geformuleerd. Zeven aanbevelingen betreffen de bijdrage van 
de verpleegkundige aan zorg en behandeling: educatie, patiënttevredenheid, 
toegankelijkheid van de zorg, ziektecontrole, psychosociale zorg, ondersteuning van 
zelfmanagement en doelmatigheid. Drie aanbevelingen richten zich op professionele 
ondersteuning voor verpleegkundigen: beschikbaarheid van richtlijnen en protocollen, 
scholing en rolontwikkeling. Bovendien werden een onderzoeksagenda en een 
scholingsagenda geformuleerd.  
 
Hoofdstuk 7. Verspreiding en evaluatie van de EULAR aanbevelingen voor de rol van de 
verpleegkundige 
Bekendheid met deze aanbevelingen en instemming van de directe betrokkenen, 
verpleegkundigen, reumatologen en patiënten, alsook kennis van barrières voor de 
toepassing ervan, zijn noodzakelijke voorwaarden voor implementatie. Daarom werd 
besloten om de aanbevelingen te verspreiden, de instemming met- en de toepassing van 
de aanbevelingen te meten, navraag te doen naar eventuele redenen om het niet eens te 
zijn met de aanbevelingen en naar belemmeringen om deze toe te passen. 
Een vragenlijst werd via internet-links verspreid onder verpleegkundigen, reumatologen 
en patiënten in Europa en in de Verenigde Staten (VS). Aan de deelnemers werd gevraagd 
om de link te verspreiden onder zoveel mogelijk collega’s of medepatiënten. De mate van 
instemming met- en toepassing van de aanbevolen zorg kon voor iedere aanbeveling 
worden ingevuld op een schaal van 0-10 (0: niet, 10: volledig). Eventuele redenen voor 
‘niet (volledig) eens’ of ‘niet (volledig) toegepast’, konden worden aangevinkt in een lijst 
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van gegeven mogelijkheden; de lijst kon worden aangevuld met andere redenen. 
Regionale verschillen met betrekking tot instemming en toepassing werden verkend. 
In totaal namen 967 verpleegkundigen, 548 reumatologen en 2034 patiënten uit 22 
Europese landen en uit de VS deel aan het onderzoek. De mate van instemming was hoog 
in de drie groepen en varieerde van 8-10 per aanbeveling. De toepassing was veel lager en 
varieerde van 0-8 per aanbeveling. Instemming en toepassing waren het laagst in Oost- en 
Centraal-Europa. De meest voorkomende reden voor niet (volledige) instemming was bij 
verpleegkundigen ‘teveel andere verantwoordelijkheden’, bij reumatologen ‘twijfels over 
de kennis van verpleegkundigen’ en bij patiënten ‘angst om contact met de reumatoloog 
te verliezen’. De meest gerapporteerde barrières voor toepassing van de aanbevolen zorg 
waren ‘tijdgebrek’ en ‘geen verpleegkundigen beschikbaar’. Voor reumatologen was 
bovendien ‘onvoldoende kennis van verpleegkundigen’ een belangrijke barrière om de 
aanbevolen zorg toe te passen. 
 
Hoofdstuk 8. Zorgbehoefte van patiënten 
De onderzoeksagenda, die samen met de aanbevelingen voor de rol van de 
verpleegkundige (Hoofdstuk 6) werd geformuleerd, dient als globale leidraad voor verder 
onderzoek in verschillende landen en voor internationaal onderzoek. Een werkgroep van 
de Nederlandse beroepsvereniging voor reumaverpleegkundigen (V&VN, afdeling 
reumatologie), werd opgericht om de onderzoeksagenda in Nederland verder vorm te 
geven. Na een discussie over het prioriteren van onderwerpen werd besloten dat de 
behoeften en verwachtingen van patiënten leidend dienden te zijn.  
Om deze behoeften en verwachtingen te inventariseren werden focusgroepen 
georganiseerd met reumapatiënten in Utrecht (n=4), Rotterdam (n=4) en Maastricht 
(n=4). In de focusgroepen werden verschillende gevolgen van het hebben van een 
reumatische aandoening besproken. Het betrof lichamelijke klachten, emoties, 
psychosociale gevolgen van de aandoening, en ervaren beperkingen in het vervullen van 
sociale rollen. Patiënten maakten kenbaar dat zij in staat wilden zijn zelf om te gaan met 
de genoemde gevolgen en dat ook vaak waren. Echter, een toename van de 
ziekteactiviteit of veranderingen in de persoonlijke situatie konden -tijdelijke- 
ondersteuning noodzakelijk maken. Aansluitend werden behoeften en verwachtingen ten 
aanzien van reumaverpleegkundige zorg uitgesproken, die werden geordend in 12 
subthema’s en uiteindelijk werden gerangschikt in vier hoofdthema’s. Patiënten hadden 
behoefte aan educatie, ondersteuning van hun zelfmanagement en aan emotionele 
ondersteuning; patiënten verwachtten goed georganiseerde zorg. In een vierde 
focusgroep in Nijmegen (n=8) werden geen nieuwe thema’s genoemd en werden de 
hoofdthema’s geverifieerd.  
De patiënten onderzoekspartners in de projectgroep speelden een bepalende rol bij de  
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keuze voor het onderwerp, de opzet van het onderzoek en bij het analyseren van de 
resultaten. De focusgroepen hebben waardevolle informatie opgeleverd voor de richting 
van reumaverpleegkundig onderzoek vanuit het perspectief van de patiënt en de 
resultaten zijn bepalend voor het vaststellen van de onderzoeksagenda voor V&VN, 
reumatologie. 
 
Hoofdstuk 9. Discussie 
In dit hoofdstuk worden een tweetal algemene overwegingen ten aanzien van 
zorgverbetering besproken. Allereerst kan de vraag worden gesteld of activiteiten, die 
beogen de zorg te verbeteren, gericht dienen te zijn op specifieke aandoeningen, óf dat 
een meer generalistische benadering de voorkeur heeft. Vanuit het oogpunt van 
zorgverbetering kunnen resultaten van activiteiten voor een bepaalde groep bruikbaar zijn 
voor een groep mensen met andere aandoeningen. Een voorbeeld is de aandacht voor 
cardiovasculaire risico’s. Echter, ziektespecifieke bijdragen aan deze risico’s, zoals 
ontstekingsactiviteit bij inflammatoire reumatische aandoeningen, dienen adequaat 
behandeld te worden hetgeen specialistische kennis vraagt. Ook is het voor patiënten 
noodzakelijk om kennis en vaardigheden ten aanzien van de aard en de behandeling van 
klachten te hebben, zodat zij beter hiermee om kunnen gaan. We denken dat de 
resultaten van onze onderzoeken kunnen bijdragen aan zorgverbetering voor mensen met 
andere (reumatische) aandoeningen. 
Een ander aandachtspunt betreft de zichtbaarheid van zorgverbetering. Hiertoe dient een 
keuze te worden gemaakt ten aanzien van uitkomstmaten, maar deze keuze wordt deels 
bepaald door het perspectief van waaruit activiteiten worden beschouwd: dat van 
patiënten, van zorgverleners of van de maatschappij. In onze onderzoeken naar de 
effecten van de MD behandeling voor mensen met fibromyalgie hebben we, naast voor 
patiënten relevante uitkomsten zoals kwaliteit van leven, gekozen voor maatschappelijk 
relevante uitkomsten zoals gebruik van gezondheidszorg en participatie. We 
veronderstelden dat een kleiner beroep op de gezondheidszorg en verbeterde deelname 
aan het arbeidsproces een resultaat konden zijn van verbeterd zelfmanagement, maar dit 
is discutabel. In ons project voor verbetering van de 1
e
 lijns zorg hebben we aan 
zorgverleners gevraagd of zij verbetering bemerkten, maar we hebben niet gemeten of dit 
daadwerkelijk leidde tot betere zorg voor patiënten.  
In toenemende mate laten onderzoeken zien dat reumaverpleegkundigen bijdragen aan 
betere zorg, maar er wordt een grote diversiteit aan uitkomstmaten gebruikt. Voor de 
vergelijkbaarheid van studies is het van belang om eenduidigheid hierin te realiseren. 
De resultaten van onze activiteiten voor zorgverbetering bij reumatische aandoeningen 
hebben geleid tot aanbevelingen voor onderzoek en voor de praktijk. 
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Aanbevelingen voor onderzoek 
Er is verder onderzoek nodig ten aanzien van zorg op maat voor mensen met fibromyalgie. 
Het gaat dan om de juiste zorg voor de juiste persoon. Kenmerken van patiënten, de 
inhoud en organisatie van de zorg, de hiermee gepaard gaande kosten voor de 
gezondheidszorg, maar ook de mate waarin bestaande richtlijnen zijn geïmplementeerd 
dienen te worden onderzocht.  
Ten aanzien van de reumaverpleegkundige zorg is nationaal en internationaal onderzoek 
op hoog niveau nodig, waarin de rollen van verpleegkundigen nauwkeurig zijn beschreven. 
Bovendien wordt onderzoek naar het definiëren van een set van uitkomsten van 
verpleegkundige interventies, die ook voor patiënten relevant zijn, aanbevolen. Dit vraagt 
een samenwerking van verpleegkundigen op wetenschappelijk gebied, hetgeen wordt 
bemoeilijkt door verschillen in opleidingsniveau van verpleegkundigen. Ondersteuning van 
nationale en internationale organisaties is noodzakelijk.  
 
Aanbevelingen voor zorg 
Nieuwe zorgmodellen voor reumapatiënten kunnen bijdragen aan duurzame, integrale 
zorg. Een getrapte benadering in de behandeling van fibromyalgie, gebaseerd op ernst van 
de klachten en disfunctioneren, waarbij eerste-, tweede- en derdelijns zorgprofessionals 
met elkaar samenwerken, is een voorbeeld van een dergelijk zorgmodel. Voor sommige 
patiënten met fibromyalgie is het omgaan met de klachten een steeds terugkerende 
opgave en voor deze groep zou laagdrempelige, frequente toegang tot een proactieve 
follow-up te overwegen zijn. Daarnaast blijkt, dat voor eerstelijns zorgverleners, maar ook 
voor specialismen buiten de reumatologie, voldoende kennis over de aandoening en de 
behandeling ontbreekt en goede scholing noodzakelijk is.  
De implementatie van reumaverpleegkundige zorg past in het streven naar duurzame en 
integrale zorg. Nationale en internationale organisaties voor reumatologie kunnen de 
ontwikkeling van de reumaverpleegkundige zorg ondersteunen door het vaststellen van 
een visie op goede kwaliteit van zorg en het definiëren van adequate scholing voor 
verpleegkundigen. 
 
Samenvattend hebben we geconcludeerd dat onze activiteiten, die beoogden om de zorg 
voor mensen met fibromyalgie te verbeteren, hebben geleid tot een beter inzicht in 
knelpunten voor goede zorg, hetgeen kan bijdragen aan zorgverbetering.  
Voor wat betreft de zorg voor mensen met inflammatoire aandoeningen hebben onze 
activiteiten, met betrekking tot de rol van de reumaverpleegkundige, bijgedragen aan een 
internationale beweging naar verdere professionalisering van de reumaverpleegkundige 
zorg.  
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‘Alles heeft betekenis’. Iedereen die je ontmoet en alles wat je doet en meemaakt, draagt 
bij aan je persoonlijke groei: het zo optimaal mogelijk verkennen en benutten van álle 
talenten, op welk terrein dan ook. Zo ook het proces dat nu resulteert in de verdediging 
van mijn proefschrift, ik heb er heel veel plezier aan beleefd.  
Een dergelijk proces is ondenkbaar zonder de hulp en steun van velen. ‘Zelf doen’ is niet 
hetzelfde als ‘alleen doen’, en een dankwoord is zeker op zijn plaats. Het risico van een 
dankwoord is dat je belangrijke mensen vergeet. Met het vorderen van de leeftijd wordt 
de kans op geheugenproblemen groter én wordt de lijst van mensen die kunnen worden 
vergeten langer. Een voordeel van ouder worden is echter dat het relativeringsvermogen 
groter wordt. Ik ben geen ‘junior’ meer en daarom durf ik het risico van onvolledigheid te 
nemen. In dit dankwoord beperk ik mij tot de periode in mijn leven die direct leidde naar 
deze dag. In aanvulling gaat mijn dank uit naar alle mensen die ik, zowel privé als in 
diverse werksituaties, heb ontmoet en waarvan ik heb mogen leren.  
Allereerst een woord van dank aan mijn promotieteam. Professor Landewé, beste Robert, 
het was een plezierig traject met jou. Dat had ik ook verwacht ☺. Het was even wennen 
voor ons beiden: jij kende mij als reumaconsulent en ik had als onderzoeker veel te leren, 
dus er ging wel eens wat mis met…….data. Uiteindelijk had je voldoende vertrouwen in mij 
om mij voor te stellen als onderzoeker in het EULAR project. Daar heb ik je al eerder voor 
bedankt. Ik waardeer je betrokkenheid en je kennis, je positieve feedback en je humor. 
Indien gevraagd was je er steeds voor mij. Professor Boonen, beste Annelies, met jou is 
het sinds jaar en dag heerlijk samenwerken. Je bent een grote inspirator voor mij en 
ondanks je eigen drukke programma ben je altijd bereid om mee te denken en je kennis 
over vele onderwerpen te delen. Mijn allereerste stap op het wetenschappelijk pad was 
het ‘infliximab naar Blankenberg’ project. Voor mij was alles nieuw dus jij hebt heel veel 
geregeld, maar de basis voor onze, door ons beide gewaardeerde, brainstormsessies is 
toen gelegd. Dr. Kroese, beste Mariëlle, jij zette de trial op die de data voor drie 
hoofdstukken van dit proefschrift leverde. We hebben in het begin intensief 
samengewerkt, daarna gingen we ieder ‘ons weegs’. Het zou leuk zijn als onze 
gezamenlijke activiteiten voor mensen met fibromyalgie uiteindelijk bijdragen aan een 
verdere zorgverbetering voor deze patiënten. Dr. van Tubergen, beste Astrid, ik vond het 
een genoegen om een aantal voor mij heel belangrijke projecten uit deze thesis samen 
met jou te doen. Het was behalve leuk ook erg leerzaam, net zoals het samen reviewen 
van artikelen. Bovendien heb jij een belangrijke rol gespeeld bij mijn terugkeer naar 
reumatologie. We zijn beiden betrokken in vervolgactiviteiten, dus onze samenwerking 
gaat gelukkig gewoon door. Fijn dat je mijn copromotor bent. 
Professor Metsemakers, professor Hazes, professor Schuurmans en dr. Vosse, beste Job, 
Mieke, Marieke en Debby, leden van de beoordelingscommissie. Ik wil jullie hartelijk 
danken voor de genomen tijd en moeite om mijn proefschrift te beoordelen op 
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wetenschappelijke kwaliteit. Marieke, jammer dat je niet in de gelegenheid bent om te 
opponeren tijdens de verdediging. Professor Westhovens, dr. Fiolet en dr. De Wit, beste 
Rene, Hans en Maarten, fijn dat jullie de promotiecommissie willen completeren. 
Anderen hebben op verschillende wijzen een essentiële bijdrage geleverd aan de 
totstandkoming van dit proefschrift, waarvoor mijn hartelijke dank.  
Monique Bessems-Beks, beste Monique, je was bekend met álle ins en outs van de 
fibromyalgieprojecten en bent bovendien altijd bereid om een handje te helpen bij een 
project waar je niet op bent ‘gelabeld’. Leuk dat we weer samenwerken in het project van 
Daisy.  
Professor Vrijhoef, beste Bert, jou leerde ik kennen als promovendus in het project 
‘Spreeuwenberg’. Daarna werd je een van mijn coaches op het pad van de wetenschap. 
Gelukkig werken we ook nu nog steeds constructief en plezierig samen.  
Dr. Tan, beste Frans, mijn grote steun en toeverlaat in de statistiek; zonder onze 
gezamenlijke sessies in het begin was het vast niet goed gekomen.  
Dr. Creemers, beste An, je hebt veel werk gehad aan de imputatie van de kostendata, 
maar de zorgvuldigheid waarmee je dat hebt gedaan, zorgt ervoor dat ik met een gerust 
hart mijn uitspraken ten aanzien van de kosten kan doen.  
Dr. Repping-Wuts, beste Han, ik ben erg blij met onze gezamenlijke activiteiten in onze 
Nederlandse werkgroep ‘verpleegkundig onderzoek’. Het was een genoegen om met jou 
en met Judy, Hanneke en Conny samen te werken in onze eerste onderzoeken en ik 
verheug me op de voortzetting. Ik hoop ook dat wij in de toekomst meer 
verpleegkundigen kunnen inspireren om onderzoek te doen. 
Chris Leenders en Heleen Schillings †, jullie zijn uren bezig geweest met het uitzoeken en 
invoeren van de kostendata, een belangrijk maar tijdrovend karwei.  
Patient research partners, Marieke Scholte, Maarten de Wit, Marianne Osseweijer, Bertha 
Maat, Monique Lieon, Marleen Bolech, Ed Pourquié, Marlou Essers †, en al die anderen: ik 
ben blij met onze activiteiten en jullie inbreng is daarbij van onschatbare waarde.  
Dr. Hill, dear Jackie, your work has been inspiring for many rheumatology nurses and 
certainly for me. I enjoyed meeting you and working together with you and the other 
members of the EULAR nursing task force in our recommendations project.  
Dear colleague nurses, HPs and patient partners in EULAR task forces, EULAR study groups 
and committees, members of the RNS, ACR-ARHP, and in other parts of the world, I am 
happy with our expanding network and with the current international activities regarding 
care improvement for patients with rheumatic diseases. Dear Sue, our collaboration 
increases: we have a lot of work to do and I am looking forward to it. Thank you for your 
inspiration and your ongoing support. 
Er zijn een aantal mensen die in de aanloop naar- en gedurende dit promotietraject op 
geheel eigen wijze van belang waren en die daarvoor hartelijk worden bedankt.  
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Beste leden van de vakgroep reumatologie, de samenwerking met jullie inspireerde me tot 
de keuze voor de studie Gezondheidswetenschappen en daarna heb ik de wereld buiten 
de reumatologie verkend. Na een omweg ben ik weer terug! Ik werd met open armen 
ontvangen en inmiddels geven we vorm aan nieuwe, gezamenlijke activiteiten. Professor 
van der Linden, beste Sjef, onze eerste tocht naar de Rheumaklinik Aachen luidde voor ons 
beiden een spannende en niet altijd gemakkelijke zoektocht in naar wat die 
verpleegkundige wel en niet kon in de reumatologie. Vandaag de dag weten we heel wat 
meer, maar nog lang niet alles.  
Ilse KleinGoldewijk, we gingen samen naar ‘Bunnik’ en we hebben de functie van 
verpleegkundig reumaconsulent in Maastricht vormgegeven. Het was mooi dat we dat 
samen hebben kunnen doen en fijn dat we nog steeds af en toe samen gaan eten of 
borrelen en lekker bijpraten over onszelf en ‘onze jongens’. Mehmet Elmacioglu, jij kwam 
erbij en versterkte ons reumaconsulententeampje. Ik vind onze filosofische 
beschouwingen erg plezierig en ik ben blij dat wij weer collega’s zijn. Claudia Vaessens, we 
delen 1 bureau en zien elkaar tot nu toe nauwelijks; als alle plannen doorgaan, leren we 
elkaar vast beter kennen.  
Drs. Hollands, beste Louk, je liefde voor kwaliteitszorg, je vermogen dat over te brengen 
en je enthousiasme om samen te werken, stonden mede aan de wieg van deze 
wetenschappelijke carrière.  
Transmurale zorg, onderdeel van het tegenwoordige Patiënt & Zorg, heeft een speciaal 
plekje in mijn hart. Vanaf de oprichting van de toenmalige BZE 7 heb ik mij er als een vis in 
het water gevoeld. Kansen creëer je zelf, daar ben ik het helemaal mee eens, maar zonder 
het scheppen van voorwaarden is excelleren een stuk ingewikkelder, zo niet onmogelijk. 
Dr. Fiolet, beste Hans, jouw vermogen die voorwaarden te willen en te kunnen scheppen 
speelt daarbij een cruciale rol.  
Drs. de Bruijn-Geraets, beste Daisy, ik ben blij dat ik bij je project ben betrokken; ik vind 
het een eer om jou te begeleiden. Het is een leuk project, jij bent een uitstekende 
onderzoeker en samen met Bert en Monique vormen we een superteam.  
Beste (oud)collega’s onderzoekers en onderzoeksassistenten van Transmurale zorg, Bert, 
Guy, Caro, Liesbeth, Henk, Joyce, Pytha, Ron, Angelique, Monique, Wendy, Carla, Diana †, 
Helene, Juliane, Jody, Alied, Trudy, Daisy, Manon, Greet, Mariëlle, Inge, Anneke, Josiane, 
George, Ron, Susan, Carin: toen waren er nog………….! Van een grote enthousiaste 
onderzoeksgroep naar een klein clubje. Dat viel niet altijd mee. Gelukkig weten we elkaar 
nog steeds te vinden. Josiane, promoveren op vrijdag de 13
e
! Dat doet niet iedereen je na. 
En ja hoor, in het vervolg sluiten we weer de gelederen na de BBQ bij Hans. 
Beste collega’s van HSR, ik ben benieuwd naar onze toekomstige samenwerking. Professor 
Ruwaard, beste Dirk en dr. Spreeuwenberg, beste Marieke, fijn dat de koffie en de vlaai 
letterlijk en figuurlijk klaarstonden.  
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Beste mede-reumatologie-promovendi, jullie ‘mama’ ben ik niet en wordt ik niet maar 
naast een gezamenlijk bezoek aan de Old Spaghetti Factory oid zijn er in de toekomst vast 
mogelijkheden om samen te werken. 
Al degenen die in allerlei projecten hebben geparticipeerd, zowel professionals als 
patiënten, wil ik expliciet bedanken. Zonder jullie bereidheid om mee te denken en te 
experimenteren is geen verandering mogelijk. 
 
En dan….. 
Familie en vrienden, tot mijn schande moet ik bekennen dat jullie er bekaaid vanaf komen. 
Het is vaak balanceren tussen werken, waar ik veel plezier aan beleef, én de tijd nemen 
om te genieten van jullie aanwezigheid en samen leuke dingen te doen. (Schoon)moeder, 
(schoon)zus(sen), (schoon)broers, (achter)neven en (achter)nichten, vrienden, allen 
bedankt voor je geduld om af te wachten tot een moment dat we iets kunnen afspreken, 
voor het accepteren van deze werkelijkheid én voor je steun. 
Jef en Mieke, vrienden van het eerste uur, geweldig dat jullie je artistieke talenten hebben 
gebruikt om de prachtige omslag van dit proefschrift te ontwerpen.  
Lief mamaatje, ik zou graag meer tijd met je doorbrengen. Weet dat ik geniet van de 
uurtjes die we wél samen hebben.  
Mijn (schoon) kinderen Siemen en Mirjam, Pepijn en Jeltsje, lieve allemaal: ik ben trots op 
jullie. Om wie je bent en om wat je doet. Ik vind het een heel prettig idee, mijn zonen als 
paranimfen; bedankt dat jullie dat voor mij willen doen. 
Lieve Paul, de laatste regels zijn voor jou. Al heel lang mijn beste maatje. Niemand kent 
mij zo goed als jij. Mijn keuzes zijn zeker niet altijd de jouwe, maar desondanks kan ik 
rekenen op je onvoorwaardelijke steun en dat is heel bijzonder. Dank je! 
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Yvonne van Eijk-Hustings was born in Heerlen, the Netherlands, 10 July 1958. Ever since 
her childhood she intended to be a nurse. After graduating from Higher General 
Secondary Education at Coriovallum College, Heerlen, in 1976, she moved to Nijmegen to 
study nursing at the Higher Vocational Nursing School where she obtained her Bachelor 
degree in 1980. As a registered nurse she worked in the care for drug and alcohol addicts, 
for psychiatric patients, for mentally retarded patients, and in the community. She always 
had a special interest in the care for chronically ill patients and eventually she has 
specialised as a rheumatology nurse.  
From 1997 to 2005, she worked at the rheumatology outpatient clinic of Maastricht 
University Medical Centre (MUMC+) and from September 2000 she combined this work 
with a part-time study Health Sciences at Maastricht University. Her interest in research 
increased during her study so, after obtaining her Master degree in 2004, she chose to 
continue her career in science. She performed research projects with regard to the care 
for patients with chronic obstructive pulmonary diseases and for patients with diabetes 
mellitus at the Department of Patient & Care (MUMC+). She additionally started her 
research with regard to improving care for patients with rheumatic diseases, that has 
resulted in this dissertation, in 2007.  
Since 2012, she combines research and practice. She participates in international and 
national multidisciplinary research groups that aim to contribute to improved quality of 
care for patients with rheumatic diseases and she participates in international and 
national research initiatives that emphasise the role of the rheumatology nurse. Also, she 
is founder and chair of two international working groups: the nurses study group for 
Research and Strategy (REST), endorsed by the European League Against Rheumatism 
(EULAR), and the ‘Defining and measuring nurse sensitive outcomes’ working group, 
supported by Outcome Measures in Rheumatology (OMERACT). She is a co-opted member 
of the EULAR Health Professionals scientific subcommittee; she is a board member of- and 
research fellow for V&VN, unit rheumatology, and she is actively involved in the founding 
of an international rheumatology nurses network.  
Furthermore, she is involved in the development of the nursing profession towards 
extended roles. She is an advisory member of the ‘College Specialismen Verpleegkunde’, 
and co-supervisor in a project initiated by the Ministery of Welfare, Health and Sports in 
the Netherlands that evaluates the impact of granting independent authorisations for 
reserved procedures to nurse practitioners and physician assistants.  
Finally, she provides outpatient nursing care for rheumatology patients and she 
contributes to initiatives for care improvement within the Department of Rheumatology 
and the Department of Patient & Care (MUMC+), in collaboration with CAPHRI, School for 
Public Health and Primary Care of Maastricht University.  
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Yvonne van Eijk-Hustings werd op 10 juli 1958 geboren in Heerlen. Al in haar kindertijd 
wilde zij verpleegkundige worden. Na het behalen van het Hoger Algemeen Vormend 
Onderwijs (HAVO) diploma, 1976, aan het Coriovallum College te Heerlen, studeerde zij 
verpleegkunde aan de Hogere Beroepsopleiding voor Verpleegkundigen (HBO-V) te 
Nijmegen, waar zij in 1980 haar diploma behaalde. Als gediplomeerd verpleegkundige 
werkte zij achtereenvolgens in de verslavingszorg, de psychiatrie, de zorg voor mensen 
met een verstandelijke beperking en de wijkzorg. Zij was altijd een bijzondere interesse in 
de zorg voor chronisch zieken en uiteindelijk heeft zij zich gespecialiseerd als 
reumaverpleegkundige. 
Van 1997 tot 2005 werkte ze op de polikliniek reumatologie van het Maastrichts 
Universitair Medisch Centrum (MUMC+) en vanaf 2000 combineerde ze dit werk met een 
studie Gezondheidswetenschappen aan de Universiteit Maastricht. Haar interesse in 
onderzoek nam gedurende haar studietijd toe en daarom koos ze, na het behalen van 
haar bul, voor een baan als onderzoeker. Ze deed onderzoeksprojecten voor de afdeling 
Patiënt en Zorg van MUMC+ met betrekking tot de zorg voor mensen met chronisch 
longlijden en met diabetes mellitus. In aanvulling hierop startte ze in 2007 met de 
onderzoeken die beschreven zijn in dit proefschrift. 
Sinds 2012 combineert ze onderzoek en praktijk. Ze maakt deel uit van een aantal 
nationale en internationale onderzoeksgroepen, die beogen de zorg voor patiënten met 
reumatische aandoeningen te verbeteren en de rol van de reumaverpleegkundige te 
verduidelijken en te versterken. Ze is oprichter en voorzitter van twee internationale 
verpleegkundige werkgroepen: de European League Against Rheumatism (EULAR) 
studiegroep voor onderzoek en beleid (REST) en de intercontinentale werkgroep voor het 
definiëren van relevante uitkomsten van reumaverpleegkundige interventies in 
onderzoek, ondersteund door Outcome Measures in Rheumatology (OMERACT). Ze is (op 
uitnodiging) lid van het wetenschappelijk subcomité van de EULAR Health Professionals, 
ze is bestuurlid van- en onderzoeker voor V&VN, reumatologie, en ze is betrokken bij de 
oprichting van een internationaal netwerk voor reumaverpleegkundigen.  
Ook is ze betrokken bij initiatieven die de ontwikkeling van het verpleegkundig beroep in 
zijn algemeenheid, door verdere specialisatie van verpleegkundigen, ondersteunen; ze is 
adviserend lid van het ‘College Specialismen Verpleegkunde’ en copromotor in een 
onderzoeksproject van het Ministerie van Volksgezondheid, Welzijn en Sport, dat de 
zelfstandige bevoegdheid voor het indiceren van voorbehouden handelingen door 
verpleegkundig specialisten en physician assistants evalueert. 
Daarnaast verleent ze gespecialiseerde zorg aan patiënten met reumatische aandoeningen 
op de polikliniek reumatologie en draagt ze bij aan projecten voor zorgverbetering binnen 
de afdeling Reumatologie en de afdeling Patiënt & Zorg, MUMC+, in samenwerking met 
CAPHRI, onderzoeksschool voor publieke gezondheid en de eerstelijn van de Universiteit 
Maastricht. 
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